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ABSTRACT OF THE DISSERTATION 
 
Antiviral Nucleoside Inhibitors of Leishmania RNA Virus 1: 
Discovery and Mechanism 
By 
John Isaac Robinson 
Doctor of Philosophy in Biology and Biomedical Sciences 
Biochemistry 
Washington University in St. Louis, 2017 
Professor Stephen M. Beverley, Chair 
Some Leishmania parasites in the Viannia sub-genus are persistently infected with 
Leishmania RNA virus 1 (LRV1), a single-segmented double-stranded RNA virus belonging to 
the family Totiviridae. Infected parasites cause greater pathology and reach higher populations in 
mouse models of Leishmania infection. In human disease, LRV1+ parasites are correlated with 
increased frequency of treatment failure and relapse. Efficient methods to detect LRV1 and 
eliminate it from parasites are required to better understand the role of LRV1 in Leishmania 
infection. We optimized multiple techniques to measure LRV1 levels in parasites, most notably 
using flow cytometry to measure the amount of viral capsid protein in individual parasites 
stained with an anti-capsid antibody. A slot-blot based assay allowed us to rapidly quantify the 
levels of viral capsid protein or viral dsRNA. Armed with these tools, we screened various 
known anti-viral compounds and nucleoside analogs for compounds that could inhibit LRV1. 
The two compounds we identified, 2‟-C-methyl-adenosine (2CMA) and 7-deaza-2CMA 
(7d2CMA), can be utilized to efficiently cure parasites of LRV1 and generate matched 
xii 
 
LRV1+/LRV1- strains for further study. These pairs allowed us to confirm the role of LRV1 in 
exacerbating disease. 
We then set out to determine the mechanism of LRV1 inhibition by 2CMA. I showed that 
the active form of 2CMA is its triphosphate (2CMA-TP), and that it directly inhibits the viral 
RNA polymerase activity with IC50 values ranging from 130 to >600 µM depending on the type 
of virus particle (empty, ssRNA, or dsRNA-containing) and the RNA product formed. However, 
this inhibition required much greater 2CMA-TP concentrations than expected based on the EC50 
of 2CMA against LRV1 replication in parasites (3 µM). Leishmania are known to accumulate 
significant amounts of other purine analogs, so I measured the concentration of 2CMA-TP in 
parasites treated with 10 µM 2CMA and found that they accumulated 410 µM 2CMA-TP. I then 
created a simulation of LRV1 inhibition and used it to show that this level of 2CMA-TP 
accumulation was sufficient to replicate the LRV1 inhibition we previously observed 
experimentally. Monitoring 2CMA-TP levels in parasites after 2CMA was removed from their 
medium showed that they retained significant amounts of 2CMA-TP even after 8 hours. 
Furthermore, culturing LRV1+ parasites in a low concentration of 2CMA slowly generated a 
significant population of LRV1-low parasites. These results suggest that our existing LRV1 
inhibitors may be sufficiently potent to inhibit LRV1 in mice infected with LRV1+ parasites and 
determine if this reduces or eliminates the increased pathogenicity associated with LRV1. The 
data summarized herein enables quantification of LRV1 and controlled study of its effects on 
both parasites themselves and the host immune system. The essential role of purine salvage for 
the potency of 2CMA highlights the importance of that pathway in drug design for Leishmania 
and suggests further methods for identifying LRV1 or Leishmania inhibitors. 
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Chapter 1: Introduction 
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Preface 
The first draft of this chapter was written by JIR. Comments from SMB were incorporated into 
the final version, presented here. 
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1.1 – Leishmaniasis: A Classic Neglected Tropical Disease 
Leishmania is a genus of single-celled eukaryotic parasites transmitted by multiple 
species of sand flies. (Weigle and Saravia 1996) Various species of Leishmania are endemic to a 
wide swath of the globe, from Central and South America to North Africa, the Middle East, and 
Central Asia. (Pigott et al. 2014) In humans, infection with Leishmania parasites causes one of 
roughly three types of disease: cutaneous, mucocutaneous, or visceral leishmaniasis. Most 
infections begin as cutaneous leishmaniasis (CL). CL manifests as a skin lesion centered on the 
point of infection and is often self-limiting. Mucocutaneous leishmaniasis (MCL) occurs when 
the parasites metastasize from the initial lesion to mucous membranes, often including the nasal 
passages. These tissues are progressively destroyed by high levels of parasite-induced 
inflammation, leading to disfiguration and significant social stigma. (Kassi et al. 2008) Visceral 
disease is characterized by parasite dissemination to the internal organs, where it is fatal if left 
untreated. (McGwire and Satoskar 2014) The factors determining disease progression are 
thought to be both host and pathogen derived. (Hartley et al. 2014; Kaye and Scott 2011) 
The total number of people at risk of leishmaniasis is over 1 billion worldwide.(World 
Health Organization 2016) Recent estimates put the number of new cases per year at around 1.2 
million, although the frequency of asymptomatic infections makes this number uncertain.(Alvar 
et al. 2012; den Boer et al. 2011) Poor reporting rates and the prevalence of asymptomatic or 
sub-clinical infections mean that the true infection rates are likely much higher.(Singh et al. 
2006; Ostyn et al. 2011; Weigle et al. 1993) Although leishmaniasis is usually not considered 
endemic in the United States, recent cases of local transmission in Texas have been 
reported.(Clarke et al. 2013) Another local risk comes from foxhounds: the majority of American 
foxhounds have chronic Leishmania infections that are transmitted from mother to pup.(Petersen 
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and Barr 2009) This particular strain of Leishmania can be transmitted by sand flies, but no 
vector-borne transmissions have yet been reported, despite the presence of sand flies in the 
United States.(Schaut et al. 2015) 
Currently-available treatments for leishmaniasis are somewhat limited. The most 
common drugs are pentavalent antimonials – antimony complexed with various organic 
compounds. These therefore exhibit significant host toxicity. Amphotericin B is another drug 
used to treat antimony-resistant leishmaniasis, but it too has severe side-effects.(Borges et al. 
2017) A non-antimony-based compound, miltefosine, has been successfully employed as an oral 
treatment for leishmaniasis.(Kuhlencord et al. 1992) However, resistance to miltefosine has been 
reported, both in the lab and in clinical leishmaniasis cases.(Srivastava et al. 2017) Efforts are 
also underway to develop vaccines against Leishmania parasites, but thus far no effective 
vaccines are available.(Gillespie et al. 2016; Reed et al. 2016; Srivastava et al. 2016) In order to 
better treat leishmaniasis, current research in the Beverley laboratory aims to understand the 
basic biology of Leishmania and  leverage that knowledge to identify potential drug targets. 
1.2– Leishmaniavirus: Infection-in-an-Infection 
Within the last 40 years, it has been discovered that several strains of Leishmania are 
infected with dsRNA viruses. The first of these was discovered in Leishmania braziliensis in the 
1980s, based on the presence of a large RNA species associated with virus-like particles. (Tarr et 
al. 1988) Shortly thereafter, other virus strains were discovered in L. braziliensis, L. guyanensis, 
and L. major. (Widmer et al. 1989; Scheffter et al. 1995; Cadd et al. 1993) These viruses were all 
grouped into a new genus, Leishmaniavirus, within the family Totiviridae. Totiviruses are 
defined by their single-segmented dsRNA genomes (Figure 1), which encode a capsid protein 
and an RNA-dependent RNA polymerase (RDRP). To aid in subsequent Leishmaniavirus 
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screening efforts, we have developed a suite of additional methods for identifying 
Leishmaniavirus in parasites. These approaches are described in detail in Chapter 2. (Zangger et 
al. 2013) Most notably, we optimized dot-blot and slot-blot assays utilizing antibodies raised 
against dsRNA, which allowed us to detect the dsRNA viral genome in a sequence-independent 
manner. This technique may be suitable for use in the field to analyze clinical isolates of 
Leishmania. Subsequent large-scale screening in the Beverley laboratory has shown that 
approximately 30% of clinical isolates from South America contain Leishmaniavirus 
(unpublished). 
Members of the genus Leishmaniavirus are divided into two species, Leishmania RNA 
Virus 1 and 2 (LRV1 and LRV2), on the basis of sequence divergence and genome arrangement 
(Figure 2). LRV1 includes multiple genetically similar virus strains that have been identified in 
various isolates of L. guyanensis and L. braziliensis. LRV2 has only been found in a few isolates 
of L. major and L. aethiopica. (Zangger et al. 2014; Scheffter et al. 1995). The most notable 
difference between LRV1 and LRV2 is the relative reading frames of the capsid and RDRP 
genes‟ open reading frames (ORFs). In LRV1 the RDRP ORF is shifted +1 relative to the capsid 
ORF, a feature which has been previously observed for a few other members of the Totiviridae 
family.(Stuart et al. 1992; Scheffter et al. 1994; Dinman et al. 1991) The LRV2 strain isolated 
from L. major has both ORFs in the same reading frame, separated by a stop codon. (Scheffter et 
al. 1995) The other LRV2 strain, from L. aethiopica, has a -1 frameshift. (Zangger et al. 2014) 
The significance of these various ORF arrangements is unclear. Leishmaniavirus is only 
transmitted vertically from mother to daughter cells during cell division. This results in specific 
virus-host pairings where each infected Leishmania strain has a corresponding Leishmaniavirus 
strain.(Widmer and Dooley 1995) The best-studied of these virus strains, LRV1-Lgy-M4147, 
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infects L. guyanensis MHOM/BR/75/M4147.(Scheffter et al. 1994) Most of the experiments 
described in this dissertation make use of this particular model LRV1 strain and its 
corresponding Leishmania strain.  
More recently, screening of Leishmania isolates for unknown large dsRNA species has 
led to the discovery of another, unrelated virus genus, Leishbunyavirus (LBV). LBV is a tri-
segmented negative sense single-stranded RNA virus in the bunyavirus family. We have found 
that LBV is both more common than LRV and more effective at increasing pathology and 
parasite burden in mouse models of leishmaniasis. Thus, LBV may ultimately prove to be more 
clinically relevant than LRV1. In Appendix A I describe preliminary work on a drug screen 
allowing LBV inhibitors to be identified at the same time as Leishmania and LRV1 inhibitors. 
1.3 – Leishmaniavirus Life Cycle Depends on its RNA Polymerase 
With the exceptions of the genus Giardiavirus (Miller et al. 1988) and an unclassified 
Totivirus infecting Atlantic salmon,(Lovoll et al. 2010) Totiviruses are non-infectious and their 
entire life-cycle is intracellular. Viruses are only passed between cells during mating and cell 
division.(Wickner et al. 2013) Recent work by our collaborator, David Sacks, has confirmed this 
for LRV2, which can be passed between L. major strains during mating in the sand fly midgut. 
(Owens, Lye, Inbar, Akopyants, Sacks, Beverley; unpublished data) Congruency of the virus and 
parasite phylogenetic trees suggests that the members of Leishmaniavirus have been transmitted 
vertically for more than 50 million years, prior to the divergence of the Old and New World 
Leishmania species.(Widmer and Dooley 1995) The persistence of LRV infection is such that, 
prior to this work, LRV+ parasites in culture had only been observed to lose their infection on 
one occasion, and this has not been replicated despite direct efforts to eliminate the virus.(Ro et 
al. 1997) Furthermore, attempts to directly electroporate purified virions into different 
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Leishmania strains have only yielded very transient infections where the virus is quickly lost. 
This suggests strong host-virus specificity. (Armstrong et al. 1993) Interestingly, the number of 
viruses per parasite cell appears to be tightly regulated. (Weeks et al. 1992) The mechanism 
behind this regulation has not yet been conclusively determined. In Chapter 3 of this dissertation, 
we quantified the normal virus titer to be 15±0.9 virions per cell.  
As a member of the family Totiviridae, the Leishmaniavirus lifecycle (Figure 3) is similar 
to that of the type species and best-characterized member of this family, the L-A virus from 
Saccharomyces cerevisiae. (Wickner et al. 2013) Electron microscopy of other Totiviruses 
suggests that the over-all virion structure is largely conserved throughout the family.(Parent et al. 
2013; Dunn et al. 2013) Mature virions contain the dsRNA viral genome plus 1-3 RDRPs, 
possibly as capsid-RDRP fusion proteins. Capsid-RDRP fusions have been observed in other 
members of the family Totiviridae. The overlap of the LRV capsid and RDRP ORFs, combined 
with the absence of a Kozak sequence for the RDRP gene and a sequence in the overlap region 
that is known to cause ribosomal frameshifting, support such a mechanism for LRV, although 
this has never directly demonstrated.(Lee et al. 1996) However, a related translation stop-start 
mechanism is known to occur in other Totivirus species. (Dinman et al. 1991; Parent et al. 2013) 
None of the high-resolution Totivirus virion structures solved to date include the RDRP 
structure, likely because the RDRP is present at only a few copies per virion.  As a result, its 
average occupancy of any one vertex would be too low for it to appear in complete virion 
structures.(Parent et al. 2013; Naitow et al. 2002; Dunn et al. 2013; Janssen et al. 2015) The 
RDRPs transcribe the dsRNA genome to create new positive-sense viral genomic transcripts, 
extruding them out of the virion.  
8 
 
These transcripts are then translated by the Leishmania ribosome to produce capsid and 
RDRP for constructing new virions. L-A virus “snatches” caps from cellular mRNAs to install 
on a fraction of its own transcripts, allowing for standard cap-dependent translation.(Fujimura 
and Esteban 2011) Interestingly, early work on LRV1 found that most viral genomes terminated 
in a phosphate group on their 5' ends, suggesting that LRV1 may not snatch caps, but capped 
viral genomes and cap-snatching activity have not been directly assayed.(Widmer et al. 1989) 
However, LRV does contain an internal ribosome entry site (IRES) in its 5' untranslated region 
(UTR) which may allow it to be translated in the absence of a 5' 7mGppp cap.(Stuart et al. 1992; 
Maga et al. 1995)  
Once translated, the capsid monomers and capsid-RDRP fusion complex self-assemble to 
form a new virion. Evidence from the L-A virus literature suggests that newly synthesized 
capsid-RDRP fusions bind free positive-sense viral transcripts and package them into new 
virions. In L-A virus, this is mediated by a conserved RNA stem-loop structure near the 3' end of 
the positive strand of its genome, but no experiments have probed the corresponding sequence in 
LRV.(Esteban et al. 1988) Once packaged into a virion, the RDRP recognizes a replication 
signal near the 3' end of the packaged positive-sense viral genomic RNA and replicates it to 
produce the mature dsRNA genome.(Weeks et al. 1992; Esteban et al. 1989) Interestingly, the 
LRV capsid protein contains an endonuclease activity which cleaves the viral genome at a 
specific site, likely destroying it.  This is thought to play a role in controlling the viral titer, 
although the lack of a reverse genetic system for LRV1 has prevented direct proof.(Ro and 
Patterson 2000; Ro et al. 2004; Ro and Patterson 2003; MacBeth et al. 1997; Macbeth and 
Patterson 1998; MacBeth and Patterson 1995) 
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1.4– LRV has Clinical Relevance 
When they were first discovered, the biological significance of LRV1 and LRV2 was 
unclear. One isogenic pair of infected and uninfected parasites was fortuitously generated, but 
the parasites' phenotypes in culture were identical, with no apparent effect on growth or 
viability.(Ro et al. 1997)  However, in 2011 our lab, in collaboration with Dr. Fasel's group, 
demonstrated that the presence of LRV1 in parasite strains is correlated with the severity of 
disease caused by those strains. In a mouse model of leishmaniasis, LRV-positive parasites 
induce a TLR3-dependent type I interferon response more typical of viral infection than parasite 
infection. The mice show a significantly greater parasite burden and more frequent metastasis 
from the infected footpad to the tail. TLR3 is an innate immune sensor of dsRNA located in the 
endosomal compartment. (Jensen and Thomsen 2012) Since Leishmania parasites take up 
residence in host macrophage endosomes, we theorize that macrophages kill parasites early in 
infection and liberate the LRV1 dsRNA genome. This would be detected by TLR3 and initiate 
the innate immune responses to viral infection. This response includes up-regulation of pro-
inflammatory cytokines, such as TNF-α and IL-6, and the type-1 interferon IFN-β. These 
signaling molecules would then induce inflammation and exacerbate disease severity. (Ronet et 
al. 2011; Hartley et al. 2012; Ives et al. 2011) Subsequent work has shown that this increased 
disease phenotype can be replicated by co-infecting mice with LRV1-negative Leishmania and a 
murine virus known to induce type I interferon. It can also be replicated by stimulating type I 
interferon directly in Leishmania-infected mice.(Rossi et al. 2017) Intriguingly, LRV1-dependent 
immune effects can be blocked by immunizing mice with the LRV1 capsid protein.(Castiglioni 
et al. 2017) This suggests that it may be possible to block the deleterious effects of LRV1 in 
human leishmaniasis by inhibiting LRV1 or immunizing against it. 
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Although this mechanism of immune modulation by a protozoan virus was novel at the 
time, it has since been observed in Trichomonas infections. Some strains of Trichomonas are 
infected by Totiviruses from the closely-related Trichomonasvirus genus.(Goodman et al. 2011a; 
Janssen et al. 2015; Bessarab et al. 2000; Parent et al. 2013; Liu et al. 1998; Goodman et al. 
2011b)  As with Leishmania, these strains induce a more severe disease phenotype.(El-Gayar et 
al. 2016; Wendel et al. 2002; Fraga et al. 2007; Fichorova et al. 2012)  
Following the discovery of LRV1-dependent disease exacerbation in mice, multiple 
groups searched for a corresponding effect in human leishmaniasis. In collaboration with several 
other groups, we showed that the presence of LRV1 in L. guyanensis correlates with the severity 
of CL.(Hartley et al. 2016) Related work has shown that the presence of LRV1 increases 
treatment failure and relapse rates in L. guyanensis and L. braziliensis cases.(Adaui et al. 2015; 
Ito et al. 2015; Cantanhede et al. 2015; Bourreau et al. 2015) Initially, we suspected that LRV1 
would be strongly linked to MCL, given the vigorous inflammatory response characteristic of 
that form of leishmaniasis. However, although some studies found that LRV1-positive strains 
generate higher rates of MCL (Hartley et al. 2014; Cantanhede et al. 2015; Bourreau et al. 2015), 
other studies failed to identify a correlation.(Adaui et al. 2015; Periera et al. 2013) In mouse 
models of leishmaniasis, LRV1 has a more substantial effect on parasite number than on host 
immune response. Since MCL is believed to depend more on host immune responses than on 
parasite load, one would expect that the correlation between LRV1 and MCL would be weaker 
than the one between LRV1 and CL severity.(Hartley et al. 2014; Banuls et al. 2011; Mears et al. 
2015; Goto and Lindoso 2010; Guerra et al. 2011) 
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1.5 – Purine Metabolism in Leishmania: an Enticing Drug Target 
Given the importance of LRV1 as a determinant of leishmaniasis severity, we began 
developing methods to eliminate it from parasites. Initially, we utilized the RNAi pathway 
present in Leishmania (Viannia) species to knock down and eventually eliminate LRV1. This 
was accomplished by introducing a strongly transcribed stem-loop construct containing LRV1 
sequences into LRV1-positive parasites. The large amount of dsRNA produced would be 
processed by the RNAi pathway and used to target and degrade viral RNAs. This method was 
successful, but also cumbersome and unsuitable for use in the clinic. (Brettmann et al. 2016) We 
then turned to small molecule anti-viral drugs. Since the LRV1 RDRP is the main driver of viral 
replication, we focused on nucleoside analogs, which are the most common class of RNA 
polymerase inhibitors. 
Another reason to investigate nucleoside analog LRV1 inhibitors is that Leishmania 
parasites are purine auxotrophs, and thus avidly scavenge purine nucleosides and nucleobases 
from the extracellular milieu. These salvage pathways make obvious targets for small molecule 
Leishmania inhibitors. This approach has been partially successful – allopurinol, an analog of 
hypoxanthine, is selectively phosphorylated by the Leishmania purine salvage pathway and 
incorporated into parasite RNAs, where it is thought to exert its toxic effects. (Marr 1983) 
Allopurinol can be used to treat leishmaniasis in humans.(Martinez and Marr 1992; Marr and 
Berens 1977) However, associated side-effects have limited the practical use of allopurinol to 
treatment of leishmaniasis in dogs, an important reservoir species in South America. (Reguera et 
al. 2016) More recent efforts have revealed that a class of nucleoside analogs called immucillins 
can inhibit Leishmania parasites and treat leishmaniasis in a mouse model of infection.(Freitas et 
al. 2015a) In vitro experiments show that these compounds act on a non-specific nucleoside 
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hydrolase that is key to the nucleoside salvage pathways, but other “off-target” effects may 
account for their potency against parasites in vivo.(Shi et al. 1999; Freitas et al. 2015b) These 
compounds have not yet been employed against human leishmaniasis. 
The Leishmania purine salvage pathway is a tightly-interconnected network of enzymes 
capable of converting every standard nucleoside into any other (Figure 4).(Boitz and Ullman 
2013; Carter et al. 2008) Extracellular nucleotides are scavenged by multiple extracellular 
phosphatases and nucleotidases that hydrolyze them to the nucleoside level prior to 
uptake.(Freitas-Mesquita and Meyer-Fernandes 2014) Parasites express multiple transporters 
with varying specificities that import the nucleosides.(Sanchez et al. 2004; Aronow et al. 1987) 
Nucleosides entering the parasite are initially degraded to nucleobases before entering the 
salvage pathway. This is accomplished by a number of nucleoside hydrolases, including a non-
specific enzyme that acts on all naturally occurring purine and pyrimidine nucleosides. (Shi et al. 
1999; Cui et al. 2001) The nucleobases are then converted to nucleoside monophosphates via 
combination with phosphoribosyl pyrophosphate.(Boitz and Ullman 2006) Salvage of adenosine, 
unlike the other nucleosides, can also proceed directly from adenosine to adenosine 
monophosphate via an adenosine kinase enzyme.(Datta et al. 1987; Bhaumik and Datta 1988; 
Iovannisci and Ullman 1984) However, most adenosine is instead hydrolyzed to adenine and 
then converted to hypoxanthine by adenine aminohydrolase.(Boitz et al. 2012) The core of the 
purine salvage network is a set of enzymes that interconvert nucleoside monophosphates to 
balance the adenylate and guanylate nucleotide pools.(Boitz et al. 2016) These are localized in 
the glycosome, an organelle unique to Leishmania and its relatives.(Shih et al. 1998; Colasante et 
al. 2013; Opperdoes and Szikora 2006) 
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1.6– Aims and Scope 
Given that the presence of LRV1 in human leishmaniasis cases significantly increases 
disease severity and negative treatment outcomes, an inhibitor of LRV1 replication could be 
useful in the clinic. The primary aim of this work is to identify such inhibitors, determine their 
modes of action, and suggest ways to improve their potency. 
Before setting out to identify LRV1 inhibitors, I developed a method for efficiently 
measuring the amount of dsRNA in Leishmania cells (Chapter 2). Since LRV accounts for most 
dsRNA in LRV+ parasites, this allowed me to estimate the amount of LRV1 per 
parasite.(Zangger et al. 2013) Using this technique and a previously-developed flow cytometry 
assay of LRV1 capsid levels, Dr. F. Matthew Kuhlmann and I screened a panel of purine analogs 
for activity against LRV1. In Chapter 3, I describe the screen and the two effective inhibitors we 
identified, 2‟-C-methyl-adenosine (2CMA) and its close relative 7-deaza-2CMA (7d2CMA). 
Using these drugs, we were able to cure Leishmania cultures of LRV1. 
Next, I investigated the mechanism of action of 2CMA. Because 2CMA and 7d2CMA 
are adenosine analogs known to inhibit the Hepatitis C virus RDRP, I hypothesized that the drug 
triphosphate (2CMA-TP) would inhibit the LRV1 RDRP.(Carroll et al. 2003; Olsen et al. 2004) 
In Chapter 4, I describe experiments which demonstrate that 2CMA-TP is the active form of 
2CMA and that it inhibits the LRV1 RDRP. Unexpectedly, the IC50 of 2CMA-TP in vitro was 
much higher than the EC50 of 2CMA in vivo. I show that this occurs because the parasites 
accumulate high concentrations of 2CMA-TP. Appendix A describes preliminary genetic and 
pharmacological manipulations I performed with the goal of improving the nucleoside analog 
sensitivity of L. guyanensis enough to enable testing their efficacy in our murine leishmaniasis 
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model. Appendix B contains pharmacokinetic calculations for 7d2CMA, plus several 
experimental options for testing the effects of treating LRV1 in mice with 7d2CMA. 
The work summarized herein contributes to our ability to study the effects of LRV1 on 
Leishmania and on host immune responses to Leishmania by allowing us to quickly and easily 
eliminate LRV1 from parasites. The unexpected role of purine salvage in the effectiveness of 
2CMA provides insight into the importance of that pathway in drug design for Leishmania. 
Forthcoming experiments in our mouse model of leishmaniasis should determine whether 
chemotherapy of LRV1 would improve disease progression. Ultimately, this knowledge may 
enable the development of anti-LRV1 therapies capable of improving treatment outcomes in 
human leishmaniasis, whether by vaccination or inhibition with nucleoside analogs. 
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1.8 – Figures 
 
Figure 1-1: Genome of LRV1 from L. guyanensis M4147.  
The 5' untranslated region (UTR) can function as an internal ribosome entry site (IRES). 
In this strain, the RDRP open reading frame is shifted +1 relative to the capsid. 
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Figure 1-2: Genomic arrangement and phylogeny of LRV strains.  
The tree was constructed with ClustalX in UPGMA mode, using L-A virus as an out-
group (not shown)(Larkin et al. 2007). The bars illustrate the coding frame of the RDRP open 
reading frame (black) relative to the capsid (white). 
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Figure 1-3: LRV life cycle.  
The RDRP (black trapezoid) transcribes the mature dsRNA genome to produce the 
positive-sense transcript (red), which is extruded from the viral capsid. The host ribosome 
translates the transcript, producing new capsid monomers (circles) and capsid-RDRP fusion 
proteins. Note that for LRV the fusion protein is hypothetical and has not been observed in vivo. 
These assemble to form a new virion, packaging a viral transcript. The RDRP replicates the viral 
transcript, forming the negative-sense strand (blue) and resulting in a new mature virion.  
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Figure 1-4: Leishmania purine salvage pathway. 
 
Diagram is based on data from the KEGG database and visualized in 
VANTED.(Kanehisa et al. 2017; Rohn et al. 2012) Compounds are unboxed text and enzymes 
are boxed. Nucleosides (bottom row) are taken up into Leishmania cells where they are 
hydrolyzed by a nucleoside hydrolase (NH) to nucleobases. Nucleobases are converted to 
nucleoside monophosphates by various phosphoribosyl transferase (PRT) enzymes. From here a 
host of enzymes facilitates interconversion between the adenylate and guanylate nucleotide 
pools. Note that adenosine can be directly phosphorylated by adenosine kinase (AK). 
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2.1 – Abstract 
2.1.1 – Background 
Patients suffering from cutaneous leishmaniasis (CL) caused by New 
World Leishmania(Viannia) species are at high risk of developing mucosal (ML) or disseminated 
cutaneous leishmaniasis (DCL). After the formation of a primary skin lesion at the site of the bite 
by a Leishmania-infected sand fly, the infection can disseminate to form secondary lesions. This 
metastatic phenotype causes significant morbidity and is often associated with a hyper-
inflammatory immune response leading to the destruction of nasopharyngeal tissues in ML, and 
appearance of nodules or numerous ulcerated skin lesions in DCL. Recently, we connected this 
aggressive phenotype to the presence of Leishmania RNA virus (LRV) in strains of L. 
guyanensis, showing that LRV is responsible for elevated parasitaemia, destructive hyper-
inflammation and an overall exacerbation of the disease. Further studies of this relationship and 
the distribution of LRVs in other Leishmania strains and species would benefit from improved 
methods of viral detection and quantitation, especially ones not dependent on prior knowledge of 
the viral sequence as LRVs show significant evolutionary divergence. 
2.1.2 – Methodology/Principal Findings 
This study reports various techniques, among which, the use of an anti-dsRNA 
monoclonal antibody (J2) stands out for its specific and quantitative recognition of dsRNA in a 
sequence-independent fashion. Applications of J2 include immunofluorescence, ELISA and dot 
blot: techniques complementing an arsenal of other detection tools, such as nucleic acid 
purification and quantitative real-time-PCR. We evaluate each method as well as demonstrate a 
successful LRV detection by the J2 antibody in several parasite strains, a freshly isolated patient 
sample and lesion biopsies of infected mice. 
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2.1.3 – Conclusions/Significance 
We propose that refinements of these methods could be transferred to the field for use as 
a diagnostic tool in detecting the presence of LRV, and potentially assessing the LRV-related 
risk of complications in cutaneous leishmaniasis. 
2.1 – Introduction 
Leishmaniasis is one of the most important human protozoan parasitic diseases 
worldwide, with a prevalence of 12 million infections and a further 350 million people living at 
risk across 98 countries [1], [2]. It mainly presents in two major clinical forms: 1) cutaneous 
leishmaniasis (CL) in which lesions are generally localized and self-healing or 2) visceral 
leishmaniasis (VL) known to fatally disseminate to viscera. CL can be caused by various species, 
either from the Leishmania (Leishmania) subgenus (e.g. L. major, L. mexicana and L. 
amazonensis) or members of the L. (Viannia) subgenus (e.g. L. braziliensis, L. 
panamensis and L. guyanensis), while VL is mostly attributed to L. donovani, L. infantum and L. 
chagasi. Beyond the intrinsic parasite factors that seem to determine disease phenotype, extrinsic 
factors within the host are also known to alter the symptomatic spectrum of leishmaniasis [3]. 
In South America, CL patients mainly infected by L. braziliensis, L. panamensis and L. 
guyanensis are at risk for developing mucosal (ML) or disseminated cutaneous leishmaniasis 
(DCL) [3], [4], [5], [6], which are complications of CL involving dissemination of parasites from 
primary lesions to secondary sites, with or without mucosal involvement, and causing lesions 
that are often associated with a highly destructive inflammatory response [7], [8], [9], [10]. 
Mucosal disease is notorious for its poor response to commonly used treatments, such as 
antimony, and is often complicated by secondary bacterial or fungal infections. Very little is 
known about the pathogenesis of metastatic and mucosal leishmaniasis; especially the source of 
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the uncontrolled inflammatory response observed in some patients. Two factors that have been 
associated with mucosal and disseminated disease include host genetic polymorphisms (e.g. in 
TNF, IL-6 and HLA genes) and HIV co-infection [11], [12], [13]. 
Recently, we suggested that the presence of a parasite dsRNA virus could contribute to 
the severity of the disease in strains of L. guyanensis [14], [15], [16]. This Leishmania dsRNA 
virus (LRV) has been found in various L. (Viannia) species as well as in one L. major strain [17]. 
Notably, in murine models of L. guyanensis infection, the LRV dsRNA genome is innately 
recognized by host Toll-like-receptor (TLR3), exacerbating the disease in a dose-dependent 
manner [14], [15]. 
Leishmania has a digenetic life cycle, with a motile extracellular promastigote form in the 
midgut of a female sand fly, and a non-motile intracellular amastigote form in the mammalian 
host macrophage. Our model proposes that the innate recognition of LRV takes place in the first 
few hours of infection. Here, some fraction of parasites die, releasing viral dsRNA that then 
binds to Toll-like receptor 3 (TLR3) trigging the subsequent IFN-type I driven inflammatory 
cascade that worsens disease [14], [18]. A high LRV burden in infecting parasites could 
therefore be a major determinant of disease severity and pathology. 
LRV is a member of the Totiviridae family that regroups viruses found in several 
kingdoms of life [16], including protozoan parasites such as Giardia, Trichomonas vaginalis, 
fungi such as Helminthosporium sp. and S. cerevisiae as well as mosquitoes [19] and 
salmon [20]. They are small and simple virions (30–50 nm), containing a dsRNA genome that 
encodes its single capsid protein and an RNA-dependant RNA polymerase (RdRp), necessary 
and sufficient for both viral genomic dsRNA replication and viral ssRNA transcription. Viral 
transcripts are translated in the host cell cytoplasm into a capsid protein and, in most Totiviridae, 
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into a fusion capsid-RdRp polypeptide (82 kDa and 176 kDa respectively). According to detailed 
studies in yeast, a single virion is composed of more than a hundred capsid protein molecules 
and one to two capsid-RdRp subunits surrounding the single genomic dsRNA molecule [21]. 
LRVs were identified and characterized several years ago 
in L. (Viannia) braziliensis and guyanensis [22], [23], [24] as well as in a single isolate of L. 
major [17]. Although their genomic organization is identical, high diversity in nucleotide 
sequence (less than 40% homology according to [17]) between LRVs of L. (Viannia) and L. 
major has categorized Leishmania viruses into the groups LRV1 and LRV2 respectively [17]. 
An important finding from our prior work is that only parasites with high levels of LRV 
exacerbated disease severity [14], [15], and previous studies have shown that considerable 
diversity in sequence is found amongst LRVs [17]. Studies looking into the role of LRV would 
thus be greatly aided by the availability of diverse methods for LRV detection and quantification, 
especially simple, rapid and reliable techniques, suitable for screening a large number of parasite 
strains in the field. To this end, we used parasite strains bearing different levels of LRV as 
standards [14]. Reliable detection and quantification was achieved by dsRNA extraction, 
quantitative real-time PCR (qRT-PCR) as well as with the immuno-detection of LRV genome in 
lysed, fixed or live parasite samples (ELISA, dot blot and fluorescence microscopy). Although 
qRT-PCR can be used efficiently and is a powerful method for detailed molecular studies on 
reference strains, it could have limited application for LRV screening on uncharacterized 
parasites from the field due to possible nucleotide and amino acid polymorphisms of LRVs. This 
problem was addressed by focusing on detection of dsRNA through the use of an anti-dsRNA 
monoclonal antibody (J2), which specifically recognizes dsRNA independent of its underlying 
nucleotide sequence. We applied this approach on several catalogued human isolates, on a 
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fresh L. braziliensis sample obtained from a patient as well as on murine lesions biopsies, 
showing the relative ease of use of these methods for field application. We propose the technique 
as having great diagnostic potential for predicting the LRV-related risk of leishmanial 
dissemination.  
2.2– Methods 
2.2.1 – Ethical statement 
This study was approved by the Ethics Committee of Canton of Vaud, Lausanne 
(Switzerland) for the analysis of Leishmania parasites isolated from patients. The two L. 
braziliensis parasites strains (MHOM/BO/2011/2169 and MHOM/BO/2011/2192) were isolated 
from a L. braziliensisinfected patient, who signed an informed consent accepting the use of 
materials for publication. Other Leishmania parasite strains used in this study are common lines 
isolated several years ago and described in several reports. 
2.2.2 – Parasite strains and cultures 
Different L. guyanensis reference strains of known LRV content [14] were used: i) two 
clones derived from the M4147 population (MHOM/BR/75/M4147) infected or not by LRV 
designated here as Lg M4147 LRVhigh (M4147/SSU:IRSAT-LUC(b)) and Lg M4147 
LRVneg(M4147/pX63HXG/SSU:IRSAT-LUC(b)) respectively [25], ii) human isolates of L. 
guyanensis Lg1398 (MHOM/BR/89/IM3597) and Lg 1881 (MHOM/BR/92/IM3862) and iii) L. 
guyanensisM5313 parasites (WHI/BR/78/M5313) and their derived non-metastatic (Lg 03 
and Lg 17) or metastatic (Lg 13 and Lg 21) clones [14], [26]. Five human isolates of L. 
braziliensis, previously shown to be LRV-infected [24], were also analyzed: 
MHOM/CO/88/1407C (Lb 1407C), MHOM/CO/88/1407M (Lb 1407M), MHOM/CO/88/1403 
(Lb 1403), MHOM/CO/86/1174 (Lb1174) and MHOM/CO/84/1064 (Lb 1064). Two strains of L. 
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braziliensis parasites were freshly isolated from an infected patient who contracted 
leishmaniasis: MHOM/BO/2011/2169 (from primary cutaneous lesion) and 
MHOM/BO/2011/2192 (from secondary/metastatic lesion), referred to in the text as Lb 2169 
and Lb 2192. 
Parasites were cultivated as promastigotes at 26°C in freshly prepared Schneider's insect 
medium (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (PAA), 10 mM 
Hepes (Amimed), 50 U/ml penicillin/streptomycin (Amimed), 0.6 mg/L biopterin (Sigma) and 5 
mg/L hemin (Sigma). 
2.2.3 – Viral dsRNA extraction from total nucleic acids 
Stationary phase Leishmania promastigotes were lysed for 20 min at RT with 0.4% 
sarkosyl and protease inhibitors (Roche) diluted in 1×PBS (108 parasites in 100 µl). The lysates 
were then incubated at 37°C, first for 30 min with 400 µg/ml of recombinant proteinase K 
(Roche), then for a further 2 h with 10 µg/ml RNase (DNase-free from Roche). Nucleic acids, 
containing genomic parasitic DNA and LRV dsRNA, were extracted from these lysates by 
phenol-chloroform (at least twice), precipitated with 0.3 M sodium-acetate in 70% ethanol, then 
washed and resuspended in water (approx. 20 µl for 108 parasites). DNA was quantified by 
spectrophotometry (Nanodrop). Pure viral dsRNA was obtained after RQ-DNase digestion 
according to manufacturer's instruction (Promega). Nucleic acids were analysed on 0.6% to 1.2% 
agarose gels containing SYBR-safe for nucleic acid staining (Invitrogen). 
2.2.4 – Quantitative real-time PCR (qRT-PCR) 
RNA was extracted from stationary phase promastigotes (approx. 3×107) using Trizol 
(Invitrogen) according to manufacturer's instruction (1 ml Trizol for a 1 ml promastigote 
culture). After extraction, precipitation and washing, RNA was resuspended in water 
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(3×107 parasites in 10 µl) and quantified by spectrophotometry. 0.5–1 µg of RNA was then used 
for cDNA synthesis with SuperScript II Reverse Transcriptase (Invitrogen), which was finally 
purified with a QIAquick PCR purification kit (Qiagen). qRT-PCR was undertaken in a reaction 
solution of 0.5 µM primer diluted in SYBR Green Master mix (LightCycler 480 system, Roche). 
The reaction consisted of an initial denaturation at 95°C for 5 min followed by 40 cycles of 
amplification: 10 s at 95°C, 10 s at 60°C, 10 s at 72°C and a fluorescence detection step at 78°C 
to quantify the amplified DNA after each cycle. The following DNA oligonucleotides 
(Microsynth, Switzerland) were used: SetA: 5′-CTG ACT GGA CGG GGG GTA AT-3′ and 5′-
CAA AAC ACT CCC TTA CGC-3′/SetB: 5′-GTC TGT TTC GTA CCC GCC G-3′ and 5′-AAG 
CTC AGG ATG TGC ATG TTC CA-3′/kmp11 specific primers: 5′-GCC TGG ATG AGG AGT 
TCA ACA-3′ and 5′-GTG CTC CTT CAT CTC GGG-3′. SetA and SetB were based on LRV1-4 
genome sequence (GenBank accession number: NC003601) and L. major kmp11 gene as 
described previously [14]. LRV transcript levels were quantified in triplicate relative to 
the Leishmania kmp11 housekeeping gene. Analysis and acquisition of data were performed with 
the LightCycler software 1.5 (Roche) using the 2−ΔΔCT method. 
2.2.5 – Anti-capsid antibody production and immunoblotting 
The LRV capsid open reading frame was amplified from a cDNA preparation 
of Lg M5313 and cloned in a pET-28a E. coli expression vector (Merck). Its sequence was found 
to be highly similar to the capsid sequence of Lg M4147 LRV1-4 (more than 98% identical 
residues, Genbank accession number: JX313126). Recombinant capsid was purified, using a 
HIS-tag, then used for rabbit immunization (Covalab, polyclonal antibody identification code: 
g018d53). Proteins from total parasite extracts were quantified by BCA, 40 µg was loaded and 
separated on a 10% polyacrylamide denaturing gel, transferred to a nitrocellulose membrane and 
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vizualised by Ponceau Red staining. After a 1 h blocking step in 5% powdered milk diluted in 
TBS+0.05% Tween20, the membrane was incubated overnight at 4°C with the g018d53 anti-
capsid polyclonal antibody (1∶5000 in 1% milk TBS-Tween20). Following 4 washes of 15 min 
at RT, the membrane was incubated for 1 h with an anti-rabbit IgG antibody coupled to 
peroxidase (Promega) (1∶2500 in 1% milk TBS-Tween20), washed again 4× and finally revealed 
by ECL chemiluminescence (Amersham). 
2.2.6 – Peptide arrays on cellulose membranes and epitope mapping 
For antibody epitope screening, seventy-four 20-mer overlapping peptides (with an 
overlap of 10 residues) that cover the whole sequence of Lg M4147 LRV1-4 capsid (Genbank 
accession number: NC003601) were synthesized and attached to cellulose membranes by the 
Protein and Peptide Chemistry Facility (University of Lausanne). 
The peptides were synthesized by using Intavis MultiPep synthesizer (Intavis 
Bioanalytical Instruments AG, Cologne, Germany). The cellulose membrane used was an 
Amino-PEG500-UC540 sheet (acid-hardened with improved stability). The membrane peptide 
linker was stable in wide range of aqueous pH (pH 0–pH 14) at ambient temperature for 12 
hours. The PEG spacer consisted of 8–10 ethylene glycol units and had free terminal amino 
groups to start the peptide synthesis. The Amino- PEG500 spacer was loaded at 400 
nmol/cm2 with a typical spot diameter of 4 mm and therefore an average of 50 nmol 
peptide/spot. The peptides were synthesized by stepwise solid phase synthesis. Amino acids that 
had N-terminal/side-chain protecting groups were spotted (if required) by robot. The amino acid 
solutions were activated using diisopropylcarbodiimide/hydroxybenzatriazole chemistry. For 
each cycle, solutions of the 20 common amino acids were dispensed along with solutions of 
modified amino acids as required (e.g. phosphorylated amino acids, acetylated amino acids, 
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methylated amino acids). Following addition of the first amino acids, the membranes were 
treated to prepare the spots for the next in sequence. This was done by removing the N-terminal 
protective group (Fmoc) by piperidine. This cycle was repeated until the peptides reached the 
required length. Arrays were then treated with trifluoroacetic acid to reveal the native side 
chains. Arrays were stored at −20°C prior to use. 
Similarly to the classic nitrocellulose membranes as described above, these peptide-
spotted membranes were incubated with the g018d53 anti-capsid polyclonal antibody (1∶5000) 
to allow the determination of the epitopes for which it was specific. 
2.2.7 – LRV sequencing 
Lg 1398 LRV genome was partially sequenced as follows: first, viral dsRNA was 
obtained from approximately 109 stationary phase promastigotes after total nucleic acids 
extraction and RQ-DNase digestion of genomic DNA (see “Viral dsRNA extraction from total 
nucleic acids” section) and purification of the 5.3 kb band after 0.8% agarose gel electrophoresis 
using Wizard SV gel and PCR clean-up system (Promega). Viral cDNA was then synthesized as 
described above (“Quantitative real-time PCR” section) and 10–50 ng was used for PCR 
amplification with 0.4 µl of GoTaq DNA polymerase (Promega) in its buffer supplemented with 
Q solution (Qiagen), 0.4 mM dNTPs (Promega) and 0.3 µM of each oligonucleotides 
(Microsynth, Switzerland). The PCR reactions consisted of 35 cycles: 1 min at 94°C, 1 min at 
55°C and 2 min at 72°C. Two PCR fragments were generated and sequenced (by Fasteris, 
Switzerland) with the following oligonucleotides: i) 5′-GGA TCC GAA ACG TAA GCA AGT 
TTC TTG-3′ and 5′-CCA ATA CCA TGG CGC CAT CAC ATT CAT-3′ (based on LRV1-1 and 
1-4 sequences) and ii) 5′-GAG AAA TAG CGA TAT CGC AGC CCA A-3′ (based on Lg 1398 
LRV sequence obtained from previous reaction) and 5′-CAC AGC CAA CGT GAC GAC CAG 
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AAA TCA C-3′ (LRV1-4). These two products allowed us to obtain 3.3 kb of Lg 1398 LRV 
genome sequence including the complete open reading frame of the viral capsid. 
2.2.8 – Immunofluorescence microscopy (IFM) 
Two different protocols were used. In protocol A, stationary phase promastigotes were 
fixed with 4% formaldehyde in PBS for 20–30 min (or overnight in 1% at 4°C), washed and 
resuspended at 2×107 parasites/ml then attached to poly-lysine (Sigma) coated slides (Thermo 
Scientific) for 30 min at RT. After a 10 min permeabilization step in PBS+0.1% TritonX-100 
(PBS-TX), cells were blocked for 45–60 min in 2% bovine serum albumin (BSA, Acros 
Organics) in PBS-TX, and incubated overnight at 4°C with the rabbit g018d53 anti-capsid 
polyclonal antibody (1∶5000) or the mouse anti-dsRNA J2 antibody (1∶800, English & 
Scientific Consulting) in 1% BSA in PBS-TX. Cells were then washed 4× in PBS, incubated for 
1 h with a goat anti-rabbit IgG coupled to Alexa Fluor 594 (1∶2000, Invitrogen) or a goat anti-
mouse antibody coupled to Alexa Fluor 488 (1∶600, Invitrogen) in 1% BSA in PBS-TX. These 
were washed twice, incubated 10–30 min with 0.5 µg/ml 4′,6-Diamidino-2-phenylindole (DAPI, 
Invitrogen), washed again and finally mounted with Vectashield diluted 100× in DABCO 
mounting solution (90% glycerol, 10% PBS and 2.5% DABCO from Sigma) or using Permafluor 
(ThermoScientific). Fluorescence visualization was performed with an Upright Axio Microscope 
at the Cellular Imaging Facility (CIF Epalinges, University of Lausanne). 
In protocol B, 106 parasites were fixed with 2% paraformaldehyde in PBS for 2 min. 
Cells were washed once in PBS and adhered to glass coverslips (Fisherbrand) by centrifugation 
(500 g for 2 min). Cells were permeabilized in blocking buffer (5% normal goat sera, 0.1% 
Triton-X100, 1× PBS) for 30 min at room temperature then incubated with mouse anti-dsRNA 
J2 antibody (1∶1000) for one hour. Cells were then washed 3× in PBS and incubated with goat 
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anti-mouse IgG AlexaFluor 488 (1∶1000, Invitrogen) for one hour. After washing again in PBS 
(3×), coverslips were rinsed briefly in water and mounted using Prolong Gold (Invitrogen). 
Microsocopy was performed using Olympus AX70 microscope and images were obtained using 
QCapturePro software (Version 5.1.1.14). Image analysis was performed using Image J (1.45). 
2.2.9 – Slot blot 
5×106 parasites were resuspended at a final concentration of 5×105 cells/ml in PBS. 100 
µl were adhered to nitrocellulose membranes using Mini-fold II Slot-Blot System (Schleicher & 
Schuell, Keane, NH). The membrane was incubated in 2% powdered non-fat milk for 1 h, then 
with mouse anti-dsRNA J2 antibody (1∶2000) and polyclonal rabbit anti-histone H2A (1∶2000; 
Wong and Beverley, in preparation) in 2% milk plus 0.2% Tween 20 for 1 h. The membrane was 
washed in 1×PBS plus 0.1% Tween 20 (PBS-T) 3× and incubated in goat anti-mouse IRDye 800 
and goat anti-rabbit IRDye 680 (1∶10000 each, Licor Biosciences, Lincoln, NE) for 1 h. The 
membrane was washed 3× in PBS-T and once in 1×PBS. Analysis was performed using the 
Odyssey Infrared Imaging System and Application Software Version 3.0.16 (LiCor Biosciences). 
The cut-off point was calculated as 3 standard deviations (S.D.) above the mean absorbance of 
the LRV negative control. 
2.2.10 – ELISA 
Stationary phase promastigotes (108 parasites/ml) were lysed in PBS+0.5% Nonidet P40 
(NP40). 20 µg of total proteins, equating to approx. 5×106 parasites (as quantified with BCA 
assay) were adhered to a 96 well plate (Thermo Scientific), which had been pre-coated with 
poly-lysine (Sigma), overnight at 4°C. After 4 washes in PBS 0.05% Tween20 (PBS-Tw20), 
lysates were blocked in assay diluent solution (eBioscience) for 2 h at RT, washed again in PBS-
Tw20, and incubated for 1 h at 37°C with the primary mouse monoclonal anti-dsRNA J2 
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antibody (1∶2000, English & Scientific Consulting). After 4 more washing steps, a secondary 
anti-mouse IgG HRP conjugated antibody (1∶2500, Promega) was added for 1 h at 37°C. Wells 
were then washed and dsRNA could be colorimetrically quantified by the addition of o-
Phenylenediamine dihydrochloride (OPD) in a phosphate citrate buffer (Sigma). The reaction 
was stopped by acidification with 0.5 M H2SO4 and measured at 490 nm with a Biotek Synergy 
HT spectrophotometer. The cut-off point was calculated as 3 standard deviations (S.D.) above 
the mean absorbance of the LRV negative control. 
2.2.11 – Dot blot 
Stationary phase promastigote pellets were resuspended in 1×PBS, and a small amount 
was lysed for BCA quantification in 0.5% NP40. Parasite samples in PBS were then adjusted to 
0.1 µg/µl of total protein and spotted onto a nitrocellulose membrane using a range of 0.5 to 4 µg 
of protein per spot (corresponding to approx. 105 to 106 parasites). To test the sensitivity of the 
method, live parasites were counted, serially diluted between a range of 10 to 1000 parasites and 
directly spotted on the nitrocellulose membrane. The membranes were then dried before 
revelation by immunodetection as described above (see “Anti-capsid antibody production and 
immunoblotting” section), using an anti-dsRNA J2 primary antibody (1∶1000, English & 
Scientific Consulting) and an anti-mouse IgG HRP conjugated secondary antibody (1∶2500, 
Promega). 
2.2.12 – Mouse infection and RNA extraction from leishmaniasis lesions 
One million stationary phase Lg M4147 LRVhigh or Lg M4147 LRVneg promastigotes 
were injected subcutaneously into the base of the hind footpad of C57BL/6 mice. Lesions were 
isolated at the peak of infection (approx. 4 weeks post-infection) and homogenized with a mortar 
and a pestle in PBS. After an initial centrifugation step to remove large debris (50 g for 2 min), 
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cell supernatant was centrifuged again (600 g for 8 min) and the pellet was directly resuspended 
in Trizol for total RNA extraction (as described in “qRT-PCR” section). Approximately 50 µg of 
RNA was obtained from each lesion (40–50 mg) and diluted in water for dot blot analysis with 
the J2 antibody (see “Dot blot” section). 
 
2.3 – Results 
In order to characterize the presence and burden of LRV in L. (Viannia) parasite 
strains viadifferent methods, we first tested four parasite isolates of varying LRV content [14]. 
Two clones derived from the L. guyanensis M4147 strain were used: Lg M4147 LRVhigh, known 
to have a high burden of LRV and Lg M4147 LRVneg in which LRV is undetectable by RT-PCR 
tests [25]. In addition, we also tested two human isolates of L. guyanensis: Lg 1398, derived from 
a metastatic lesion and known to bear high levels of LRV and Lg 1881, from a CL patient and in 
which LRV is present at a very low level (at least 10'000 fold less [14]). To best compare the 
various LRV detection techniques, each was performed on material from a single sample 
preparation (except for the slot blot). The data shown are representative of the trend gleaned 
from several independent experiments. 
2.3.1 – LRV detection by gel electrophoresis and quantitative real-time PCR 
As a starting point, LRV content was estimated using two previously used methods [14]. 
Firstly, total nucleic acids were extracted from promastigote cultures and analyzed by agarose 
gel electrophoresis. Here, a 5.3 kb band corresponding to the size of the viral dsRNA genome 
was detectable in Lg M4147 LRVhigh and Lg 1398 extracts, which was weaker in the latter 
(Figure 1A, upper panel). This band could be seen more clearly when parasite genomic DNA 
was eliminated by DNase treatment (Figure 1A, lower panel). As expected, LRV dsRNA was not 
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detectable in Lg M4147 LRVneg or in the LRVlow strain Lg 1881. Using a serial dilution of 
nucleic acids from LRV-infected parasites, we estimated that the amount of LRV dsRNA was 
approximately three to four times higher in Lg M4147 LRVhigh than in Lg 1398 (Figure 1B). 
We then quantified LRV transcript levels, after RNA extraction followed by cDNA 
synthesis, using two different primer sets that we have already successfully used for LRV 
detection in LgM4147 and Lg M5313 strains and their clonal derivatives: SetA, which amplified 
a 124 nucleotide fragment on the 5′-end of the viral RNA (nucleotide 153 to 277 of the LRV1-4 
sequence) [14], and SetB, which amplified a 103-nucleotide fragment in the RdRp open reading 
frame (nucleotide 3591 to 3694 of LRV1-4). Quantitative RT-PCR was performed and 
normalized to both the amplification obtained from the conserved kmp11 housekeeping gene and 
the signal obtained from Lg M4147 LRVhigh. With the SetA primers, Lg 1398 showed nearly half 
the LRV transcripts than Lg M4147 LRVhigh, while the Lg M4147 LRVneg line and Lg 1881 
showed no detectable LRV product. Notable is that no product was obtained with the SetB 
primers from Lg 1398 despite having high levels of LRV (Figure 1B vs Figure 1C). Preliminary 
sequencing data of the Lg 1398 LRV RdRp open reading frame explained this negative result (H. 
Zangger, unpublished data), and illustrated a potential problem of a PCR-based approach for 
LRV screening in uncharacterized parasites. 
2.3.2 – LRV detection by a capsid-specific antibody 
Detection of LRV can also be performed via the recognition of viral proteins [27]. A 
high-affinity rabbit polyclonal antibody (g018D53) was raised against the capsid polypeptide 
of Lg M5313 LRV (>98% identical to Lg M4147 LRV1-4, Genbank accession number: 
JX313126) and then tested on control strains by immunoblotting and fluorescence microscopy. 
With both techniques, LRV detection was achieved in Lg M5313 (and its derivative 
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LRVhigh clones, Lg 13 and Lg 21; data not shown) as well as in Lg M4147 LRVhigh, showing a 
strong staining throughout most of the cytosol of promastigotes (Figures 2A and 2B). As 
expected, no staining was visible in Lg 17 (LRVlow derivative clone of Lg M5313), Lg M4147 
LRVneg and Lg 1881, but neither in the LRV-infected human isolate Lg 1398 which is probably 
due to LRV sequence diversity. Partial Lg 1398 LRV sequencing was performed and surprisingly 
revealed a high identity of its capsid as compared to Lg M4147 throughout the entire open 
reading frame (91% identical residues, Genbank accession number: JX313127). Epitopes 
mapping using a 20-mer peptide arrays representing the complete Lg M4147 LRV capsid 
sequence showed that g018D53 recognized uniquely Lg M5313 LRV C-terminal capsid 
sequence, which is poorly conserved in Lg 1398, thus explaining why it is not recognized by 
g018D53 in this strain (Figure 2C and 2D). 
2.3.3 – Immunodetection of LRV by a dsRNA-specific antibody 
The J2 monoclonal mouse antibody directed against dsRNA allows the detection of 
various dsRNA viruses independently of their sequences [28], [29]. To gauge its utility for LRV 
detection, it was first tested on control parasites by fluorescent microscopy using two different 
fixation protocols (Figures 3A and 3B). For both protocols the staining pattern with the J2 
antibody was similar to that seen with the anti-capsid antibody (Figure 2B). Interestingly, a 
signal was obtained with the strain Lg 1398, suggesting that the anti-dsRNA antibody was not 
limited by differences in sequence amongst LRVs as noted earlier in the qRT-PCR and anti-
capsid studies. 
From the images acquired via the second protocol (Figure 3B), histograms were 
constructed to show the distribution of signal intensity between individual cells (Figure 3C). A 
distinct peak was seen in the Lg M4147 LRVhigh line that was quite separated from that obtained 
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with the LRVnegline or controls (Figure 3C). The spread of the Lg M4147 LRVhigh peak was 
somewhat broader than might have been anticipated for a homogeneous population, suggesting 
some heterogeneity in LRV levels may exist. Similar results have been obtained with anti-capsid 
antisera (FMK and SMB, not shown). 
We also tested the use of a slot-blot technique for estimating LRV load. In this protocol, 
cells were „slotted‟ onto nitrocellulose membranes and reacted with J2 to detect dsRNA and anti-
histone H2A to control for parasite numbers. Clear differences in LRVhigh and LRVneg parasites 
were again observed (Figures 4A and 4B). Both logarithmic and stationary cells were tested 
showing that the dsRNA signal intensity does not significantly change during culture of the 
parasite. 
The results obtained in IFM or „slot‟ blotting prompted us to explore more rapid and 
simple protocols for the use of the J2 anti-dsRNA antibody that may be suitable for screening of 
field isolates, where sequence divergence amongst LRVs is expected. It was thus transferred to 
the other immunodetection techniques of ELISA and dot blot. The J2 ELISA method used crude 
parasite lysate (NP40); it allowed relative quantitation of LRV and confirmation that it was 
approximately four times more abundant in Lg M4147 LRVhigh than in Lg 1398 (Figure 5A). 
However a clear limitation of this approach is the requirement for high LRV load as illustrated 
here with a relatively low signal obtained with the Lg 1398 strain in comparison to LRV-
low/negative strains. 
Dot blot tests were performed with whole live parasites spotted directly on nitrocellulose 
membranes. Distinction between infected or non-infected promastigotes was remarkably reliable 
(Figure 5B), permitting a relative quantification that reproduced the difference in LRV load 
between Lg M4147 LRVhigh and Lg 1398 (Figures 1B and 5A). In addition to being a simple 
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technique that is independent of LRV sequence, the dot blot had the advantage of only requiring 
a very low number of parasites as shown in Figure 5C. Here, LRV could be detected in less than 
a hundred parasites from the Lg M4147 LRVhigh line. 
2.3.4 – Screening for LRV infection in human isolates 
To assess the applicability of our anti-dsRNA dot blot on field isolates, we used it for 
LRV screening in human isolates from another Leishmania species that had been previously 
typed and catalogued as LRV positive [24]. Five strains were screened, corresponding to L. 
braziliensis isolated from human lesions (Figure 6). As expected, we were able to confirm LRV 
presence in these isolates. This study suggested that the dot blot method using J2 was a valid 
approach that can be extended to clinical Leishmania isolates from human biopsy. 
2.3.5 – Screening for LRV presence in L. braziliensis isolated from an infected patient 
To demonstrate that our anti-dsRNA immunodetection approach may be a relevant 
diagnostic tool in a clinical setting, it was tested on freshly isolated Leishmania parasites 
obtained from an L. braziliensis infected patient. The subject contracted leishmaniasis in Bolivia, 
which was later typed by PCR as being L. braziliensis (data not shown). Two parasite samples 
were taken: Lb2169 and Lb 2192, derived respectively from a primary cutaneous lesion before 
treatment, and a secondary/metastatic lesion appearing some time after treatment had started. 
Parasites from these biopsies were cultivated and directly tested for LRV presence by dot blot 
using the anti-dsRNA antibody as described above. Lg M4147 LRVhigh and Lg M4147 
LRVneg parasites were used as positive and negative controls respectively. As shown in Figure 
7A, a clear signal, although weaker than for Lg M4147 LRVhigh, was detected in both parasite 
isolates from this infected patient. To ascertain that this positive signal was genuinely due to the 
presence of LRV, the samples were retested using some of the other LRV detection techniques, 
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i.e. immunofluorescence microscopy (Figure 7B) and isolation of viral dsRNA, with clear 
detection of a ssRNase- and DNase-resistant 5.3 kb band (Figure 7C). Sequencing of this newly 
identified LRV is currently in progress. Because the presence of LRV may be an aggravating 
factor in the development of refractory metastatic disease, early diagnosis of LRV content may 
aid diagnosis and be used to guide treatment strategies. This experiment demonstrated the ease 
and accuracy of dsRNA detection and reinforced the broad applicability of the anti-dsRNA 
antibody in the detection of LRV across Leishmania species. 
2.4 – Discussion 
The presence of LRV in Leishmania (Viannia) species is suspected to be a major 
aggravating factor in the dissemination and persistence of leishmaniasis. Therefore, the detection 
of LRV might prove clinically beneficial, guiding treatment or providing prognostic information. 
In this study, we evaluated several approaches of LRV detection, starting with the identification 
of a 5.3 kb viral dsRNA band in total parasitic nucleic acid (Figure 1A) [14]. This method, 
however, had the marked disadvantage of requiring at least 108 parasites and a high LRV load. 
On the contrary, the qRT-PCR approach is both highly sensitive as well as quantitative but its 
use as a first line diagnostic could be limited in the field in case of LRV genetic polymorphism 
(as illustrated with the SetB primers in Figure 1C). Further work would be required to identify 
the highly conserved regions amongst all LRV genomes in divergent parasite strains in order to 
avoid such a problem. Immunodetection by anti-LRV antibodies also proved to be clinically 
applicable with the advantage of qualitative analysis by fluorescence microscopy, revealing an 
interesting cytosolic clustering of viral particles (Figure 2B). Anti-capsid antibodies, however, 
have the same potential limitation as qRT-PCR due to their dependence on the underlying capsid 
sequence. 
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In this report, we describe new sequence-independent LRV detection techniques, using 
the anti-dsRNA J2 antibody, which could then be used in the field against any LRV strain 
circumventing the problem of sequence specificity that could occur. It was found to be effective 
and quantitative in microscopy, slot blot, ELISA and dot blot assays using parasites or lesions 
extracts, where it detected LRV in all LRV-positive control strains. All the strains analyzed in 
this study and the results obtained from each method are summarized in Table 1. The anti-
dsRNA-based dot blot technique stood out as the candidate method for use in the field, having 
sufficient sensitivity and ease of use to allow rapid LRV detection at a relatively low cost that 
could be performed at a large scale in a clinical setting (Table 1). 
In our previous analysis [14], we showed that the metastatic parasites in the Golden 
hamster model as well as a human ML isolate were positive for LRV, while non-metastatic and a 
human CL-derived strain were negative or very poorly infected. From the analysis reported here, 
we could detect the presence of LRV in other Leishmania isolates, including again L. 
guyanensis, but in addition in freshly isolated L. braziliensis parasites from human lesions. 
Finally, we showed that LRV could also be detected directly from minute lesion biopsies in mice 
thus avoiding parasite isolation and promastigote cultivation, which is a clear advantage when 
adapting of the technique such a diagnostic technique for field applicability. We propose that this 
approach could now be finalized for use on a mass-scale to determine the prevalence of LRV 
in L. (Viannia). This would greatly aid in confirming the correlation between LRV presence and 
clinical phenotype. If a significant trend is established, LRV detection could be used as a 
prognostic tool, perhaps guiding treatment strategies to prevent the metastatic complications 
often observed in some Leishmania (Viannia) infected patients. 
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2.7 – Table 
Table 2-1: LRV status of the analyzed strains according to detection method. 
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2.8 – Figures 
 
 
Figure 2-1: Detection of LRV in nucleic acid extracts.  
A and B. Visualization of viral genomic dsRNA by gel electrophoresis. A. Total nucleic 
acid from stationary phase promastigotes was treated with ssRNase then migrated in a 1% 
agarose gel. The sample was either kept intact (1 mg, upper panel) or digested with RQ-DNase 
(5 mg, lower panel). B. To quantify viral dsRNA in Lg 1398 relative to Lg M4147 LRVhigh, 
various concentrations of nucleic acid (2, 1 and 0.5 mg) were digested with RQ-DNase and 
migrated as above. C. Quantification of LRV transcript by qRT-PCR. Total parasitic and viral 
cDNA was prepared for qRT-PCR and amplified using primers specific for LRV (SetA and 
SetB, see material and methods for sequences). Viral transcript was quantified as normalized to 
the parasitic housekeeping gene kmp11 then adjusted relative to Lg M4147 LRVhigh.  
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Figure 2-2: Detection of LRV with a polyclonal anti-capsid antibody (g018d53) and epitope 
mapping.  
A. Western blot. Total parasitic protein extract (40 mg) was separated on a 10% 
acrylamide denaturing gel then transferred onto a nitrocellulose membrane where the LRV 
capsid could be detected using the rabbit polyclonal antibody g018d53 (upper panel). A Ponceau 
staining of the same membrane shows total parasitic protein (lower panel). B. 
Immunofluorescence microscopy. Red: capsid (g018d53 Ab). Blue: DAPI integrated into 
kinetoplast and nuclear DNA. Capsid immunofluorescence was visualized with a standardized 
exposure time in all images. C. 74 overlapping peptides (20-mer) covering the complete 
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sequence of Lg M4147 LRV1-4 capsid were spotted on a cellulose membrane (30 peptides per 
lane as indicated) and incubated with the g018d53 antibody to identify the recognized epitopes. 
D. Sequence alignment of the LRV capsids from Lg M4147, Lg M5313 and Lg 1398 in the C- 
terminal region covering the epitopes recognized by the g018d53 antibody (shown in C). The 
residues that are not identical to the Lg M5313 LRV sequence are highlighted in a black box.  
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Figure 2-3: Detection of LRV with a monocolonal anti-dsRNA (J2) antibody by 
immunofluorescence microscopy.  
A. Reference strain analysis (protocol A, see „„Material and methods‟‟). Green: dsRNA 
(J2 Ab). Blue: DAPI (standardized exposure time in all images). B. Phase and 
immunofluorescent images of Lg M4147 LRVhigh or LRVneg cells were obtained in the 
presence or absence of J2 antibody (protocol B). C. Quantitative immunofluorescence (protocol 
B). The fluorescent intensity per cell was assessed using Image J software on Lg M4147 
LRVhigh or LRVneg cells following IFM with the J2 antibody. Cells from phase images were 
identified and the fluorescent intensity average over the area of the cell was recorded. 108–160 
cells from 2 distinct fields were measured, and histogram plots were made using Excel software. 
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LRVhigh, no primary antibody (square symbol, dashed line); LRVhigh with J2 (square symbol, 
solid line); LRVneg, no primary antibody (circle symbol, dashed line); LRVneg with J2 (circle 
symbol, solid line).  
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Figure 2-4: Detection of LRV using slot blots and J2 antibody.  
A. 56104 parasites were blotted onto nitrocellulose membranes and incubated with J2 or 
anti-histone H2A antibodies. B. Quantification of the signal intensity for cells in logarithmic or 
stationary growth phase: dsRNA signal was quantified relative to the histone H2A signal. The 
cut-off line was calculated as 3 standard deviations (SD) above the mean absorbance of the 
LRV- negative that showed the highest value (log phase).  
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Figure 2-5: Detection of LRV in total parasite lysate using J2 antibody.  
A. ELISA. Total lysates from 56106 promastigotes were coated on 96 wells plates and 
dsRNA was quantified colorimetrically at 490 nm relative to Lg M4147 LRVhigh after 
background subtraction (uncoated control wells). The cut-off line was calculated as 3 standard 
deviations (SD) above the mean absorbance of the LRV-negative that showed the highest value 
(Lg 1881). B. Dot blot. 105 to 56105 promastigotes were spread directly onto a nitrocellulose 
membrane and dsRNA was detected using the J2 antibody (upper panel). A Ponceau stain of the 
membrane shows total protein concentration was similar across samples (lower panel). C. Dot 
blot sensitivity screening. A dot blot was performed in a serial dilution of 1000 to 10 parasites 
from LRV-positive and negative control strains (Lg M4147 LRVhigh and Lg M4147 LRVneg).  
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Figure 2-6: Screening for LRV in human isolates of Leishmania.  
Parasites of 5 different L. braziliensis strains previously shown to harbor LRV [24] were 
analyzed by dot blot (1 to 4 mg total protein/spot).  
  
62 
 
 
Figure 2-7: Screening for LRV in freshly-isolated human L. braziliensis.  
A. Dot blot analysis of two parasite samples obtained from separate lesion biopsies in an 
infected patient: Lb 2169 and Lb 2192. Live parasites (1 to 4 mg total proteins) were spotted on a 
nitrocellulose membrane for LRV dsRNA detection by dot blot (J2 antibody). Lg M4147 
LRVhigh and LRVneg were used as positive and negative controls. Upper panel: dsRNA detection 
by dot blot (J2). Lower panel: verification of protein quantity by Ponceau staining. B. J2 anti-
dsRNA analysis of Lb 2169 by fluorescence microscopy. Green: dsRNA (J2 Ab). Blue: DAPI. 
C. Isolation of viral genomic dsRNA from the Lb 2169 strain. Intact and DNase-digested total 
nucleic acids from Lb 2169 parasites and Lg M4147 LRVhigh as a control, were analyzed by gel 
electrophoresis (similarly to Figure 1A). Note: with high resolution gels such as presented here 
(in contrast to Figure 1), the viral genome often appears as a doublet.  
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Figure 2-8: Detection of LRV in mice footpad lesions.  
Dot blot analysis on total RNA extracted from mice lesions infected with Lg M4147 
LRVhigh and Lg M4147 LRVneg. Whole parasite („total‟) and RNA extracts from Lg M4147 
promastigotes were also loaded as a control. The amount of protein and RNA loaded is indicated 
on the left and right side of the figure respectively.  
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3.1 – Abstract 
The endogenous double stranded RNA virus Leishmaniavirus (LRV1) has been 
implicated as a pathogenicity factor for leishmaniasis in rodent models and human disease, and 
associated with drug treatment failures in L. braziliensis and L. guyanensis infections. Thus 
methods targeting LRV1 could have therapeutic benefit. Here we screened a panel of antivirals 
for parasite and LRV1 inhibition, focusing on nucleoside analogs to capitalize on the highly 
active salvage pathways of Leishmania, which are purine auxotrophs. Applying a new capsid 
flow cytometry assay, we identified two 2‟-C-methyladenosine (2CMA) analogs showing 
selective inhibition of LRV1. Treatment resulted in loss of LRV1 with first order kinetics as 
expected for random virus segregation, and elimination within 6 cell doublings, consistent with a 
measured LRV1 copy number of about 15. Viral loss was specific to antiviral nucleoside 
treatment and not induced by growth inhibitors, in contrast to fungal dsRNA viruses. 
Comparisons of drug-treated LRV1+ and LRV1- lines recapitulated LRV1-dependent pathology 
and parasite replication in mouse infections, and cytokine secretion in macrophage infections. 
Agents targeting Totiviridae have not been described previously, nor are there many examples of 
inhibitors acting against dsRNA viruses more generally. The compounds identified here provide 
a key proof of principle in support of further studies identifying efficacious antivirals for use in 
in vivo studies of LRV1-mediated virulence.  
3.2 – Introduction 
Protozoan parasites of the genus Leishmania are responsible for leishmaniasis in many 
regions of the world, with 12 million current cases (accompanied by at least 10-fold more 
bearing asymptomatic infections), and nearly 1.7 billion people at risk (1-5). The disease has 
three predominant clinical manifestations, ranging from the relatively mild, self-healing 
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cutaneous form, to mucocutaneous lesions where parasites metastasize to and cause destruction 
of mucous membranes of the nose, mouth, and throat, or fatal visceral disease. Disease 
phenotypes segregate primarily with the infecting species; however, it is not fully understood 
which parasite factors affect severity and disease manifestations.  
One recently identified parasite factor contributing to disease severity in several 
Leishmania species is the RNA virus Leishmaniavirus (6, 7). These endobiont viruses classified 
within the Totiviridae are comprised of a single-segmented dsRNA genome that encodes only a 
capsid protein and an RNA-dependent RNA polymerase (RDRP) (8, 9). Leishmaniavirus is most 
frequently found in New World parasite species in the subgenus Viannia (as LRV1) such as L. 
braziliensis (Lbr) and L. guyanensis (Lgy), which cause both cutaneous and mucocutaneous 
disease (6), and is found sporadically in Old World subgenus Leishmania species (as LRV2) (10, 
11). Mice infected with LRV1-bearing strains of Lgy exhibit greater footpad swelling and higher 
parasite numbers than mice infected with LRV1-negative Lgy (7). Similarly, macrophages 
infected in vitro with LRV1+ Lgy or LRV2+ L.aethiopica release higher levels of cytokines, 
which were dependent on Toll-like receptor 3 (7, 10). Recently, methods for systematically 
eliminating LRV1 by RNA interference have been developed, enabling the generation of 
isogenic LRV1 negative lines allowing the extension of the LRV1-dependent virulence paradigm 
to L. braziliensis (12).  
A key question is the relevancy of the studies carried out in murine models to human 
disease. For Lgy, patients infected with LRV1+ strains show an increased severity of cutaneous 
disease (13). In humans, Lbr is associated with cutaneous leishmaniasis, as well as the larger 
share of the more debilitating mucocutaneous leishmaniasis (MCL). Thus far there are no data 
available in humans permitting tests of the association of LRV1 with Lbr parasite burden nor the 
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severity of CL, which can show a range of presentations (14, 15). In lieu of such information, 
studies have focused on the association of LRV1 with MCL vs CL, which is thought to reflect 
primarily immunopathology, rather than parasite numbers (2, 6, 14-16). While in some studies 
LRV1 was not correlated with MCL clinical manifestations (17, 18), in others there was a strong 
association (6, 19, 20). The basis for these discrepancies is of considerable interest, hypotheses 
for which include other parasite or host factors known to play a significant role in the 
development of MCL (13, 21, 22), or microbial sources including the microbiota or coinfections 
(23). Recent studies show that the presence of LRV1 in clinical isolates of Lbr and Lgy correlates 
with drug treatment failure (17, 20), phenomena that could readily be explained by the increased 
parasite numbers and/or altered host responses predicted from animal models (7, 13, 24). Thus, 
current data support a role for LRV1 in increasing disease severity in human leishmaniasis (13). 
This suggests that therapies targeting LRV1 specifically could be applied towards amelioration 
of disease pathology. As one approach, murine vaccination using the LRV1 capsid results in 
significant protection against LRV1+ Lgy (25).  
Here we describe a complementary approach, targeting LRV1 directly using small 
molecule inhibitors. While effective antivirals are available for many viral targets including 
retroviruses, DNA viruses and ssRNA viruses (26), little effort has gone into agents acting 
against dsRNA viruses (27). These comprise at least ten viral families (Birnaviridae, 
Botybirndaviridae, Chrysoviridae, Cystoviridae, Megabirnavirdae, Partitiviridae, 
Picobirnaviridae, Quadriviridae, Reoviridae and Totiviridae), infecting a wide array of hosts 
including fungi, plants and animals (28). Some constitute important agricultural pathogens while 
rotaviruses (Reoviridae) cause serious human disease. For protozoan viruses, their role in the 
exacerbation of human disease is only now beginning to be appreciated (6, 29). Since viral 
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elements are critical factors acting to exacerbate the disease where studied, candidate anti-LRV1 
agents should be viewed as „anti-pathogenicity‟ treatments rather than sterilizing cures (30), 
which could be used alone or more likely in combination with existing anti-leishmanial agents in 
the treatment of ongoing infection.  
As a starting point we focused on nucleoside analogs, a class which includes many 
widely used and effective antivirals (Table S1) (26). Following uptake and activation to the 
triphosphate form, these primarily target viral replication, with different classes acting 
preferentially against viral DNA or RNA polymerases (RDRP) or reverse transcriptases, as well 
as cellular metabolism. A second rationale was that Leishmania are purine auxotrophs, with 
highly active and multiply redundant pathways for uptake and activation of nucleobases and 
nucleosides (31). Indeed, a great deal of prior effort has been devoted to the development of anti- 
leishmanial nucleoside analogs; however, while allopurinol is commonly used as a veterinary 
agent, it has proven more difficult to find agents of sufficient potency and selectivity against 
Leishmania to be used widely against human leishmaniasis (32). We reasoned that the highly 
divergent properties of Totiviridae RDRPs, relative to the polymerases of both the Leishmania 
and mammalian hosts (as well as other viral RDRPs), could prove fertile grounds for antiviral 
discovery, especially when coupled with potentiation by the parasite‟s powerful nucleoside/base 
salvage pathways.  
3.3- Methods 
3.3.1 – Parasites and growth media.  
Most studies were performed using luciferase-expressing transfectants of L. guyanensis 
(MHOM/BR/78/M4147) described previously (LRV1+ LgyM4147/SSU:IR2SAT-LUC(b)c3 and 
LRV- LgyM4147/pX63HYG/SSU:IR2SAT-LUC(b)c4 (54)); these lines are termed LgyLRV1+ 
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and LgyLRV1- respectively. Two strains of LRV1+ L. braziliensis were examined, LEM2780 
(MHOM/BO/90/CS) and LEM3874 (MHOM/BO/99/IMT252 n°3) (12). Parasites were grown in 
Schneider‟s media (Sigma, St. Louis, MO) prepared according to the supplier‟s instructions with 
pH adjusted to 6.5 and supplemented with 0.76 mM hemin, 2 Pg/ml biopterin, 50 U/ml 
penicillin, and 50 Pg/ml streptomycin, and 10% heat inactivated fetal bovine serum. Cell 
concentrations were determined using a Coulter Counter (Becton Dickinson).  
3.3.2 – Drug inhibition tests.  
Compounds were purchased or obtained as summarized in Table S1, and the structure of 
the two most active anti-LRV1 compounds are shown in Fig. S1. Stock solutions were prepared 
as recommended by the source, typically in DMSO at 50 mM, and tested against parasites at 100 
μM or the maximum concentration permitted by drug solubility (Table S2). Parasites were 
inoculated at 2 x 105
 
cells/ml into Schneider‟s media lacking supplemental adenine. Growth was 
evaluated after 2 days, prior to the controls reaching stationary phase growth, at which time 
parasite numbers had increased nearly 100 fold. Experiments were performed in sets of 10 test 
compounds, along with LRV1+ and negative controls; the agreement amongst independent 
experiments amongst the controls was excellent, and the results are shown averaged together 
across all experiments (Table S2).  
3.3.3 – LRV1 capsid flow cytometry.  
107 cells were fixed at room temperature (RT) using 2% paraformaldehyde (Thermo 
Fisher) in PBS for 2 minutes. They were then incubated in blocking buffer (10% normal goat 
serum (Vector Laboratories) and 0.2% Triton X-100 in PBS) for 30 min at RT. Anti-Lgy LRV1 
capsid antibody (35) was added (1:20,000 dilution) and incubated at RT for 1 hr. After two 
washes with PBS, cells were resuspended in in 200 ul PBS with Alexa488-labeled goat anti- 
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rabbit IgG (Alexafluor, Invitrogen, Eugene, OR,1:1,000; or Thermo Fisher, 1:2,000 dilution), 
and incubated 1 hr at RT. After two additional washes with PBS, cells were subjected to flow 
cytometry, gating for single cells using forward and side scatter and the data analyzed using 
CellQuest© software (BD Bioscience).  
3.3.4 – RNA purification, cDNA preparation, and qRT-PCR.  
107 cells were resuspended in 350 μl TRIzol® Reagent and RNA was extracted using the  
Direct-zol RNA purification kit according to protocol (Zymo Research). RNA was then treated 
with DNAse I (Ambion) for 1 hour at 37°C and re-purified using RCC-5 column purification 
(Zymo Research). cDNA was prepared using Superscript III (Invitrogen) and random priming 
according to protocol. RNA denaturation occurred at 65°C for 5 min. RT-PCR tests were 
performed using LRV1-specific primers (SMB4647 5‟-TBRTWGCRCACAGTGAYGAAGG 
and SMB4648 5‟CWACCCARWACCABGGBGCCAT) or β-tubulin mRNA (SMB5023 5‟- 
AACGCTATATAAGTATCAGTTTCTGTACTTTA and SMB2110 5‟- 
GACAGATCTCATCAAGCACGGAGTCGATCAGC). Quantitative RT-PCR (qRT-PCR) was 
performed as previously described (36), with a 123 bp fragment of LRV1 capsid mRNA 
amplified with primers SMB5335 (5‟-CTGACTGGACGGGGGGTAAT) and SMB5336 (5‟- 
CAAAACACTCCCTTACGC), and a 100 bp fragment of KMP-11 (a Leishmania housekeeping 
gene) with primers SMB5548 (5‟-GCCTGGATGAGGAGTTCAACA) and SMB5549 (5‟- 
GTGCTCCTTCATCTCGGG). The reaction utilized Power SYBR® Green (Applied Biosystems) 
in an ABI Prism 7000. Initial denaturation was at 95°C for 10min followed by 40 cycles of 
amplification with 15s at 95°C, and 1 min at 60°C. Data was analyzed using ABI 7000 SDS 
software (version 1.2.3) and normalized using ΔΔCT method (60). RNA slot blot analysis was 
performed as described (36). The LRV1 copy number per cell was estimated in comparison to a 
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standard curve generated using DNA from a plasmid bearing the LRV1 capsid gene (B6760, 
pBSKLRV1-4) and the average yield of RNA/cell across multiple Lgy RNA preparations (5.12 
±1.17 μg/107 cells; n = 34).  
3.3.5 – Isolation of LRV1+ and LRV1- clonal lines by brief treatment with 2CMA.  
LgyLRV1+ parasites were grown for one passage in media containing 25 μg/ml 
nourseothricin (Werner BioAgent, Jena, Germany) to verify the presence of the integrated LUC 
gene (54). Cells were then grown 1 passage in the absence of nourseothricin, and inoculated into 
Schneider‟s media at a concentration of 2 x 105 cells/ml into media containing 10 μM 2CMA. 
Growth was measured and LRV1 quantitated by capsid flow cytometry. At various times, cells 
were either plated directly, or transferred to drug-free media, and allowed to grow an additional 6 
cell doublings prior to plating. For both, the semisolid M199 media contained 50 μg/ml 
nourseothricin, and cells were diluted so that no more than ~100 colonies were obtained per 
plate.  
3.3.6 – Macrophage infections, cytokine assays, and mouse infection.  
Infections of C57BL/6 mouse bone marrow derived macrophages (BMDM) and cytokine 
assays were performed as previously described (7, 10). Poly I:C was obtained from Invivogen 
and used at 2 μg/ml. For mouse infections, 5 to 6 week old C57BL/6 mice were purchased from 
Jackson Laboratories (United States). Parasites were grown into stationary phase (2 full days) 
and 106 parasites were injected on the plantar aspect of the left foot. Measurement of footpad 
swelling was performed weekly using a Vernier caliper. Parasite numbers were assessed by 
luminescence of an integrated firefly luciferase reporter, measured using an IVIS 100 instrument 
as described previously (7, 54) and analyzed with Living Image software version 2.60 (Perkin 
Elmer, Waltham, MA).  
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3.3.7 – Statement identifying institutional and/or licensing committee approving animal 
experiments.  
Animal handling and experimental procedures were undertaken with strict adherence to 
ethical guidelines relevant in both host countries. These are set out by the SFVO and under 
inspection by the Department of Security and Environment of the State of Vaud, Switzerland. 
Experiments were carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the United States National Institutes of Health. Animal 
studies were approved by the Animal Studies Committee at Washington University (protocol 
#20090086) in accordance with the Office of Laboratory Animal Welfare's guidelines and the 
Association for Assessment and Accreditation of Laboratory Animal Care International.  
 
3.4 – Results 
3.4.1 – Measurement of LRV1 levels by capsid flow cytometry.  
As LRV1 (like most Totiviridae) is not shed from the cell (33, 34), we developed a flow 
cytometric assay to measure intracellular LRV1 capsid levels on a per-cell basis. To detect 
LRV1 we used binding to a rabbit anti-LgyLRV1 capsid antiserum (35) followed by detection 
with AlexaFluor488-conjugated goat anti-rabbit IgG. We found that fixation with 2% 
paraformaldehyde followed by permeabilization with Triton X-100 yielded a clear LRV1- 
dependent profile (Fig 1A). Titration of the anti-capsid antiserum showed that dilutions around 
1:16,000 gave a strong signal with excellent selectivity between LgyLRV1+ and LRV1- (Fig. 
1B), with little background staining evident in immunofluorescence microscopy (not shown). 
Under these conditions and as seen in previous immunofluorescence studies (36), LgyLRV1+ 
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showed a strong, homogeneous LRV1 distribution (Fig. 1A). We attempted similar studies with 
anti-dsRNA antibodies (36), but were unable to identify fixation conditions that gave similarly 
clear discrimination between LgyLRV1+ and LRV1- by flow cytometry.  
3.4.2 – Inhibition tests. 
We acquired a collection of 81 compounds, primarily nucleoside or nucleobase analogs, 
including ones shown previously to be active against diverse viruses, tumor cells, or Leishmania 
(Table S1, S2; Fig. S1). These were examined for their ability to inhibit the growth of 
LgyLRV1+ and virus levels by LRV1 capsid flow cytometry. LgyLRV1- parasites grew similarly 
to LgyLRV1+, and were used as virus-negative controls. These data revealed three patterns (Fig. 
2). For most compounds, LRV1 capsid levels were not significantly affected, within a factor of 
~3 (Figs. 2, black or red dots within large dashed gray and red circles; Table S2, Fig. S2). All 
nucleobase analogs fell within this group, as did foscarnet (a structure analog of pyrophosphate). 
Within this group, a subset showed more than 10-fold inhibition of Lgy growth (Fig. 2, red 
circle; Table S2, Fig. S3a/b), including known anti-leishmanials such as allopurinol, 
mycophenolic acid and APP. Several additional compounds showed leishmanial inhibition at the 
concentration tested (Table S1,S2, Figs 2, S2A), however these were deprioritized for various 
reasons including known mammalian cell toxicity. In the initial screens several compounds 
showed modest elevation of LRV1, often accompanied by growth inhibition (Figs. 2, S2A; Table 
S2). However, this effect was not always reproducible and was not pursued further.  
Two compounds strongly reduced LRV1 capsid levels with minimal impact on parasite 
growth (Fig. 2, green circle; Fig. S1, Table S2). 2‟-C-methyladenosine (2CMA) and 7-deaza-2‟- 
C-methyladenosine (7d2CMA) resulted in 12- fold reductions in LRV1 capsid levels, showing 
30% and 90% inhibition of parasite density respectively when tested at 100 μM. Both had 
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previously been shown to inhibit the HCV RDRP following activation (37, 38). In contrast, 2‟- 
C-methylcytidine or guanosine had little effect on LRV1 levels or Lgy growth (Fig.2, blue dots). 
Compounds bearing a variety of other 2‟ modifications (alone or in combination, with various 
bases) showed little effect on LRV1. These included sofosbuvir and mericitabine (related to 2‟- 
C-methyl-2‟-F uridine or cytidine respectively), both of which show strong activity against HCV 
(39, 40), or NITD008, which shows good activity against flaviviruses (41). These data suggest a 
strong preference for both the nature of the 2‟-C substitution, as well as adenine as the base. Note 
that these data cannot discriminate between effects arising from direct inhibition of RDRP or 
other viral processes, nor drug metabolism (phosphorylation and/or resistance to nucleoside 
hydrolases).  
Previously a Leishmania cysteine proteinase activity was implicated in the cleavage of 
the LRV1 capsid-RDRP fusion protein, potentially important for LRV1 biogenesis (42). 
However, no effects on Lgy growth and only minimal effects on LRV1 capsid levels were 
observed with three cysteine proteinase inhibitors tested (E64, E64d and CA-074; Table S2), 
relative to the effects of 2CMA or 7d2CMA.  
3.4.3 – 2CMA preferentially inhibits LRV1 replication.  
Titrations were performed to quantitate the potency of 2CMA and 7d2CMA against Lgy 
growth and LRV1, measuring the relative cellular growth rate to better assess fitness effects. For 
2CMA, the EC50 was estimated to be ~3 μM for LRV1 capsid inhibition, versus >100 μM for 
parasite growth (Fig. 3A), at least 30-fold selective. To assess the effects on replication of the 
dsRNA LRV1 genome directly, we used quantitative anti-dsRNA slot blots (Fig. 3A (36)), which 
showed an EC50 of ~ 1 μM, slightly less than seen with capsid inhibition and consistent with the 
anticipated targeting of the RDRP. With 7d2CMA, an EC50 of ~5 μM was seen against LRV1 
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capsid expression, versus ~ >100 μM for Lgy growth, again with about >20-fold selectivity (Fig. 
3B). Several studies were carried out with L. braziliensis strains bearing LRV1 (12). The 2CMA 
EC50 for LbrLRV1 was similar to that seen with LgyLRV1 (~3 μM), however parasites were 
somewhat more susceptible to growth in inhibition (EC50 50-100 μM). As the available 
quantities of 7d2CMA were limiting and both compounds were similarly selective for Lgy, we 
focused thereafter on 2CMA.  
3.4.4 – 2CMA LRV1 inhibition is unaffected by exogenous adenine nor is synergy seen with anti- 
leishmanial nucleobases.  
We asked whether the 2CMA potency was affected by the presence of exogenous 
adenine, present at about 5-33 μM in the yeast extract component of Schneider‟s medium (43). 
The addition of exogenous adenine up to 400 μM had no impact on LRV1 inhibition by 100 μM 
2CMA nor did it alter LRV1 levels in LgyLRV1+ (Fig. S3C). APP (4-aminopyrazolopyrimidine) 
showed similar inhibition of Lgy growth and LRV1 levels, while at the highest concentration 
tested, allopurinol inhibited Lgy growth or LRV1 capsid levels by 30 or 60% respectively (Fig. 
S3A). We then explored potential interactions between 2CMA and antileishmanial nucleobases. 
However, no change in the EC50 for 2CMA inhibition of Lgy growth or LRV1 capsid synthesis 
was seen with increasing concentrations of allopurinol (~ 3 μM; Fig. S3D).  
3.4.5 – LRV1 inhibition is independent of Leishmania growth inhibition.  
Agents inducing stress and/or growth arrest have been employed to cure fungal 
Totiviridae, with cycloheximide (CHX) used often (44, 45). Growth of Lgy at 10 or 100 nM 
CHX resulted in an increase in population doubling time, from ~7.7 hr to 11.2 or 44.7 hr 
respectively, without significant cell death as evidenced by resumption of WT growth following 
CHX removal (Fig. 4A). Despite the strong effects on growth, LRV1 capsid levels were 
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unaffected nor was the emergence of a “LRV1-negative” parasite population seen at any CHX 
concentration (Figs 4B,C). Similar results were obtained with clotrimazole, which inhibits 
Leishmania growth through inhibition of sterol synthesis (Fig. 4D). Lastly, no correlation was 
seen between LRV1 levels and growth rate in our test compound screening (Figs. 2, S2) or 
exposure to hygromycin B (46). Thus, inhibition of Leishmania growth alone does not alter 
LRV1 levels.  
3.4.6 – Viral loss occurs by random dilution.  
The availability of an inhibitor with strong selectivity for LRV1 over parasite growth 
provided the first opportunity to test the assumption that cytosolic Totiviruses are passed 
randomly to daughter cells during mitosis (34, 47). For maximal LRV1 inhibition, parasites were 
inoculated into 100 μM 2CMA, which increased the population doubling time from 6.4 hr to 8.5 
(Fig. 3). The average LRV1 levels immediately declined, with capsid and RNA levels falling in 
parallel (Fig 5A, B). Importantly, when plotted as a function of number of cell divisions, loss of 
LRV1 capsid and RNA followed a first order linear relationship, with a 50% loss at every 
doubling (Fig. 5A, B). When visualized at the population level by flow cytometry, LRV1 capsid 
levels/cell declined homogeneously at every time point tested until only background staining was 
evident by 6 cell doublings (Fig. 5C). Both of these observations closely match the expectation 
for the random distribution of LRV1 particles to daughter cells during mitosis and successive cell 
divisions.  
3.4.7 – 2CMA induces LRV1 negative populations.  
To explore the loss of LRV1 further, we performed a series of „washout‟ experiments, 
growing LgyLRV1+ in 100 μM 2CMA for 1, 3, 4 or 6 cell doublings followed by transfer to drug 
free media. After one doubling, a time when LRV1 levels had only decreased 2-fold, LRV1 
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capsid levels rapidly returned to WT levels and distribution. In contrast, when 2CMA was 
maintained for 3 or 4 cell doublings, resulting in a homogeneous population showing on average 
8- or 16-fold less LRV1 capsid expression, the „washout‟ lines now showed two distinct 
populations (Figs. 5C, D). One expressed LRV1 at levels similar to control LgyLRV1+, while 
the other resembled LgyLRV1- (Fig 5D, first 2 panels). Parasites with LgyLRV1+ capsid levels 
were the majority (55%) in the 3 doubling washout population, whereas these had declined to 
36% percent in the 4 doubling washout population (Fig 5D). The LgyLRV1- population 
increased from 31 to 50% of the total cell population during this time. Lastly, after six cell 
doublings of growth with 2CMA, the LRV1 capsid profile was indistinguishable from that of the 
LgyLRV1- and the 6 doubling washout population revealed only parasites maintaining the 
LgyLRV1- capsid staining profile (Fig. 5D). This population was maintained for at least 6 
passages (~40 cell doublings) without return of any demonstrable LRV1+ parasites.  
Several conclusions emerge from these studies: first, the effective LRV1 copy number 
per cell must be relatively low, as otherwise an LRV1- negative population could not emerge 
after only 3-6 cell doublings (Fig. 5), roughly corresponding to copy numbers of 8-64 (2
3 
- 2
6
) 
and consistent with fraction of LRV1- cells emerging in the washouts (Fig. 5D). LgyLRV1 copy 
number was previously estimated as 24-100 by competitive PCR assay (48). To assess LRV1 
copy number independently in the clonal LgyLRV1+ line studied here, we isolated total RNA 
quantitatively from a known number of cells, and estimated LRV1 copy number by quantitative 
reverse-transcriptase PCR, using a standard curve established from a cloned LRV1 genome 
(Methods). This yielded an estimated average LRV1 copy number of 15 ± 0.9 / cell (n=3), 
consistent with range estimated from the rate of drug induced loss above.  
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Secondly, after „washout‟ 2CMA treated parasites, which originally showed 
homogeneous low levels of LRV1, now reverted to biphasic populations showing WT or 
„negative‟ LRV1 levels. The recovery of the WT population suggests that there may be a „set 
point‟ for LRV1 levels. As only populations but not clones were studied we cannot be sure that 
this occurred intracellularly, however the rapidity with which LRV1 levels rebounded suggests 
this may be more likely.  
3.4.8 – Rapid recovery of matched clonal WT and LRV1-cured lines  
Our findings suggested that it should be relatively easy to recover LRV1- clonal lines 
from the 2CMA-treated population. However, we were concerned that despite small effects on 
growth, the relatively high concentration of 2CMA used above could itself have unwanted 
selective effects on Lgy. Support for this concern arose when in pilot studies, several clonal lines 
obtained after growth in 100 μM 2CMA lacked LRV1, but showed decreased growth inhibition 
by 2CMA. Thus we repeated the LRV1 cure using 10 μM 2CMA, a concentration showing less 
of an effect on parasite growth but retaining strong inhibition of LRV1 levels (Fig. 3). Again, 
loss of LRV1 proceeded homogeneously (Fig. 6A). When clonal lines were recovered directly by 
plating from this population, very few were LRV1- (1/30). However, if the population was 
allowed to grow in the absence of 2CMA for another ~6 cell doublings (washout), a „bimodal‟ 
population for LRV1 capsid levels emerged, as seen previously. Analysis of 12 clonal lines 
obtained by direct plating from this „washout‟ population showed that 6 exhibited LRV1 capsid 
levels/profiles identical to the LgyLRV1- control, while 2 showed profiles identical to the 
LgyLRV1+ parent (representatives shown in Fig. 6B). Interestingly, 4 lines showed more 
complex profiles, with populations showing range of intensities spanning those from LRV1- to 
LRV1+ controls (representative shown in Fig. 6B). These complex lines were not studied further. 
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The „set point‟ hypothesis predicts that upon further growth, those lines would ultimately revert 
to bimodal populations.  
We chose two LRV1+ and LRV1-cured lines which had experienced identical 2CMA 
treatment and culture manipulations. Growth tests confirmed these were not resistant to 2CMA, 
and RT-PCR and western blot tests confirmed the presence or absence of LRV1 (Fig. 6 C, D). 
These clones thus constituted „matched‟ WT and LRV1-cured lines appropriate for subsequent 
studies of LRV1 effects.  
3.4.9 – LRV1 correlates with increased cytokine secretion and mouse infectivity.  
With matched 2CMA-treated LRV1+ and LRV1- (cured) lines, we asked whether LRV1 
was correlated with elevated pathology and hyperinflammatory responses as expected (7, 12). 
Infections were performed with bone marrow derived macrophages in vitro, followed by assays 
for secretion of two characteristic LRV1-dependent cytokine reporters, IL6 and TNFα. Cytokine 
secretion induced by the LRV1+/2CMA treated lines was comparable to that of the parental 
LgyLRV1+ line, while cytokine secretion induced by the 2CMA cured lines was considerably 
less, and comparable to that of the LgyLRV1- control (Fig. 7A, B).  
Infections of susceptible BALB/c mice were performed followed by measurement of 
pathology (footpad swelling) and bioluminescent imaging of parasite numbers. A strong LRV1- 
dependency for both pathology and parasite abundance was observed in comparisons of the 
„matched‟ 2CMA-treated LRV1+ vs. LRV1- (cured) lines (Figs 7C, D). Importantly, the 
response to the 2CMA-treated LRV1+ lines closely matches that to the control parental 
LgyLRV1+ line and similarly, the response to the 2CMA-treated LRV1- negative line closely 
matches that to the LgyLRV1- control (Figs 7C, D), both of which were studied previously (7).  
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3.5 – Discussion 
In this study we report the first compounds specifically targeting the LRV1 dsRNA virus 
from L. guyanensis and Totiviruses in general. Our findings have relevance for the specific 
therapeutic inhibition of Leishmaniavirus, basic studies of viruses within the Totiviridae, the 
development of anti-virals directed against dsRNA viruses generally, and the development of 
new tools for assessing the role of LRV1 in elevating Leishmania pathogenicity.  
To facilitate the search for LRV1 inhibitors, we first developed a capsid flow cytometry 
assay to rapidly monitor LRV1 capsid levels (Fig. 1). This assay can be performed in only a few 
hours, and while these studies employed it in a relatively low throughput manner, it should be 
scalable for higher throughput. The results were confirmed by anti-capsid or anti-dsRNA western 
or slot blotting, or quantitative RT-PCR (Figs. 6C, D). Additionally, this assay provides useful 
information about the cellular heterogeneity of LRV1 levels not readily achievable by other 
methods, which informed studies probing the inheritance of LRV1 as well as in the generation of 
LRV1-negative lines.  
We focused on known antivirals for several reasons: first, despite significant advances in 
targeting many retroviruses, DNA viruses or single-stranded RNA viruses, very little effort or 
progress has been devoted on inhibition of dsRNA viruses. Thus there seemed a reasonable 
potential for „repurposing‟ known antivirals against the dsRNA Leishmaniavirus. Moreover, 
since many antivirals are nucleoside analogs and that Leishmania is a purine auxotroph (31) the 
pharmacokinetics of drug uptake and metabolism could well favor the efficacy of such 
compounds against Leishmaniavirus. As a collateral benefit, these studies had the potential to 
uncover new lead inhibitors against Leishmania itself, as auxotrophy has prompted many 
investigators to target purine metabolism for anti-leishmanial therapy. Several new compounds 
82 
 
not previously reported to inhibit Leishmania were identified (Fig 2; Tables S1,S2), but were not 
pursued further here.  
We identified two compounds which showed preferential inhibition of LRV1, 2‟-C- 
methyladenosine or 7-deaza-2‟-C-methyladenosine (Figs. 3, S1). The two active compounds 
were effective in the micromolar range, with >20-fold selectivity for LRV1 versus L. guyanensis 
growth inhibition and were also active against LbrLRV1, albeit with somewhat less selectivity 
over growth. The EC50 measured using dsRNA or capsid levels were similar, with that of the 
dsRNA being somewhat less, consistent with the anticipated mode of action targeting the RDRP 
and genome replication. Both compounds have demonstrated activity against Hepatitis C Virus 
(HCV), where they target the viral RDRP by chain termination (37, 38, 49). By molecular 
modeling of the Lgy LRV1 RDRP domain against other RDRPs such as HCV, we were able to 
generate a view of the active site including residues putatively binding to the nucleotide 
substrates (Fig. S4). Notably, these included sites homologous to those mutated in HCV 
nucleoside analog-resistant lines (50). This supports our working hypothesis that both anti-LRV1 
compounds are activated to triphosphates where they act to inhibit RDRP activity. These 
compounds represent the first such identified against any member of the Totiviridae, and indeed 
one of the few candidates described inhibiting dsRNA viruses generally.  
Common features of the two selective anti-LRV1 compounds include the 2‟-C methyl 
and the adenine base moieties, although 2‟C-methyl G and C were inactive against both 
Leishmania and LRV1. A similar pattern was observed for dengue virus RDRP inhibitors, where 
only adenosine analogs demonstrated anti-viral activity (51). Following uptake, in Leishmania 
most purine nucleosides are metabolized to nucleobases, the major exception being adenosine 
which is phosphorylated directly by adenosine kinase (31). This could contribute to the 
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superiority of 2‟-C-methyladenosine analogs. However, all other 2‟C-modified analogs tested 
failed to inhibit LRV1 or Leishmania, including ones bearing adenine or related moieties as the 
nucleobase (Fig. 2, Tables S1,S2). Other factors may include differential ability to be 
phosphorylated, often the rate limiting step for antiviral nucleoside activation (52, 53), or 
susceptibility to nucleoside hydrolases or phosphorylases, which Leishmania possess in 
abundance (31), and affinity of the phosphorylated analog with the LRV1 RDRP itself. 
Additional studies will be required to assess the contributions of each of these factors to anti- 
LRV1 activity and the design of more potent inhibitors.  
3.5.1 – Anti-LRV1 agents as a tool for studying Leishmaniavirus replication and biology.  
The LRV1 selectivity of 2CMA and 7d2CMA provided the foundation for several studies 
probing LRV1 biology. Under 2CMA inhibition, a first order kinetic loss of LRV1 was 
observed, (measured by either capsid or dsRNA genome levels), with a homogeneous 50% loss 
at every cell doubling (Fig. 5A, B). This fits exactly the prediction assumed by a random 
inheritance model of LRV1 particles during mitosis. Although widely assumed for the 
inheritance of most persistent dsRNA viral infections, these findings now provide direct 
evidence of random segregation. These data also provide a mechanistic explanation for the 
failure to identify compounds inhibiting both LRV1 and Lgy in our screen, as without continued 
parasite growth LRV1 cannot be lost by dilution, and indeed may increase somewhat (Fig. 2).  
Ultimately LRV1 levels declined to levels approaching those of LRV-free parasites 
within 3-6 cell doublings following 2CMA treatment (Fig 5). This implies the viral copy number 
was relatively low, less than 8-64 (23-6), significantly less than previous estimates of 120 for 
LgyLRV1 and often many thousands for other Totiviridae (34, 48). However, quantitative 
analysis of cellular LRV1 and total RNA led to an estimate of about 15, consistent with estimates 
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of LRV1 abundance from recent whole genome RNA sequencing by our group, to be reported 
elsewhere. If this unexpectedly low value for LRV1 copy number applies generally to LRV1s in 
other Leishmania strains or species, it could provide a new perspective on the observation that 
thus far, no images of LRV1 in situ by electron microscopy appear in the literature.  
The rapid decline of LRV1 following 2CMA treatment suggested that it would be 
relatively easy to recover LRV1-free clonal lines. Following washout of 2CMA after 3-6 cell 
doublings and a brief period of growth without drug, cultures manifested two distinct parasite 
populations by capsid flow cytometry: one similar to LgyLRV1+ and a second similar to 
LgyLRV1- (Fig. 5,6). The fraction of LgyLRV1- parasites grew progressively with increasing 
2CMA treatment, reaching levels approaching 100%. To recover parasites suited for studies 
focusing on the biological properties of LRV1-negative parasites, we adopted a protocol in 
which parasites were treated for only a brief period of time with 10 μM 2CMA, a concentration 
showing little effect on parasite growth but relatively high inhibition of LRV1 (Fig. 3), followed 
by brief passaging and then plating on drug-free media. Importantly, this procedure allowed the 
recovery of both LRV1+ and LRV1- „matched‟ clonal lines, which had experienced identical 
treatment, thereby facilitating comparisons probing LRV1 effects (below). Interestingly, in all of 
these studies the LRV1 levels in „washout‟ lines showed a strong tendency to recover from the 
low levels seen in drug to those comparable to LRV1+ controls (Fig. 5). These findings suggest 
that the LRV1 copy number is maintained at a specific „set point‟, perhaps through a balance 
between replication and the RNAi pathway (12, 54). Previous studies examining LRV1 
transcripts during growth phase also concluded that LRV1 copy number is regulated (48).  
For other fungal dsRNA viruses, treatments engendering cell stress or growth inhibition 
have been used to generate virus-free lines at significant frequencies, one common example 
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being the use of CHX to cure the yeast L-A virus (44). Although in one prior study LRV1 cure 
was obtained during a series of transfection and hygromycin selection steps, this appears to have 
been successful only once, and our laboratories have been unable to repeat this (12, 46). Here we 
were unable to show any correlation between LRV1 loss and drug induced stress or growth 
inhibition with CHX, the ergosterol synthesis inhibitor clotrimazole, or within the large panel of 
test compounds (Figs. 2,4, S2; Table S1,2). Thus LRV1 appears to be relatively stable to growth 
inhibitory stresses. However, given its relatively low cellular copy number (<20), on a strictly 
probabilistic basis LRV1-negative variants might occur at a low frequency, which occasionally 
may emerge or be recovered by methods more sensitive than employed here.  
3.5.2 – Antiviral cures and the generation of isogenic LRV1- lines for the study of LRV1-
dependent virulence.  
2CMA treatment enables the controlled and reproducible generation of matched LRV1+ 
and LRV1-cured lines without difficulty. In vivo, 2CMA-cured LRV1- parasites showed less 
pathology and lower parasite numbers and induced less cytokine secretion, than LRV1+ 
parasites, comparable to the single spontaneous LRV1- lines described previously (Fig. 7). Thus 
our LRV1‟ „toolkit‟ now includes two independent, reproducible and efficient methods for 
generating isogenic LRV1 negative lines, which will facilitate tests probing the biology of 
LRV1-dependent pathogenicity in diverse parasite backgrounds. Depending on the relative 
selectivity of the antivirals and the presence of an RNAi pathway, one method may be superior 
for a given Leishmania species or strain.  
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3.5.3 – The potential for anti-totiviral therapy in the treatment of dsRNA-bearing parasites and 
disease.  
There are now ample data suggesting that LRV1 contributes to the severity in human 
leishmaniasis (6, 13, 17, 19, 20, 55), suggesting that anti-LRV1 inhibitors could be clinically 
useful, alone or in conjunction with existing anti-leishmanials. Unfortunately, pharmacokinetic 
studies of the two compounds studied here in mammals suggest that neither of these are good 
candidates for testing of this hypothesis just yet, as the concentration needed for LRV1 
elimination (10 μM) is above the maximum achievable serum concentration in various 
mammalian models, typically less than 1 μM (38, 49, 56). Thus, future efforts must focus on the 
development of compounds with higher potency targeting LRV1, without significant human host 
toxicity. For therapeutic purposes a compound simultaneously targeting both would likely be 
superior. However, because Leishmania growth is required for LRV1 to be lost by progressive 
dilution (Fig. 5), a screening method different than that employed here will be required to detect 
such agents. Dilutional loss following anti-LRV1 inhibitor treatment in vitro predicts that very 
low levels of LRV1 could persist after treatment in vivo, whether measured on a total or per cell 
basis (Fig. 5). Importantly, previous data show that below a certain threshold parasites bearing 
low LRV1 levels are controlled as effectively as LRV1-negative lines (7).  
Our studies also raise the possibility of treating other diseases caused by protozoans 
bearing dsRNA viruses which show endogenous virus dependent pathogenicity, including 
Totiviridae present within Trichomonas vaginalis (Trichomonasvirus), Giardia lamblia 
(Giardiavirus), or Eimeria (Eimeravirus) (34, 57) and Partitiviridae within Cryptosporidium 
parvum (Cryspovirus) (58, 59). Potentially, agents targeting these putative pathogenicity factor 
viruses could prove similarly valuable for laboratory studies of these viruses as well.  
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3.8 – Tables 
Table 3-S1: Compounds studied Table S1.   Compounds studied       
      
 
 
Identifier 
Alternative 
Names / 
Abbreviations 
 
Pub 
Chem ID 
 
 
Uses 
 
 
Source 
 
 
Reference 
2'C modified nucleoside/nucleotides       
     2'C-Methy adenosine 2CMA, E6 500900 RNAV G. Bluemling, Emory 
University 
(1) 
     2’C-Methyl-7-deaza-adenosine 7d2CMA 3011893 RNAV Carbosynth, Berksire, U.K. (2) 
     2'C-Methyl cytidine 2CMC 500902 RNAV Sigma, St. Louis, MO (3) 
     2'C-Methyl guanosine 2CMG, E7 58697480 RNAV G. Bluemling, Emory 
University 
(4) 
2-((5-(2,4-dioxo-3,4-dihydro-2H-
pyrimidin-1-yl)-4-fluoro-3-
hydroxy-4 -
methyltetrahydrofuran- 2-
ylmethoxy) 
phenoxyphosphorylamino)propio
nic acid isopropyl ester 
PSI-7977, 
Sofosbuvir 
45375808  MedChem Express, 
Monmouth Junction, NJ 
(5) 
     2'-fluoro-2'-methyl-3',5'-
diisobutyryldeoxy cytidine 
R-7128, 
Mericitabine 
16122663  MedChem Express, 
Monmouth Junction, NJ 
(5) 
     2'-fluoro-2'-deoxycytidine E1 101507 RNAV G. Bluemling, Emory 
University 
(6) 
     2'-fluoro-2'-deoxyinosine E5 196148 RNAV G. Bluemling, Emory 
University 
(7) 
     2'-fluoro-2'-deoxyguanosine E4 196536 RNAV G. Bluemling, Emory 
University 
(3) 
     2'-fluoro-2'-deoxyadenosine E3 100253 RNAV, 
Tumor 
G. Bluemling, Emory 
University 
(7) 
     2'-fluoro-2'-deoxyuridine E2 150851  G. Bluemling, Emory 
University 
(7) 
 7-(2-Ethynyl-beta-D-ribofuranosyl)- NITD008 44633776 RNAV BEI Resources, Manassas, (8) 
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7H-pyrrolo[2,3-d]pyrimidine-4-
amine 
VA 
 
     
Other nucleoside/nucleotides  
     
     Ribavirin Rib 37542 RNAV, 
DNAV 
AKSci, Union City, CA (9) 
     4'-azido cytidine R-1479, 
Balapiravir 
457388  MedChem Express, 
Monmouth Junction, NJ 
(5) 
     Entecavir ETV 153941 DNAV, RTV LKT Laboratories, St. Paul, 
MN 
(10) 
     Tenofovir monohydrate TDF, PMPA 5481350 DNAV, RTV LKT Laboratories, St. Paul, 
MN 
(10) 
     Lamivudine 3TC 60825 DNAV, RTV LKT Laboratories, St. Paul, 
MN 
(10) 
     Ganciclovir DHPG,Ganc 3454 DNAV Sigma, St. Louis, MO (11) 
     Cidofovir CDF 60613 DNAV Sigma, St. Louis, MO (12) 
     Acyclovir ACY 2022 DNAV Sigma, St. Louis, MO (9) 
     Didanosine ddi, 2'3' 
dideoxyinosine 
50599 RTV LKT Laboratories, St. Paul, 
MN 
(13) 
     Zidovudine AZT, 
azidothymidine 
35370 RTV AKSci, Union City, CA (13) 
     Stavudine d4T 18283 RTV AKSci, Union City, CA (13) 
     5-fluoro-5'-deoxyuridine 5F5D, 
doxifluridine 
18343 Tumor Sigma, St. Louis, MO (14) 
      
Nucleobase analogs          
     Mycophenolic Acid MMA 446541 RNAV, 
immunosup
pression 
Sigma, St. Louis, MO (15) 
     8-azahypoxanthine 8AH 75895 Tumor Sigma, St. Louis, MO (16) 
     5-azauracil 5AU 6275 Tumor Sigma, St. Louis, MO (14) 
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     8-azaguanine 8AG 8646 Tumor Sigma, St. Louis, MO (17) 
     6-azauracil 6AU 68037 Tumor Sigma, St. Louis, MO (18) 
     5-fluorouracil 5FU 3385 Tumor Sigma, St. Louis, MO  
     allopurinol ALL 2094 Leishmania, 
gout 
Sigma, St. Louis, MO (19) 
     4-aminopyrazolopyrimidine APP 75420 Leishmania  Sigma, St. Louis, MO (19) 
     Favipiravir T-705 492405 RNAV MedChem Express, 
Monmouth Junction, NJ 
(5) 
     3’-azido-3’-hydroxyethyl cyclobutyl         
adenine 
E8 No ID  G. Bluemling, Emory 
University 
(20) 
     3’-azido-3’-hydroxyethyl cyclobutyl 
adenine 
E9 No ID (entant-
iomer of 
E8) 
G. Bluemling, Emory 
University 
(20) 
     3’-hydroxyethyl cyclobutyl adenine E10 57450866  G. Bluemling, Emory 
University 
(20) 
      
Cysteine Proteinase Inhibitors          
     E-64  123985  Cayman Chemical, Ann 
Arbor, MI 
 
     E64-d Aloxistatin 65663  Cayman Chemical, Ann 
Arbor, MI 
 
     CA-074 Me  6610318  Enzo Life Science, 
Farmingdale, NY 
 
      
Other          
      Foscarnet Phosphono-
formic acid 
3415 DNAV LKT Laboratories, St. Paul, 
MN 
(9) 
      sulfaguanidine   5324 antifolate Sigma, St. Louis, MO (21) 
      Celgosivir 6-O-butanoyl 
castano-
spermine 
60734 glucosidase 
inhibitor 
BEI Resources, Manassas, 
VA 
(22) 
      Clotrimazole CTZ 2812 antifungal  Sigma, St. Louis, MO (23) 
      Cycloheximide CHX 6197 eukaryotic  A.G. Scientific, San Diego,  
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Abbreviations: DNAV, DNA viruses; RNAV, RNA viruses; RTV, retroviruses.  
 
References for Table S1: 
1. Chen YL, et al. (2010) Inhibition of dengue virus RNA synthesis by an adenosine 
nucleoside. Antimicrob Agents Chemother 54(7):2932-2939.   
2. Olsen DB, et al. (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of 
protein 
synthesis 
inhibitor 
CA 
       
Chembridge ('nucleoside like library')          
Chembridge 5106522 CB1 254731  Chembridge, San Diego, CA  
Chembridge 5135608 CB2 2829334  Chembridge, San Diego, CA  
Chembridge 5141196 CB31 2998527  Chembridge, San Diego, CA  
Chembridge 5141213 CB3 249989  Chembridge, San Diego, CA  
Chembridge 5141214 CB4 330408  Chembridge, San Diego, CA  
Chembridge 5141245  CB5 2829731  Chembridge, San Diego, CA  
Chembridge 5141262 CB6 No ID  Chembridge, San Diego, CA  
Chembridge 5141271 CB7 2829733  Chembridge, San Diego, CA  
Chembridge 5141274 CB8 2829734  Chembridge, San Diego, CA  
Chembridge 5141597 CB9 232480  Chembridge, San Diego, CA  
Chembridge 5141601 CB10 3091582  Chembridge, San Diego, CA  
Chembridge 5141604 CB11 254686  Chembridge, San Diego, CA  
Chembridge 5141605 CB12 248866  Chembridge, San Diego, CA  
Chembridge 5141608 CB13 6612425  Chembridge, San Diego, CA  
Chembridge 5144558 CB14 259811  Chembridge, San Diego, CA  
Chembridge 5237407 CB15 5069886  Chembridge, San Diego, CA  
Chembridge 5312810 CB16 No ID  Chembridge, San Diego, CA  
Chembridge 5315625 CB17 9585602  Chembridge, San Diego, CA  
Chembridge 5323146 CB18 2841452  Chembridge, San Diego, CA  
Chembridge 5482485 CB19 315071  Chembridge, San Diego, CA  
Chembridge 5487823 CB20 232480  Chembridge, San Diego, CA  
Chembridge 5489087 CB21 3093658  Chembridge, San Diego, CA  
Chembridge 5491596 CB22 2849215  Chembridge, San Diego, CA  
Chembridge 5492915 CB23 2849283  Chembridge, San Diego, CA  
Chembridge 5493580 CB24 3300105  Chembridge, San Diego, CA  
Chembridge 5584034 CB25 6095322  Chembridge, San Diego, CA  
Chembridge 5668881 CB26 2860060  Chembridge, San Diego, CA  
Chembridge 5670488 CB27 241893  Chembridge, San Diego, CA  
Chembridge 5671073 CB28 2860348  Chembridge, San Diego, CA  
Chembridge 5675149 CB29 325243  Chembridge, San Diego, CA  
Chembridge 5676375 CB30 2861016  Chembridge, San Diego, CA  
Chembridge 5705708 CB32 325243  Chembridge, San Diego, CA  
Chembridge 5788245 CB33 286003  Chembridge, San Diego, CA  
Chembridge 5789784 CB34 283288  Chembridge, San Diego, CA  
Chembridge 5790592 CB35 
 N,N-dimethyl 
adenosine 
348206  Chembridge, San Diego, CA  
Chembridge 5790637 CB36 2868728  Chembridge, San Diego, CA  
Chembridge 5790716 CB37 286481  Chembridge, San Diego, CA  
Chembridge 7972230 CB38 2978428  Chembridge, San Diego, CA  
Chembridge 7978592 CB39 2980412  Chembridge, San Diego, CA  
 
References for Tabl  S1 
 
1. Chen YL, et al. (2010) Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob Agents Chemother 54(7):2932-2939. 
2. Olsen DB, et al. (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent 
pharmacokinetic properties. Antimicrob Agents Chemother 48(10):3944-3953. 
3. Leyssen P, De Clercq E, & Neyts J (2008) Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 78(1):9-25. 
4. Eldrup AB, et al. (2004) Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus 
RNA replication. J Med Chem 47(21):5284-5297. 
5. Eltahla AA, Luciani F, White PA, Lloyd AR, & Bull RA (2015) Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. 
Viruses 7(10):5206-5224. 
6. Smith DB, et al. (2007) Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus 
replication: the discovery of R1479. Bioorg Med Chem Lett 17(9):2570-2576. 
7. Tuttle JV, Tisdale M, & Krenitsky TA (1993) Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents. J Med Chem 36(1):119-125. 
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Pharmacol Toxicol 20:259-284.   
10. Thio CL (2009) Hepatitis B and human immunodeficiency virus coinfection. Hepatology 
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11. Razonable RR (Antiviral drugs for viruses other than human immunodeficiency virus. 
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12. De Clercq E & Holy A (2005) Acyclic nucleoside phosphonates: a key class of antiviral 
drugs. Nat Rev Drug Discov 4(11):928-940.   
13. De Clercq E (2010) Antiretroviral drugs. Curr Opin Pharmacol 10(5):507-515.   
14. Walker RT, DeClercq E, & Eckstein F (1979) Nucleoside Analogues Chemistry, 
Biology, and Medical Applications (Plenum Press, New York).   
15. Kitchin JE, Pomeranz MK, Pak G, Washenik K, & Shupack JL (1997) Rediscovering 
mycophenolic acid: a review of its mechanism, side effects,  and potential uses. J Am 
Acad Dermatol 37(3 Pt 1):445-449.   
16. Vaughan MH & Steele MW (1971) Differential sensitivity of human normal and 
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17. Nelson JA, Carpenter JW, Rose LM, & Adamson DJ (1975) Mechanisms of action of 6-
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Drugs 9(6):424-447.  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Table 3-S2: Parasite growth and LRV1 levels in response to test compounds  
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Compound names and abbreviations (Table S1) are provided in column 1. Inhibitors were 
dissolved and used as indicated in column 2. Parasite density was measured after 2 d in culture 
and normalized to the percent growth of the diluent-treated control in column 3. LRV1 capsid 
signal was assessed at the same time as growth in column 4. Columns 5 and 6 provide the rank 
position for each compound as depicted in Fig. S2. Red shading represents inhibition of L. 
guyanensis. Green shading represents inhibition of LRV1. Yellow shading denotes control 
parameters. N/A, not applicable.  
*Actual rank: 1 = 42, 2 = 12.  
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3.9 – Figures 
 
Figure 3-1: Anti-LRV1 capsid flow cytometry. 
LgyLRV1+ and LgyLRV1- parasites were fixed and permeabilized followed by staining 
with increasing dilutions of anti-capsid antibody and fluoresceinated secondary antibody. A) 
Profiles obtained with LgyLRV1+ (solid line) and LgyLRV1- (filled) after selection for single 
cells. A representative experiment is shown, performed at a dilution of 1:16,000; subsequent 
studies were performed using a dilution of 1:20,000 (n>11) . B) Mean fluorescence of 
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LgyLRV1+ (■) and LgyLRV1- (□) for each antibody dilution. The ratio of LRV1+/LRV1- 
staining (●) is plotted as a solid line.  
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Figure 3-2: Antiviral inhibition of Lgy growth vs. LRV1 inhibition.  
The figure shows data from Table S2 plotted; LRV1 capsid levels (Y-axis) vs. Lgy 
growth (X- axis). The large dashed gray circle marks compounds (black dots) showing little 
effect on LRV1 or Lgy, the red circle marks compounds preferentially inhibiting Lgy growth, and 
the green circle marks compounds preferentially inhibiting LRV1, blue dots depict 2‟C 
substituted nucleosides without anti-LRV1 activity. LgyLRV1+ and LgyLRV1- controls are 
shown in brown. Abbreviations for compounds discussed further in the text can be found in 
Table S1.  
103 
 
 
Figure 3-3: 2CMA and 7d2CMA inhibition of Lgy growth and LRV1 capsid or RNA levels.  
The figure shows the rate of growth or LRV1 capsid levels (y-axis) as a function of drug 
concentration. A), 2CMA; B), 7d2CMA. Growth rate (●, solid line) and normalized LRV1 
capsid (□, dashed line) or RNA (Δ, dashed line) are shown. The results of one representative 
experiment are shown for 2CMA (n = 2 for RNA and capsid) and a single experiment for 
7d2CMA.  
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Figure 3-4: LRV1 levels are unaffected by agents inhibiting Lgy growth.  
A) LgyLRV1+ was treated with 10 nM cycloheximide (CHX; □, dashed line), 100 nM 
CHX (○, dashed line), or no treatment (■, solid line). After 72 hours, cells treated with 100 nM 
CHX were placed into fresh media (●, dashed line). B) Profiles obtained by LRV1 flow 
cytometry after 48 h growth for WT (shaded) or cells treated with 100 μM CHX (solid line), or 
10 μM CHX (dashed line). C) Plot of growth rate of LgyLRV1+ (●) or LRV1 capsid levels (□, 
dashed line) after 48h propagation in increasing concentrations of CHX. D) As in panel C but for 
clotrimazole (CTZ). A representative experiment is shown (n = 3).  
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Figure 3-5: Kinetics of and cellular distribution of LRV1 loss after treatment with 100 μM 
2CMA.  
A and B) LgyLRV1+ was inoculated into media without (●) or with (□,Δ) 100 μM 
2CMA, and growth and LRV1 capsid (□, dashed line) and RNA levels (Δ, dashed line) measured 
by capsid flow cytometry (A) or qRT-PCR (B). For A, results at each time are shown normalized 
to LRV1+ and LRV1- control levels using the formula log2 ((2CMA Treated - LRV1-)/( LRV1+ 
- LRV1-)). For B, the log2 ddCT values are shown. A theoretical 1:2 dilutional loss is shown 
(thin gray line); error bars represent ± 1 SD. C). LRV1 capsid flow cytometry of control parasites 
(top panel) and populations grown for 1, 3, 4 or 6 cell doublings in 100 μM 2CMA. D). LRV1 
capsid flow cytometry of parasites grown for 3, 4 or 6 doublings in 100 μM 2CMA, and then 
grown for an addition 6 cell doublings in drug-free media (washouts). Thick and thin gray 
dashed lines represent LgyLRV1+ and LgyLRV1- respectively.  
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Figure 3-6: Generation of matched LRV1+and cured lines after limited 10 μM 2CMA treatment.  
A). Workflow for treatment of parasites with 10 μM 2CMA prior to isolation of clonal 
lines. First drug treatment for 6.4 cell doublings generates a population containing low average 
LRV1 levels, then the washout for 6 cell doublings allows resolution into fully negative or 
LRV1+ lines. B). Representative LRV1 capsid profiles for a cured line (Lgy clone 10-5), a WT-
like line (Lgy clone 10-10) and a mixed profile line (Lgy clone 10-1; for clarity the leading „10‟ 
is omitted from the figures). C). RT-PCR tests confirming presence or absence of LRV1 in 
treated lines. RT+, reverse transcription performed prior to PCR; RT-, no reverse transcription 
step. M, 1 kb+ ladder, Invitrogen. The expected LRV1 capsid and β-tubulin amplicons of 496 
and ~450 nt were found. D). Western blotting with anti-Lgy LRV1 capsid antisera confirms 
absence of LRV1 in cured lines Lgy 10-5 and 10-6. M, molecular weight marker. The arrowhead 
marks the position of the 95 kDa LRV1 capsid band.   
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Figure 3-7: Matched 2CMA-treated LRV1+ and LRV1- cured lines recapitulate LRV1-dependent 
virulence.  
A, B). Cytokine secretion by BMM infected 24 hr after infection with Lgy lines or 
treatment with poly I:C (2 μg/ml), M = media. A), TNFα; B), IL-6. The figure shown is 
representative of three experiments each done in triplicate; error bars represent ± SD. C, D): 
Infections of matched 10 μM 2CMA treated LgyLRV1+ and LgyLRV1-. Parasite numbers 
(luminescence from luciferase reporter) (C) or footpad swelling (D) was measured at the peak of 
the infection (28 days). Each bar represents pooled data from 8 mice total, 4 for each Lgy line 
used. LRV1+ (clones 10-9,10-10) and LRV1- (clones 10-5,10-6) lines are shown; error bars 
represent ± SD. Data for control parasites are replotted from Ives et al. (7).  
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Figure 3-S1: Structures of compounds showing activity against LRV1 relative to adenosine. 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Figure 3-S2: Inhibition results ordered by effects on relative LRV1 (A) or Leishmania 
guyanensis growth (B).  
Dashed lines show the WT control growth rate (red) or LgyLRV1+ or LgyLRV1− capsid 
levels (blue).  
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Figure 3-S3: LRV1 inhibition by 2CMA is insensitive to exogenous adenine and does not show 
synergy with allopurinol.  
(A) Plot of growth rate of LgyLRV1+ (●) or LRV1 capsid levels (○) after 48-h 
propagation in increasing concentrations of allopurinol. LRV1 percentages were calculated 
relative to untreated controls. (B) As in A, but with APP. (C) Effect of increasing concentrations 
of adenine on LgyLRV1+ treated with 100 μM 2CMA for six cell doublings (○, dashed line) or 
without 2CMA (●, solid line). LgyLRV1− (●) is shown for a reference without adenine. (D) The 
EC50 for 2CMA inhibition of LRV1 after 48 h is unaltered in the presence of allopurinol. The 
geometric mean capsid intensity is plotted relative to an untreated control. None (●, solid line), 
0.1 μM (■, solid line), 1 μM (●, dashed line), 10 μM (■, dashed line), and 100 μM (○, dashed 
line). Results from a single experiment are shown, other than C (n = 3).  
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Figure 3-S4: Active site model for L. guyanensis RDRP.  
A) Overall structural alignment of the Lgy LRV1 RDRP core domain‟s predicted 
structure (green) to a crystal structure of the Hepatitis C virus RDRP (light blue; PDB 4wti; (1)) 
created with the UCSF Chimera MatchMaker tool (2). For clarity, only the portion of the HCV 
RDRP (residues 103-422) that corresponds to the LRV1 RDRP core is shown. The HCV RDRP 
structure contained bound RNA and GDP. The GDP is shown in this figure to locate the NTP 
binding pocket. The Lgy LRV1 RDRP structure was predicted using the intensive method on the 
PHYRE2 web service (3), which yielded a high-confidence (≥90%) region between residues 337 
and 660. Given just this core region, PHYRE2 produced a very high-confidence structure (100% 
confidence over 94% of residues) with an active site very similar to the HCV structure. B) 
Predicted structure of the nucleotide binding pocket in the LRV1 RDRP. The GDP molecule 
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from panel A is shown for clarity. Surface colored yellow represents the locations of residues 
forming a binding site predicted by the 3DLigandSite server with high confidence (average 
MAMMOTH score 29.7, where ≥7 is significant) (4). Areas colored green mark residues which, 
when mutated in the HCV RDRP, confer resistance to the 2‟-C-methyl family of nucleoside 
analogs (5-7). The “Rotamers” tool in UCSV Chimera was used to fix side-chains given 
unfavorable conformations by the PHYRE2 server (8). C) Table of predicted binding site 
residues in LgyM4147 LRV1 RDRP and their corresponding residues in the HCV RDRP.  
 
References for Figure 3-11.  
1. Appleby TC, et al. (2015) Viral replication. Structural basis for RNA replication by the 
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sequence-structure analysis with UCSF Chimera. BMC Bioinformatics 7:339.   
3. Kelley LA, Mezulis S, Yates CM, Wass MN, & Sternberg MJ (2015) The Phyre2 web 
portal for protein modeling, prediction and analysis. Nat Protoc 10(6):845-858.   
4. Wass MN, Kelley LA, & Sternberg MJ (2010) 3DLigandSite: predicting ligand-binding 
sites using similar structures. Nucleic Acids Res 38(Web Server issue):W469-473.   
5. Lam AM, et al. (2014) Molecular and structural basis for the roles of hepatitis C virus 
polymerase NS5B amino acids 15, 223, and 321 in viral replication and drug resistance. 
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terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J 
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12(4):431-440.   
 
  
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Accumulation of 2’C-methyladenosine 
triphosphate in Leishmania guyanensis enables 
specific inhibition of the Leishmania RNA virus 1 
polymerase 
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4.1– Abstract 
Leishmania is a widespread Trypanosomatid protozoan parasite causing significant 
morbidity and mortality in humans. The dsRNA virus Leishmania RNA virus 1 (LRV1) 
chronically infects some Leishmania strains, where it leads to increased parasite numbers and 
pathology in murine leishmaniasis models, and correlates with increased treatment failure and 
relapse in human disease. Previously, we reported that 2‟-C-methyladenosine (2CMA) was a 
potent inhibitor of LRV1 in L. guyanensis (Lgy) and L. braziliensis, rapidly eradicating LRV1 at 
concentrations around 10 µM. Here, we probe the mechanism of 2CMA inhibition. Inhibition of 
RDRP activity by 2CMA triphosphate (2CMA-TP) was assayed by measuring incorporation of 
[α-32P]-UTP by cesium chloride gradient-purified Lgy virions. IC50s ranged from 130 to >600 
µM depending on the density of the virion particle (empty, ssRNA- and dsRNA-containing) and 
product formed. Inhibition was specific and was not seen with 2CMA or dATP. Lgy parasites 
incubated in vitro with 10 µM 2CMA accumulated 2CMA-TP to 410 µM, well beyond that 
needed to inhibit LRV1 replication. We developed a quantitative model that showed good 
agreement between the degree of LRV1 RDRP inhibition and LRV1 levels, supporting a model 
where 2CMA exerts its effects through metabolism to 2CMA-TP and accumulation to levels 
sufficient for RDRP inhibition and LRV1 loss. This attests to the powerful Leishmania purine 
uptake and metabolism pathways that allow even a weak RDRP inhibitor to effectively eradicate 
LRV1 at micromolar concentrations. These data suggest the possibility that 2‟C-methyl-
substituted adenosine analogs may have potential therapeutic applications to ameliorate the 
increased pathogenicity conferred by LRV1. 
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4.2 – Introduction 
The neglected tropical disease leishmaniasis is caused by various species of the genus 
Leishmania, which are single-celled eukaryotic parasites transmitted by multiple species of sand 
flies. (1) In South America, infection by Leishmania guyanensis (Lgy)1 or Leishmania 
braziliensis (Lbr) initially causes a self-resolving skin lesion (cutaneous leishmaniasis, CL). In 
some cases (primarily Lbr), however, the infection re-emerges and parasites metastasize to other 
locations, especially the mucus membranes (mucocutaneous leishmaniasis, MCL) (2). The 
factors determining disease progression and responsiveness to treatment are unclear, but are 
thought to be both host- and pathogen-derived. (3,4) 
Many isolates of Leishmania within the subgenus Viannia, primarily Lbr and Lgy, bear a 
single-segmented dsRNA virus known as Leishmania virus 1 (LRV1) (5-7). Previous work has 
shown definitively that mice infected with parasites containing the endobiont LRV1 exhibit 
greater pathology, higher parasite numbers, and increased metastasis (8,9) These studies have 
benefited from the availability of isogenic LRV1+ or LRV1- lines, generated spontaneously or 
by defined methods such as RNA interference or antiviral drug treatment (10-12). The role of 
LRV1 in human leishmaniasis has been more challenging to establish definitively. When 
comparing rates of CL and MCL, some studies find that LRV1+ strains generate more MCL (13-
15), while others do not (16,17). These discrepant findings may be explained by other parasite or 
host factors known to play a significant role in the development of MCL (18-20).  Alternatively, 
co-infections with viruses, especially those that can induce the Type I interferon responses, were 
shown recently to exacerbate Lgy pathology and metastasis (21,22). The presence of LRV1 in 
                                                 
1 The abbreviations used are: Leishmania guyanensis (Lgy), Leishmania braziliensis (Lbr), Leishmania RNA virus 1 
(LRV1), 2‟-C-methyladenosine (2CMA), 2‟-C-methyladenosine triphosphate (2CMA-TP), RNA-dependent RNA 
polymerase (RDRP), 7-deaza-2‟-C-methyladenosine (7d2CMA), cesium chloride (CsCl), low-density (LD), medium 
density (MD), high density (HD). 
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clinical isolates of Lbr or Lgy correlates with drug-treatment failure (14,16), which could be 
explained by the increased parasite numbers or altered host responses predicted from animal 
models (8,18,23). Treatment failure and relapse rates are also significantly higher in infections 
where Lbr or Lgy bear LRV1 (14,16). Overall, there is good reason to postulate a role for LRV1 
in increasing disease severity in human leishmaniasis (18). 
Like most other Totivirus species, LRV1 is neither shed nor infectious and is inherited 
vertically (6,24). Indeed, phylogenetic evidence suggests that LRV1 strains may persist and co-
evolve with their Leishmania host over millions of years (6). LRV1 follows a typical Totivirus 
life cycle (Fig. 1) (25), where mature virions contain one dsRNA genome and several RNA-
dependent RNA polymerases (RDRPs). The viral RDRP transcribes positive-sense genomic 
ssRNAs encoding two large overlapping reading frames encoding the capsid and RDRP, 
respectively. The second is thought to be translated via a frameshift, generating a capsid-RDRP 
fusion (26-28). The capsid monomers then self-assemble into immature virions (29), 
incorporating the positive-sense ssRNA transcript, which the RDRP replicates into the mature 
dsRNA genome. 
Importantly, murine vaccination using the LRV1 capsid results in significant protection 
against LRV1+ Lgy (30), suggesting that therapies targeting LRV1 specifically might aid in 
reducing disease pathology. One such approach is specific inhibition of LRV1 by small 
molecules. Previously, we surveyed a small library of antiviral nucleosides and identified two 
closely-related adenosine analogs, 2‟Cmethyl adenosine (2CMA) and 7-deaza-2‟-C- methyl 
adenosine (7d2CMA), which specifically inhibit LRV1 replication in Leishmania cells (Fig. S1). 
These compounds exhibited EC50s of 3-5 µM for viral inhibition and rapidly eradicate LRV1 at 
concentrations above 10 µM. This allowed us to easily create isogenic LRV1- lines (11). These 
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studies did not address the mechanism of anti-LRV1 activity, which was postulated to arise 
through direct inhibition of the LRV1 RDRP by the triphosphorylated form of 2CMA. Here we 
provide support for these hypotheses, as well as evidence that hyper-accumulation and retention 
of 2CMA-TP is sufficient to overcome its relatively weak inhibition of the LRV1 RDRP activity. 
4.3 – Results 
4.3.1 – Purification and separation of virion populations.  
RDRP assays were carried out with LRV1 virions purified from Lgy strain M4147 by an 
established cesium chloride (CsCl) equilibrium ultracentrifugation procedure (5,31). Following 
separation, virus particles were detected and quantified by their reactivity with an anti-capsid 
antibody (Fig. 2). We reproducibly observed three overlapping „peaks‟, designated low-, 
medium-, and high-density (LD, MD and HD) in order of increasing density. In previous studies 
of the yeast L-A Totivirus, similar peaks were shown to correspond to virions that were primarily 
„empty‟ or contained ssRNA or dsRNA, respectively (32,33). The densities of the Lgy LRV1 
LD, MD and HD peaks were 1.29, 1.36 and 1.41 g/mL, in good agreement with the densities of 
L-A virus particles bearing ssRNA- and dsRNA- (1.31 and 1.41 g/mL, respectively) (34). 
Preliminary data from S1 nuclease digestion of viral RNA from these fractions were consistent 
with these assignments (data not shown). 
4.3.2 – In vitro assay of LRV1 RDRP activity. 
To measure RDRP activity, purified virions were allowed to incorporate [α-32P]UTP in 
the presence of the remaining nucleoside triphosphates for 1 hr, a time chosen to allow one round 
of transcription or replication of the viral genome (31). RNA was purified and separated by 
native gel electrophoresis, and the products were visualized and quantified. Two products were 
found: one about 5 kb, presumably corresponding to the full-length LRV1 genome, and a 
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smaller, heterogeneous product ranging from 0.1 – 0.5 kb, which we attributed to abortive 
transcripts (Fig. 3A). Neither extending the incubation time nor increasing the concentration of 
UTP significantly altered the profile obtained (not shown). Importantly, neither full-length nor 
small products were produced by corresponding preparations from LRV1-negative parasites 
(Fig. 3B), and thus were specific to LRV1. 
4.3.3 – 2CMA-TP specifically inhibits viral RDRP activity. 
Incubation of the three LRV1 populations with 2CMA-TP reduced synthesis of both the 
full-length and small RDRP products (Figs. 3 - 4). The synthesis of each product was quantitated 
and normalized to that obtained with drug-free controls, from which IC50s were calculated 
(Table 1). These data showed a range of IC50s, from 130 μM for full-length product synthesis by 
LD virions to over 500 µM for the small products (Table 1, Fig. 4). These IC50s were 
unexpectedly high, greatly exceeding the extracellular concentration of 2CMA shown previously 
to cause 50% inhibition of LRV1 abundance (~3 µM) (11). We were concerned that this arose 
artificially from 2CMA-TP degradation during the assay. However, HPLC tests of RDRP 
reactions before or after the 1 hr incubation showed that only 3.7 ± 0.6% (n = 3) of the 2CMA-
TP was degraded to what appeared to be 2CMA-DP during the course of the assay. Thus, drug 
degradation was unlikely to significantly reduce its potency. 
 As anticipated, 2CMA did not measurably inhibit RDRP activity when tested at 
concentrations up to 1000 µM (Fig. 5). Similarly, dATP, which lacks both the 2‟-hydroxyl and 
methyl groups of 2CMA (Fig. S1), failed to inhibit RDRP activity at the highest concentration 
tested (600 µM; Fig. 5). These data suggest that despite its relatively low potency, 2CMA-TP 
inhibition of LRV1 RDRP activity was specific under these conditions. 
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4.3.4 – 2CMA activation to 2CMA-TP and accumulation in parasites. 
To account for the relative sensitivity of Lgy LRV1 to 2CMA compared to the 
insensitivity of LRV1 RDRP activity to inhibition by 2CMA-TP, we hypothesized that parasites 
take up and activate 2CMA, accumulating high 2CMA-TP concentrations. We first identified an 
HPLC protocol capable of resolving both synthetic 2CMA-TP and a smaller peak we presume to 
be 2CMA-DP from natural ribonucleotides and the internal standard, dGTP (Fig. 6A-B). 
Standard mixtures of known concentration were used to generate a standard curve relating peak 
area to 2CMA-TP amounts (Fig S3). We then tested several protocols for extracting parasite 
nucleotides and determined that extraction with 1:1 acetonitrile:water performed best (Methods). 
Using this protocol, we compared the nucleotide profiles of LRV1+ Lgy grown in the presence or 
absence of 10 µM extracellular 2CMA for 20 hours, a time chosen because it corresponds to 
about two rounds of parasite replication. Under these conditions, we observed a peak co-eluting 
with synthetic 2CMA-TP that was absent from untreated parasites (Fig. 6B), establishing the 
parasite‟s capacity to phosphorylate 2CMA. 
 We then measured steady-state levels of intracellular 2CMA-TP following incubation of 
late-log-phase parasites with 2CMA for 20 hours. To determine the intracellular concentration of 
2CMA-TP under these conditions, we measured the average volume of the parasites (roughly 23 
fL; see Methods). The steady state concentration of 2CMA-TP was measured at external 2CMA 
concentrations of 1 - 10 µM, bracketing the EC50 for LRV1 inhibition (3 µM) and extending to a 
concentration sufficient to completely inhibit LRV1 replication (10 µM) (11). Over this range of 
concentrations, internal 2CMA-TP levels exceeded external 2CMA concentrations by 40- to 80-
fold (Fig. 7A), attesting to the potency of the parasite‟s purine salvage pathway. 
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When propagated in 10 µM external 2CMA, the intracellular 2CMA-TP concentration 
reached 410 ± 110 μM (n=4) (Fig. 7A). This is well in excess of the minimum IC50 seen for 
RDRP inhibition (130 µM for full-length products from LD virions; Table 1). When treated with 
3 µM external 2CMA, which is the EC50 for LRV1 inhibition, the intracellular 2CMA-TP 
concentration was 152 ± 43 μM (n = 4), comparable to the RDRP IC50. Finally, at 1 µM external 
2CMA, a concentration with minimal effect on LRV1 levels, the intracellular 2CMA-TP 
concentration was 78 ± 9.0 μM, well below the lowest IC50 for RDRP inhibition (n=4) (Fig. 
7A). Thus, the steady-state levels of 2CMA-TP corresponded reasonably well to the effects on 
LRV1 inhibition predicted from RDRP inhibition alone. 
Finally, we measured the rate of 2CMA-TP accumulation by adding 10 µM 2CMA to 
late-log-phase cells and measuring the intracellular 2CMA-TP concentration after 0.5, 1, 2, 4, or 
8 hours (n=2). We observed measurable 2CMA-TP accumulation as early as 1 hour after 2CMA 
addition (Fig. 7B). The concentration surpassed the lowest IC50 for RDRP inhibition (130 µM) 
within 4 hours and reached the 20-hour steady-state concentration by 8 hours. This indicates that 
intracellular 2CMA-TP reaches inhibitory concentrations relatively quickly after exposure to 
2CMA. 
4.3.5 – Parasites retain 2CMA-TP after removal of drug pressure. 
It has been shown that some nucleoside analogs, once phosphorylated by cells, are 
retained as nucleoside analog-triphosphates for a significant period following removal of cells 
from the nucleoside itself (35). Because longer retention may increase drug efficacy, we 
measured parasite retention of 2CMA-TP. Lgy M4147 LRV1+ parasites were incubated for 18 hr 
in 10 µM 2CMA, washed, and resuspended in drug-free medium. Remarkably, parasites retained 
approximately 50% of their accumulated 2CMA-TP after 4 hours, while after 8 hours the 
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average 2CMA-TP concentration was 170 ± 100 µM (n = 5) (Fig. 8). These values were not 
corrected for dilution of 2CMA-TP due to parasite replication during incubation in drug-free 
medium. Correcting for population growth, the intrinsic 8 hour concentration was estimated to be 
230 ± 130 µM . Compared to the 0.3-hour half life of 2CMA in rat serum (36), these data 
establish that once formed, 2CMA-TP has much greater intracellular persistence than the 2CMA 
serum concentration would suggest. 
4.3.6 – Simulating virus inhibition replicates experimental results.  
The studies above suggest that inhibition of LRV1 RDRP activity alone may be sufficient 
to explain the elimination of LRV1 infection by 2CMA. As a further test of this hypothesis, we 
asked whether a simple computational model using the relative rates of parasite and viral 
replication could quantitatively describe our experimental data. We developed a model based on 
Gibson and Bruck‟s next-reaction modification to Gillespie‟s stochastic simulation algorithm 
(37), which directly simulates the occurrence of individual events over time by picking the next 
event-time from an associated probability distribution (Methods; Supplemental File 2). For this 
model, the two events we are simulating are parasite division and virus replication. Thus, the 
primary parameters defining the model are parasite and virus replication rates as defined by the 
experiments presented in this study. Replication rates were calculated based on the parasite 
population doubling time. We used the experimentally-measured parasite doubling time of 7.5 
hours and assumed that in the absence of drug pressure the relative parasite and virus replication 
rates were identical. The effect of 2CMA was modeled by adjusting the ratio of LRV1 to parasite 
replication rates (V:P) based on experimental values determined in this study (explained in detail 
below). Simulations began with an initial population of 1000 cells, each infected with 16 LRV1 
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particles (11). Using these conditions, the simulation correctly maintains the LRV1 population at 
an average of 16 virions per parasite over time in the absence of drug pressure (Fig. 9A).  
To model LRVI elimination by 2CMA, we decreased the LRV1 replication rate so that 
the ratio of virus to parasite replication rates (V:P) was 1:2, 1:3, and 1:4. This yielded LRV1 loss 
profiles which closely matched those determined experimentally (11) (Fig. 9A; solid lines 
simulation, dashed lines experimental). To see if these replication rate ratios were consistent with 
our in vitro experimental results, we compared them to the degree of inhibition caused by 
2CMA-TP on RDRP activity. 
LRV1 RDRP activity on substrates from low density virions was most sensitive to 
2CMA-TP in vitro (IC50 130 µM for full-length product synthesis by LD virions; Table 1; Fig. 
4A). Therefore, we assumed that the concentration-dependent effect of 2CMA on the LRV1 
replication rate directly depends on the effect of 2CMA-TP on the most sensitive RDRP activity. 
We plotted both normalized RDRP activity and parasite division rates as a function of 2CMA-TP 
and 2CMA, respectively (Fig. 9B). Fitting the RDRP inhibition data yielded a function 
representative of RDRP inhibition by 2CMA-TP and, by extension, of LRV1 replication by 
2CMA. This allowed us to calculate the ratio of RDRP activity to parasite division rates for each 
parasite division point (Fig. 9B, blue line). As can be seen in the graph in Figure 9B, the ratio of 
rates at 10 µM 2CMA, when RDRP activity is strongly inhibited, falls exactly within the 1:2 to 
1:4 range that accurately reproduced LRV1 loss in our model. Specifically, at 10 µM 
extracellular 2CMA, intracellular 2CMA-TP is 410 µM, and the ratio of rates is ~1:3 (Fig. 9). 
The results of our simulations suggest that, despite the complexity of viral replication, the system 
behaves as though RDRP activity is rate limiting for viral replication and our in vitro 
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measurements of 2CMA-TP inhibition are consistent with our in vivo measurements of viral 
elimination time courses. 
4.4– Discussion 
Previously, we showed that two 2‟-C-methyl-adenosine analogs selectively inhibit the 
replication of Lgy and Lbr LRV1, to the point that LRV1 could be eradicated with exposure to 10 
µM inhibitor (11). In that study the mechanism of action was presumed but not shown to follow 
the classic antiviral nucleoside paradigm of uptake, conversion to the nucleoside triphosphate, 
and inhibition of the viral RDRP. In this study, we provide evidence that this is in fact the case 
for Lgy LRV1 inhibition following 2CMA treatment. 
We first established an assay for RDRP from partially-purified virions, following the 
incorporation of radiolabeled UTP. As virions were purified on CsCl density gradients, we 
assayed low, medium and high density fractions, which are virion mixtures where the 
predominant species correspond to different steps of viral maturation (Figs. 1, 2). For all 
samples, activity was dependent on the presence of LRV1 and yielded two major products, 
corresponding to the full length viral genome as well as a heterogeneous collection of small and 
presumably abortive transcripts (Fig. 3). Quantitative analysis showed that overall the IC50s for 
the full-length product synthesis were lower than measured for small transcript synthesis (130 - 
410 vs. 510 – 1000 µM; Table 1), and less for the low density virions than the high density 
(130/510 vs. 410/1000 µM), although these differences were not quite statistically significant (p 
< 0.07 or 0.1, respectively; Table 1). These differences may signify different intrinsic 
sensitivities of the RDRP activity within mature and immature viral particles, perhaps related to 
the initiation of positive-strand (mRNA) vs negative-strand synthesis. This is the first such report 
for Totiviruses, for which antiviral drugs have only recently been reported (11). Differential 
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effects on replicase versus transcriptase have also been seen in reoviruses, where ribavirin 
triphosphate inhibits replicase but not transcriptase activity (38). Our current studies are limited 
because the RDRP assay depends on native RNA substrates from incompletely purified virions. 
This prevents complete separation of RDRP transcription and replication activities, and 
precludes the use of tightly controlled initiation and elongation assays. More precise work with 
purified RDRP and well-defined synthetic substrates will be required to fully elucidate the 
mechanism of action of 2CMA-TP. 
2CMA itself was completely inactive for RDRP inhibition, as was dATP (Fig. 5). The 
lack of 2CMA activity was expected, as this activation to triphosphate form is common and often 
rate limiting amongst nucleoside analog drugs (39-41). It was shown previously that the 
triphosphate form of 2CMA, but not the analog itself, was active against the Hepatitis C virus 
RNA polymerase (42). 
Notably, 2CMA-TP inhibition of the LRV1 RDRP activity was not very potent, (>130 
µM; Table 1), in contrast to inhibition of LRV1 within parasites by 2CMA exposure (3 µM) 
(11). We resolved this discrepancy by showing that the parasites avidly scavenged 2CMA from 
the medium and efficiently convert it to the active triphosphate form (Fig. 6), reaching 2CMA-
TP concentrations more than 40-fold above the 2CMA concentration in the medium within 8 
hours of drug exposure (Fig. 7). Strong accumulation of toxic anti-leishmanial purines was also 
noted earlier in studies (43,44). Interestingly, the rate of 2CMA-TP accumulation is similar to the 
previously-measured accumulation of formycin B triphosphate in L. donovani (43). These results 
underscore the importance of the purine salvage pathway in designing drugs targeting 
auxotrophic Leishmania parasites, which must avidly scavenge all naturally occurring purines 
from their environment (45). In the case of 2CMA, the salvage pathway converts 2CMA-TP, an 
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admittedly poor inhibitor of the LRV1 RDRP, into a potent tool for eliminating the virus. One 
particularly important step is likely the adenosine kinase (46,47), which may mediate the initial 
and often rate limiting phosphorylation of antiviral nucleosides (40,48). 
 Importantly, the accumulated levels of intracellular 2CMA-TP closely matched the 
consequences of RDRP and LRV1 loss. At 10 µM external 2CMA, 410 µM internal 2CMA-TP 
was attained, which was well over the minimal LRV1 RDRP IC50 (130 µM). In contrast, at 1 
µM external 2CMA, internal 2CMA-TP concentrations were only 80 µM, well below that 
needed for RDRP inhibition, and little effect was seen on LRV1 levels (11). These data suggest 
that inhibition of LRV1 RDRP activity by 2CMA-TP alone is sufficient to account for the rapid 
loss of LRV1. In further support of this contention, we used a Gillespie (49) simulation to model 
LRV1 loss, with good correspondence between predictions and experimental data gathered 
previously (11). While our studies did not examine other potential 2CMA-TP targets, such as the 
capsid endonuclease (50-54), collectively our data show that the elimination of LRV1 by 2CMA 
can be largely explained by the direct inhibition of LRV1 RDRP activity by 2CMA-TP. 
 These and previous studies raise the question of whether treatment of anti-LRV1 agents 
could be used therapeutically to ameliorate the severity of Lgy and Lbr infections. In animal 
models, 2CMA has a short serum half life (0.3 hours), although 7d2CMA has a half life of 1.6 hr 
(55). Interestingly, 7d2CMA shows an EC50 against Zika virus in cultured mammalian cells 
comparable to those observed against LRV1 (10 µM vs. 5 µM) (56,57). For Zika, regular dosing 
regimens have been able to achieve sufficient concentrations to show significant inhibition in 
animal models (56,57), suggesting that it might likewise be possible to achieve inhibition of 
LRV1 in vivo as well. The rate of 2CMA-TP accumulation also supports the feasibility of LRV1 
inhibition, because 2CMA-TP levels reach inhibitory concentrations within 4-8 hours at 10 µM 
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2CMA. Rough pharmacokinetic predictions suggest that 7d2CMA levels above 10 µM could be 
maintained in mice for approximately the same length of time. 
Importantly, we also showed that once formed 2CMA-TP is retained for a considerable 
period of time within parasites, suggesting that even a brief exposure at a sufficient 2CMA dose 
may lead to prolonged intracellular therapeutic levels of 2CMA-TP (Fig. 8). Assuming that 
7d2CMA shows a similar retention profile, as seems likely, the efficacy of both of these 
compounds may be extended beyond that predicted by serum level.  
A second line of inquiry would of course be the development of anti-LRV1 agents with 
improved potency. Preliminary studies expressing a promiscuous HSV TK gene within 
Leishmania did not increase the spectrum of activity significantly for those analogs tested from 
our previous study (11), suggesting that the lack of activity may reflect failure to inhibit LRV1 
RDRP itself rather than lack of metabolism. Indeed, we found that while high levels of 2CMA-
TP were formed in L. major strain 5-ASKH bearing the related virus LRV2, no inhibition of 
virus levels was seen (data not shown). Similarly, we found that several immucillins shown 
previously to inhibit Leishmania nucleoside hydrolases had little effect on drug potencies 
(Immucillin A, DADMe-Immucillin A, Immucillin H, and DADMe-Immucillin H; data not 
shown). (58,59) Although nucleoside analogs themselves, they showed no inhibition of LRV1 
levels when tested at concentrations up to 100 µM (data not shown). Thus, future efforts 
focusing on improved potency against the RDRP activity itself may prove most fruitful. 
Thus, our work now sets the stage for future studies exploring the possibility that LRV1-
targeted therapies may ameliorate the pathology of those Leishmania species and strains that 
bear this fascinating virus. 
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4.5 – Methods 
4.5.1– Parasite strains and media.  
Luciferase-expressing isogenic clones of L. guyanensis strain M4147 
(MHOM/BR/75/M4147) were utilized for these studies. LRV1+ clone LgyM4147/SSU:IR2SAT-
LUC(b)c3 and LRV1− clone LgyM4147/pX63HYG/SSU:IR2SAT-LUC(b)c4 were described 
previously. (60) For some experiments a LgyM4147/LRV1+ line expressing GFP+ 
[LgyM4147/SSU:IR2SAT-LUC(b)c3/SSU:IR3HYG-GFP+(b)] was used (provided by E. 
Brettmann). Schneider‟s medium (Sigma Aldrich, St. Louis, MO) was prepared following the 
manufacturer‟s instructions, supplemented with 10% heat-inactivated FBS, 0.76 mM hemin, 2 
µg/mL biopterin, 50 U/mL penicillin, and 50 µg/mL streptomycin, and adjusted to a final pH of 
6.5. M199 medium was prepared with 2% heat-inactivated FBS, 2% filter-sterilized human 
urine, 0.1 mM adenine, 1 µg/mL biotin, 5 µg/mL hemin, 2 µg/mL biopterin, 50 U/mL penicillin, 
50 µg/mL streptomycin, and 40 mM HEPES, pH 7.4 (61). No significant differences were 
observed in the properties of virus preparations from either medium. Cells were counted using 
either a hemocytometer or a Coulter counter (Beckton Dickinson). 
4.5.2 – Virion fractionation.  
Parasites were grown to early stationary phase in M199 or Schneider‟s medium (3×107 or 
9×107 cells/mL, respectively). 1×1010 cells were pelleted at 2200×g for 15 min at 4°C and 
washed twice with 10 mL ice-cold TMN buffer (100 mM Tris, pH 7.5; 50 mM MgCl2; 1.5 M 
NaCl). Cells were then resuspended in 1 mL ice-cold lysis buffer (TMN buffer plus 1 mM DTT, 
1× Complete protease inhibitor cocktail (Roche) and 1% (v/v) Triton X-100), homogenized by 
pipetting 10-12 times with a 1-mL micropipette, and incubated on ice for 20-30 minutes. Lysis 
was completed by passing the mixture repeatedly through a 27G needle, after which it was 
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clarified by centrifugation at 15,000 × g for 10 minutes at 4°C. Density gradients were prepared 
by thoroughly mixing the clarified lysates with enough 10×TMN buffer, saturated CsCl, and 
distilled water to make 12 mL of solution at a final density of 1.35 g/mL (2.82 M CsCl). 
Gradients were spun in a pre-chilled SW41Ti rotor (Beckman) at 32,000 rpm and 4°C for 
approximately 72 hours. Twelve 1-mL fractions were recovered immediately from each gradient 
using a density gradient fractionator (Isco). 
The distribution of capsid protein across each gradient was determined by binding of 50 
µL aliquots of each fraction to a nitrocellulose membrane using a Mini-fold II Slot-Blot System 
(Schleicher & Schuell, Keane, NH). The membrane was incubated on a roller with blocking 
buffer (2% non-fat powdered milk in PBS) for 1 hour, then stained with 1:2500 rabbit anti-capsid 
antibody (62) in blocking buffer plus 0.2% TWEEN-20 (TWEEN buffer) for another hour. The 
membrane was then washed 3 times for 5 minutes in 1×PBS plus 0.1% TWEEN-20 (PBST). 
Membranes were next incubated in TWEEN buffer for 1 hour with 1:10,000 goat anti-rabbit 
antibodies conjugated to IRDye 680 (LiCor Biosciences). Finally, the membranes were washed 
3× in PBST and once in PBS. Membranes were scanned with an Odyssey Infrared Imaging 
System (LiCor Biosciences). The density of each fraction was measured by taking its refractive 
index with an Abbe refractometer (Bausch and Lomb) and converting to density using published 
formulas (63). Gradient fractions of interest (Fig. 2) were dialyzed twice against 1×TMN and 
once in 1×TMN plus 20% glycerol (4° C), reaching CsCl concentrations less than 2 μM. 
Fractions were flash frozen and stored at -80°C prior to use. 
4.5.3– RDRP assay.  
RDRP activity of purified virions was measured using an [α-32P]UTP incorporation assay 
described previously(31). Briefly, 20 µL reactions contained 10 mM Tris-HCl (pH 7.5); 150 mM 
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NaCl; 3 mM MgCl2; 4 mM DTT; 50 μM each ATP, CTP, and GTP; 20 µCi [α-32P]UTP; and 10 
µL virions. Reactions were incubated at room temperature for 1 hour and quenched by addition 
of 350 µL TRIzol (Ambion). A corresponding gradient fraction from LRV1- parasites was 
included as a negative control in each set. RNA was purified using a Direct-Zol RNA miniprep 
kit (Zymo Research) and run on a native 1.2% agarose-TAE gel in a vertical gel apparatus (Owl 
Scientific) along with dsDNA sizing standards. The standards lane was excised and stained with 
ethidium bromide, while the radiolabeled products were detected by exposing an imaging plate 
for 24 hours and reading it with a FLA-5100 phosphoimager (Fuji). The amount of radiolabeled 
UTP in each RDRP product was quantified using the gel analysis tool in FIJI/ImageJ (64). 
Equivalent regions from the negative control reaction were also integrated to calculate the 
background (Fig. 3). 
To study inhibition of the viral RDRP by 2CMA-TP, varying amounts of the compound 
were added to standard RDRP reaction mixtures. 2CMA-TP was custom synthesized by Jena 
Bioscience, and its identity was confirmed using electrospray ionization with a Fourier-transform 
mass spectrometer in negative ion mode (Thermo Scientific). The stock concentration of 2CMA-
TP was calculated by UV absorption at 260 nm, assuming that its molar extinction coefficient 
was identical to ATP. To measure the amount of 2CMA-TP which is non-specifically hydrolyzed 
over the course of an RDRP reaction, mock reactions were run using LRV1- gradient fractions, 
cold UTP, and 300 μM 2CMA-TP. The 20-µL reactions were diluted to 80 µL with distilled 
water and immediately analyzed by HPLC as described below. 
4.5.4– Measurement of parasite volumes.  
Cultures of WT or GFP-expressing LRV1+ Lgy M4147 were seeded at 2×105 cells/mL 
and analyzed when they reached early, mid, or late log phase. From each sample, one aliquot was 
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analyzed by light scattering on a flow-cytometer, while another was immobilized by treatment 
with 20 mM sodium azide and imaged by spinning-disk confocal microscopy (65). Cell volumes 
were calculated using a custom ImageJ script (64). (Supplemental Text 1). A standard curve 
relating forward scattering intensity to measured volume was developed and used to estimate 
metabolite concentrations (Fig. S2).  
4.5.5– Metabolite extraction from Leishmania parasites.  
For drug metabolism studies, 108 late-log phase parasites in 5 mL of Schneider‟s medium 
were treated with indicated drug concentrations. Each replicate of each time point was obtained 
from a separate culture. For accumulation experiments, 108 parasites were harvested after 0.5, 1, 
2, 4, and 8 hours in 10 µM drug. To measure steady-state 2CMA-TP levels, 108 cells were grown 
for 20 hours before harvesting. In „washout‟ experiments, each culture was grown for 20 hours in 
10 µM drug. These cultures were spun down, resuspended in drug-free medium, centrifuged 
again, and finally suspended in 5 mL drug-free Schneider‟s medium. After 2, 4, or 8 hours, 
nucleotides were extracted from 108 parasites from individual washed cultures and analyzed by 
HPLC. 
For each sample, cells were collected by centrifugation at 2200 × g, 4° C for 5 min, re-
suspended in 1 mL ice-cold PBS and re-centrifuged. The cell pellet was gently re-suspended in 
100 µL ice-cold 0.5×PBS plus 7 nmol dGTP as a recovery and elution standard. Although dGTP 
occurs naturally, its intracellular concentration of approximately 5 µM is well below the limit of 
detection for this assay and thus does not interfere with its use for this purpose.(66). Cells were 
immediately lysed by rapidly re-suspending in 900 µL ice-cold 5:4 acetonitrile:water mixture (67 
) and vortexing continuously for 5 min at 4°C. Insoluble debris was pelleted at 16,000 × g for 5 
minutes and the clarified extract was transferred to a fresh tube. The solvent was removed by 
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evaporation in a Savant SpeedVac concentrator (Thermo Scientific) with the heater off and the 
vacuum pump refrigeration on. Samples were re-suspended with 80 µL distilled water, flash 
frozen, and stored at -80°C prior to HPLC analysis.  
4.5.6– HPLC separation of nucleotides.  
Nucleoside di- and tri-phosphates were separated by isocratic HPLC as described (68). 
Briefly, cel extracts were clarified by centrifuging for 2 min. at 16,000×g and a 20 µL aliquot 
was injected onto a Zorbax SB-C18 column (5 μm particle size, 250 mm × 4.6 mm, Agilent) and 
eluted at 1 mL/min with 150 mM KH2PO4 (pH 6.0); 4.2 mM tetrabutylammonium hydroxide; 
and 5.4% methanol. Eluting compounds were monitored by UV absorbance at 254 nm. The 
elution times of nucleoside triphosphates as well as 2CMA and 2CMA-TP were determined by 
running them individually. A minor peak present in each standard was presumed to represent the 
di-phosphate form of that nucleoside. A mixture containing 200 μM ATP, GTP, CTP, UTP, and 
dGTP was used periodically to assess column performance. Peak areas were integrated using 
Millenium32 software (Waters), showing that peak are varies linearly with compound amount 
injected, above 50 pmol (Fig. S3). 
 
4.5.7– Gillespie simulation of LRV1 inhibition.  
We modeled the effects of 2CMA treatment on LRV1 using the next-reaction 
modification to the Gillespie algorithm (code is provided in Supplemental Text 2) (37). The 
parameters used to define the system were as follows: number of parasites, number of virions per 
parasite, parasite growth rate, and virus replication rate. All simulations were initialized with 
1000 parasites and 16 virions per cell. Each cell and virus was assigned an amount of time 
remaining until it divided or replicated, respectively. Because these delay times were composed 
of an unknown but large number of elementary chemical reactions, they were selected from 
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Gaussian distributions about the mean parasite division and virion replication times, rather than 
the Poisson distributions used for elementary reactions (37,49). At each step, the event with the 
shortest time remaining was selected, the simulation time incremented, and the model updated 
accordingly. 
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4.8 – Table 
Table 4-1: Effect of 2CMA-TP on Lgy LRV1 RDRP activity. 
Data represent IC50 values for the inhibition of full-length and small RDRP products. 
Values are means of 3-4 experiments ±S.D., calculated with Microsoft Excel. IC50 values 
greater than 600 µM were extrapolated from available data. 
RDRP 
Product 
Low Density 
(n=3) 
Medium Density 
(n=3) 
High Density 
(n=4) 
 
Full-Length 130 ± 67 260 ± 190 410 ± 140 
p<0.1 Small 510 ± 330 740 ± 400 1000 ± 480 
  p<0.07   
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4.9 – Figures  
 
Figure 4-1: Life cycle of LRV1 within the Leishmania cytoplasm. 
RNAs are indicated in color (+strand blue, -strand red); the dsRNA genome within the 
mature virion is shown as straight line while ssRNA are shown as jagged lines. The viral RDRP 
(black trapezoid) is shown fused to a capsid monomer (white circle), reflecting the current theory 
that the RDRP is generated through frame shift translation (26-28). 
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Figure 4-2: Distribution of viral capsid protein across a CsCl density gradient. 
Clarified parasite lysates were separated on a CsCl density gradient and the relative 
amount of viral capsid protein in each fraction was measured. Data for one representative 
gradient are shown out of the 7 performed. The “peak” fractions of low-, medium- and high-
density (LD, MD and HD), which were taken for RDRP assays, are labeled. 
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Figure 4-3: Radiolabeled RNAs produced by purified Lgy LRV1 RDRP in vitro. 
Panel A. RDRP in LD, MD, and HD fractions (Fig. 2) was assayed using [α-32P]UTP 
incorporation, as described in “Experimental Procedures.” Radiolabeled RNAs were run along-
side pure [α-32P]UTP on a native agarose gel. The full-length and small RDRP products are 
labeled for reference. Panel B. . RDRP reactions were performed in the presence of 0, 10, 30, 
100, 300, or 600 µM 2CMA-TP. As a negative control, the RDRP reaction was run using a mock 
HD fraction isolated from LRV1- Lgy parasites. Native agarose gels of radiolabeled RDRP 
products showed that RDRP activity decreased with increasing 2CMA-TP concentrations. A 
representative titration using the HD fraction is shown here. 
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Figure 4-4: Inhibition of RDRP activity of purified Lgy LRV1 virions by 2CMA-TP. 
RDRP reactions were run in the presence of 2CMA-TP and the amounts of full-length 
and small products were quantified. These amounts were normalized to the amount of product 
formed in the absence of 2CMA-TP. The averages and SDs (calculated with Microsoft Excel) 
from three LD virion titrations and four HD virion titrations are shown. MD virions show 
intermediate profiles (not shown; see Table 1). Effect of 2CMA-TP on production of full-length 
(Panel A) and short (Panel B) RNAs by RDRP activity in HD (solid line) and LD (dotted line) 
virions. 
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Figure 4-5: Specificity of Lgy RDRP inhibition by 2CMA-TP relative to 2CMA and dATP. 
RDRP reactions were run for 1 hour in the presence of 1 mM 2CMA, 600 µM dATP, or 
600 µM 2CMA-TP. The amount of full-length (left) and small products (right) were measured 
and normalized to untreated control reactions. The averages and ranges are shown for two 
experiments. 
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Figure 4-6: Lgy M4147 LRV1+ parasites synthesize 2CMA-TP. 
Panel A. Standards establishing the HPLC elution time of 2CMA-TP relative to dGTP, 
the exogenous internal standard (although present naturally, the concentrations are far below that 
added here). The figure shows the HPLC elution profiles of a mixture of ATP and the dGTP 
internal standard with (black) or without (gray) 2CMA-TP. The small peak eluting in the 2CMA-
TP containing experiment between dGTP and ATP is presumed to be 2CMA-DP. Panel B. 
Detection of 2CMA-TP in Lgy incubated in 10 µM 2CMA for 20 hours. In order to correct for 
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variation in extraction efficiency and HPLC elution times, all samples have 7 nmol dGTP spiked 
in immediately prior to extraction. Standards are as in panel A. 
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Figure 4-7: L. guyanensis parasites accumulate high levels of 2CMA-TP. 
Panel A. Graph showing the measured intracellular concentration of 2CMA-TP formed 
after 18 hr incubation in the indicated concentration of external 2CMA. Intracellular nucleotides 
were extracted and quantified by HPLC, and concentrations estimated from cell volumes 
estimated from a standard curve of forward scattering measurements (Experimental Procedures; 
Fig. S2). For reference, the LRV1 EC50 is marked on the X axis (black arrow) and the minimum 
RDRP IC50 on the Y axis (grey arrow). The ratio of internal 2CMA-TP to external 2CMA 
concentrations is plotted in blue. Panel B. Plot of 2CMA-TP accumulation after adding 10 µM 
2CMA to late-log-phase cells (n=2). Each point represents a concentration measured from a 
separate culture. 
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Figure 4-8: Retention of 2CMA-TP following removal of 2CMA. 
LRV1+ Lgy M4147 parasites were incubated for 19 hr in the presence of 10 µM 2CMA; 
at that time, cells were harvested and resuspended in drug free medium, and intracellular 2CMA-
TP levels were measured as described in the legend to Fig. 7 at 2, 4, or 8 hours after removal of 
drug. Each individual data point (black circles) is the concentration from a single culture. This 
experiment was repeated twice using two independent cultures per time point (n=4). The 
averages and standard deviations of each time point are plotted in as black dashed lines. Panel A. 
Data uncorrected for cell growth. Panel B. Data corrected for cell growth (about 1.4-fold over 
the course of the experiment). 
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Figure 4-9: Parameterization and output for Gillespie simulation of LRV1 loss. 
Panel A. Results of Gillespie simulation assuming relative inhibition of LRV1 and 
parasite replication to be 1/1 to 1/4. A theoretical plot for total inhibition of viral replication and 
ideal viral dilution is shown (gray dotted line), and two experimental data sets from Kuhlmann et 
al (11) are shown as dark dashed lines. Panel B. RDRP and parasite growth inhibition data 
relevant to parameterization of the Gillespie simulation. The X axes relate the external 2CMA 
and intracellular 2CMA-TP concentrations (Fig. 7). The rate of parasite growth in the presence 
of 2CMA (solid line; Δ) and the rate of RDRP activity (LD virions making full-length products) 
in the presence of 2CMA-TP (●) were normalized relative to untreated controls. The best-fit 
IC50 curve (grey dashed line) was fitted to the RDRP activity data. Assuming that the most 
drug-sensitive RDRP activity defines the rate of virus replication, the relative inhibition ratio 
(blue dotted line; ■) was defined as the ratio of RDRP activity to parasite growth. 
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Figure 4-S1: Structures of LRV1 Inhibitors. 
Chemical structures of (A) adenosine, (B) 2‟-C-methyladenosine, and (C) 7-deaza-2‟-C-
methyladenosine. 
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Figure 4-S2: Relationship Between Parasite Volume and Light Scattering 
 
Relationship between L. guyanensis M4147 parasite volume and forward-scattering 
intensity at three points in log phase growth. Leishmania cells are known to decrease in volume 
as cell density increases toward stationary phase where they differentiate to smaller metacyclic 
forms. (Sacks & Perkins, 1984) 
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Figure 4-S3: Standard curves for HPLC trace area vs. compound amounts. 
HPLC chromatogram peak areas correlate linearly with amounts of nucleotide injected. 
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4.10 – Supplementary Text 
4.10.1 – Supplementary Text 1: Conversion of flow cytometric scatter profiles to cellular 
volumes (Image J implementation) 
Image stacks of GFP-expressing Leishmania parasites were obtained by spinning-disk 
confocal microscopy (see main methods for more detail). We implemented a ImageJ script to 
automatically identify parasites and measure their volumes (1). This script takes the 3D confocal 
microscopy stack and re-slices it along the x- and y-axes to create two new images. Automatic 
local thresholds are then calculated for each slice of the x-, y-, and z-stacks using Bernsen‟s 
method (2). Each thresholded stack is then re-sliced to the original orientation and all three 
stacks are added together. This yields an image stack where the value of each voxel corresponds 
to the number of dimensions in which it was deemed to be part of a cell. Cell volumes were 
reliably defined by those voxels identified in 2 or 3 dimensions. Volumes were estimated using 
the ImageJ 3D Objects Counter with the threshold set to 2 (3). Cells in direct contact were 
occasionally counted as one object. These were manually identified and corrected by dividing the 
volume of the combined object by the number of cells within it. 
 
3_Way_Local_Threshold.ijm 
// 3_Way_Local_Threshold 
// John I Robinson 
 
method = "Bernsen"; 
radius = "25"; 
 
// create working copy of current image 
tempTitle = getTitle() + "-thresholded"; 
run("Duplicate...", "title=" + tempTitle + " duplicate"); 
 
setBatchMode(true); 
rename(tempTitle); 
 
run("8-bit"); 
 
// reslice stack from top and left 
run("Reslice [/]...", "output=0.270 start=Top avoid"); 
155 
 
rename("top"); 
selectWindow(tempTitle); 
run("Reslice [/]...", "output=0.270 start=Left avoid"); 
rename("left"); 
 
// calculate local threshold on each view 
selectWindow(tempTitle); 
run("Auto Local Threshold", "method=" + method + " radius=" + radius + " 
parameter_1=0 parameter_2=0 white stack"); 
selectWindow("top"); 
run("Auto Local Threshold", "method=" + method + " radius=" + radius + " 
parameter_1=0 parameter_2=0 white stack"); 
selectWindow("left"); 
run("Auto Local Threshold", "method=" + method + " radius=" + radius + " 
parameter_1=0 parameter_2=0 white stack"); 
 
// convert back to standard view 
selectWindow("top"); 
run("Reslice [/]...", "output=0.212 start=Top avoid"); 
selectWindow("left"); 
run("Reslice [/]...", "output=0.212 start=Top rotate avoid"); 
 
// merge results 
selectWindow(tempTitle); 
run("Subtract...", "value=254 stack"); 
selectWindow("Reslice of top"); 
run("Subtract...", "value=254 stack"); 
selectWindow("Reslice of left"); 
run("Subtract...", "value=254 stack"); 
imageCalculator("Add stack", tempTitle,"Reslice of top"); 
imageCalculator("Add stack", tempTitle,"Reslice of left"); 
 
// apply a useful LUT so we can see the results 
reds = newArray(256); 
reds[3] = 255; 
greens = newArray(256); 
greens[1] = 121; 
blues = newArray(256); 
blues[2] = 255; 
setLut(reds, greens, blues); 
 
// clean up 
selectWindow("top"); 
close(); 
selectWindow("left"); 
close(); 
selectWindow("Reslice of top"); 
close(); 
selectWindow("Reslice of left"); 
close(); 
setBatchMode(false); 
print("Done processing " + tempTitle); 
selectWindow(tempTitle); 
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References for Supplementary Text 1: 
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Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., 
Hartenstein, V., Eliceiri, K., Tomancak, P., and Cardona, A. (2012) Fiji: an open-source 
platform for biological-image analysis. Nat Methods 9, 676-682 
2. Sezgin, M., and Sankur, B. l. (2004) Survey over image thresholding techniques and 
quantitative performance evaluation. ELECTIM 13, 146-168 
3. Bolte, S., and CordeliÈRes, F. P. (2006) A guided tour into subcellular colocalization 
analysis in light microscopy. Journal of Microscopy 224, 213-232 
 
4.10.2 – Supplementary Text 2: Gillespie simulation of LRV1 loss under 2CMA inhibition and 
Java implementation 
As described in the main text, this simulation models Leishmania and LRV1 replication. 
It utilizes the next-reaction modification (NRM) to the Gillespie algorithm (1). The model 
implements two kinds of entity: parasites and virions. Each parasite can contain a number of 
virions. The model also includes two types of process: parasite division and virion replication. 
The NRM algorithm works by first randomly picking times remaining until each entity 
completes a process, using a probability distribution defined by that process‟ rate. The traditional 
Gillespie algorithm, which simulates elementary chemical reactions, uses an exponential 
distribution of waiting times, which is appropriate for Poisson-type processes (2). Here, since 
cell division and virus replication are complex processes involving many steps, we pick 
individual event times from Gaussian distributions about the mean parasite doubling and virus 
replication times (1). The selected waiting times are then sorted in a priority queue. At each step, 
the process with the shortest waiting time is executed and any dependent processes have their 
waiting times updated. Given only two processes, this model‟s behavior is defined by the 
relationship between those processes‟ rates. For simplicity‟s sake, we let the parasite division 
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time be exactly 8 hours. Given that the number of virions per parasite remains roughly constant, 
we assume that the effective virion replication rate is equal to the parasite division time under 
normal conditions (3,4). If the unit of time in this simulation is converted from hours to multiples 
of the parasite division time, the simulation‟s behavior depends entirely on the ratio between the 
virion replication time and the parasite doubling time. 
 The secondary parameters defining this model are the initial number of cells and the 
initial number of LRV1 particles per cell. We found that modeling an initial population of 1000 
cells over time, tracking the viral titer in each cell, gave indistinguishable profiles across multiple 
runs, so we used this value for each simulation. Initial LRV1 numbers were set at 16 per cell, 
consistent with previous studies (3). 
Modeling parasite division required also modeling the distribution of virions between the 
daughter cells. Previously, we have shown that virions are distributed roughly equally when 
parasites divide (3). In theory, this would be modeled using a binomial distribution. However, 
such a mechanism would allot all virions to one daughter cell frequently enough (1 in 6.6×105 
divisions with a full 16 virions) to make LRV1+ populations unstable and cause spontaneous 
virus loss far more often than actually observed (5). Instead, we assumed that virion partitioning 
is not entirely random, but instead based on location, resulting in daughter cells receiving closer 
to 50% of the parent‟s virions. To model this, the proportion of virions given to new daughter 
cells was selected from a Gaussian distribution with mean of 50% and standard deviation of 
6.25%. This standard deviation was selected to give a vanishingly small chance of stochastically 
“curing” a daughter of a parasite with 16 virions. 
 
Java implementation 
 
NRSMain2.java 
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This class includes the overarching logic that controls simulations. Several arrays of 
parameters allow users to define and run a series of simulations automatically. This program 
makes use of the Apache Math Library, version 3.6.1. 
 
package nrs; 
 
import java.io.File; 
import java.io.FileNotFoundException; 
import java.io.PrintStream; 
import java.util.HashMap; 
import java.util.LinkedList; 
import java.util.Map.Entry; 
import java.util.PriorityQueue; 
import java.util.TreeMap; 
import java.util.concurrent.ForkJoinPool; 
import java.util.concurrent.TimeUnit; 
 
// Apache Math 3.6.1 from http://commons.apache.org/proper/commons-math/ 
import org.apache.commons.math3.random.MersenneTwister; 
import org.apache.commons.math3.special.Erf; 
 
public class NRSMain2 { 
  
 private static MersenneTwister RAND = new MersenneTwister(); 
  
 private static double SD_SCALE = 16; 
 private static double DEFAULT_CELL_T2 = 8; 
 private static double DEFAULT_VIRUS_T2 = 8; 
 /** 
 Number of parasites to put into each simulation initially. 
 */ 
 private static int POPULATION_SIZE = 1000; 
 /** 
 How many hours to run the simulation for. 
 */ 
 private static double STOP_TIME = 48; 
 /** 
 How many intermediate population snapshots to record. 
 */ 
 private static double SNAP_INTERVAL = 8; 
 
 /** 
  * @param args 
  */ 
 public static void main(String[] args) { 
  Parasite newCell; 
  Virion vir; 
  Simulation sim; 
  LinkedList<Simulation> sims; 
  PriorityQueue<Process> equilPop, popClone; 
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  // Set parameters for the simulations we'll be running. 
  // Each column corresponds to the parameters for one simulation. 
   
  // Parasite doubling times 
  double[] cellT2s = {8,8,8,8,8,8}; 
  // Virus replication times 
  double[] virusT2s = { 8*2, 8*2, 8*2, 8*3, 8*3, 8*3 }; 
  // How many virions per cell initially 
  int[] initVirions = { 16, 16, 16, 16, 16, 16 }; 
  // Limit on the number of virions per cell. Keep this >>16. 
  int[] maxVirions = { 80, 80, 80, 80, 80, 80 }; 
   
  // create initial population 
  equilPop = new PriorityQueue<>(); 
  int startPop = POPULATION_SIZE; 
  for(int k = 0; k < startPop; k++) 
  { 
   // we'll handle the virions belonging to each parasite here 
too 
   newCell = new Parasite(NRSMain2.initialTau(DEFAULT_CELL_T2,  
     DEFAULT_CELL_T2/SD_SCALE)); 
   // clone all the virions 
   for(int j = 0; j < initVirions[0]; j++) 
   { 
    // we're messing with virus T2, so we need to 
recalculate tau 
    vir = new Virion(newCell,  
      NRSMain2.initialTau(DEFAULT_VIRUS_T2,  
      DEFAULT_VIRUS_T2/SD_SCALE)); 
    newCell.addVirion(vir); 
    equilPop.add(vir); 
   } 
   equilPop.add(newCell); 
  } 
   
  // set up thread pool to handle all the simulations concurrently 
  ForkJoinPool threadPool = new 
ForkJoinPool(Runtime.getRuntime().availableProcessors() - 1); 
   
  // now run the actual simulations 
  sims = new LinkedList<>(); 
  for(int i = 0; i < maxVirions.length; i++) 
  { 
   // Clone each parasite and virion 
   popClone = new PriorityQueue<>(); 
   for(Process p : equilPop) 
   { 
    if(p instanceof Parasite) 
    { 
     // copy constructor clones the virions too 
     newCell = new Parasite((Parasite)p); 
     popClone.add(newCell); 
     popClone.addAll(newCell.getVirionsView()); 
     // need to update tau values to reflect new 
rates 
     newCell.setTau(NRSMain2.initialTau(cellT2s[i], 
cellT2s[i]/SD_SCALE)); 
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     for(Virion v : newCell.getVirionsView()) 
     { 
      v.setTau(NRSMain2.initialTau(virusT2s[i], 
virusT2s[i]/SD_SCALE)); 
     } 
    } 
   } 
   sim = new Simulation(popClone, cellT2s[i], virusT2s[i], 
maxVirions[i], 
     STOP_TIME, SNAP_INTERVAL); 
   sims.add(sim); 
   threadPool.execute(sim); 
  } 
   
  // wait for all the simulations to end 
  try { 
   threadPool.shutdown(); 
   threadPool.awaitTermination(Long.MAX_VALUE, TimeUnit.DAYS); 
  } catch (InterruptedException e1) { 
   e1.printStackTrace(); 
  } 
  System.out.println("Done!"); 
  System.out.println(sims.getFirst().getSnapshots()); 
   
  // print out the data to files 
  for(int i = 0; i < sims.size(); i++) 
  { 
   try { 
    PrintStream ps = new PrintStream(new File("sim-" + i 
+ ".csv")); 
    printSimulation(sims.get(i), ps); 
    ps.close(); 
   } catch (FileNotFoundException e) { 
    System.err.println("Failed to open file: sim-" + i + 
".csv"); 
    e.printStackTrace(); 
   } 
  } 
 } 
  
 /** 
  * Pick a random tau value for a process, assuming that instances of 
that 
  * process are at steady state. 
  * @param mu the mean tau value 
  * @param sigma the standard deviation of tau values 
  * @return the random tau value 
  */ 
 private static double initialTau(double mu, double sigma) 
 { 
  double a = mu/(sigma*Math.sqrt(2)); 
  double b = (1+Erf.erf(a))*Math.PI*Math.exp(a*a); 
  double slope = b/(mu*b + sigma*Math.sqrt(2*Math.PI)); 
  return RAND.nextDouble()/slope; 
 } 
  
 private static void printSimulation(Simulation sim, PrintStream ps) 
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 { 
  HashMap<Integer, Long> snap; 
  long count, sum; 
  double gSum, time; 
  StringBuilder hdr, line; 
   
  // get maximum number of virions allowed in the simulation 
  int maxVirions = sim.getMaxVirions(); 
  // get the list of snapshots 
  TreeMap<Double, HashMap<Integer, Long>> snaps = 
sim.getSnapshots(); 
   
  // build header and write it 
  hdr = new StringBuilder("Time,"); 
  for(int i = 0; i <= maxVirions; i++) 
  { 
   hdr.append(i); 
   hdr.append(','); 
  } 
  hdr.append("Total,GeoMean"); 
  ps.println(hdr); 
   
  line = new StringBuilder(); 
   
  // loop over all the snapshots 
  for(Entry<Double, HashMap<Integer, Long>> entry : 
snaps.entrySet()) 
  { 
   time = entry.getKey(); 
   // write out the time stamp 
   line.append(time); 
   line.append(','); 
    
   // write out the parasite counts 
   snap = entry.getValue(); 
   sum = 0; 
   gSum = 0; 
   for(int i = 0; i <= maxVirions; i++) 
   { 
    if(snap.containsKey(i)) 
    { 
     count = snap.get(i); 
    } 
    else 
    { 
     count = 0; 
    } 
    sum += count; 
    gSum += count*Math.log(i+1); 
    line.append(count); 
    line.append(','); 
   } 
   // write out total and geometric mean (Williams' 
modification) 
   line.append(sum); 
   line.append(','); 
   gSum = Math.exp(gSum/sum) - 1; 
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   line.append(gSum); 
   // write the line 
   ps.println(line); 
   // reset the line 
   line.setLength(0); 
  } 
 } 
 
} 
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Simulation.java 
 
This class implements an individual LRV1 simulation, given an initial parasite population 
and a set of parameters and options. 
 
package nrs; 
 
import java.util.HashMap; 
import java.util.HashSet; 
import java.util.LinkedList; 
import java.util.Map.Entry; 
import java.util.PriorityQueue; 
import java.util.TreeMap; 
import java.util.concurrent.ForkJoinTask; 
import java.util.concurrent.RecursiveAction; 
 
// Apache Math 3.6.1 from http://commons.apache.org/proper/commons-math/ 
import org.apache.commons.math3.distribution.NormalDistribution; 
import org.apache.commons.math3.random.MersenneTwister; 
 
public class Simulation extends RecursiveAction { 
 private static final long serialVersionUID = -2016479837671294476L; 
 private static final double SD_SCALE = 16; 
 // Narrows the standard deviation of the proportion of virions given to 
a 
 // new daughter cell. 
 private static final double DIVISION_SD_SCALE = 2; 
  
 private MersenneTwister myRand; 
 private double myCellT2, myVirusT2; 
 private int myMaxVirions; 
 private double myStopTime, mySnapInterval; 
  
 private NormalDistribution myCellPDF, myVirusPDF; 
 private TreeMap<Double, HashMap<Integer, Long>> mySnapshots; 
 private PriorityQueue<Process> myPopulation; 
  
 public Simulation(PriorityQueue<Process> population, double cellT2,  
   double virusT2, int maxVirions, double stopTime, double 
snapInterval) { 
  myPopulation = population; 
  myCellT2 = cellT2; 
  myVirusT2 = virusT2; 
  myMaxVirions = maxVirions; 
  myStopTime = stopTime; 
  mySnapInterval = snapInterval; 
   
  myRand = new MersenneTwister(); 
  myCellPDF = new NormalDistribution(myRand, myCellT2, 
myCellT2/25.74); 
  myVirusPDF = new NormalDistribution(myRand, myVirusT2, 
myVirusT2/25.74); 
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  mySnapshots = new TreeMap<>(); 
 } 
 
 /** 
  * Get a map of the snapshots taken by this simulation. 
  * @return the snapshots 
  */ 
 public TreeMap<Double, HashMap<Integer, Long>> getSnapshots() { 
  return mySnapshots; 
 } 
  
 /** 
  * @return the maxVirions 
  */ 
 public int getMaxVirions() { 
  return myMaxVirions; 
 } 
 
 private void run() { 
  double time, mean, sd; 
  int numVirions, d1, d2; 
  LinkedList<Double> snapTimes; 
  Double nextSnap; 
  Process rxn; 
  Parasite cell, daughter; 
  Virion vir, newVir; 
   
  // list of processes with changed tau values 
  HashSet<Process> needsUpdating = new HashSet<>(); 
   
  // calculate the list of snapshot times 
  snapTimes = new LinkedList<Double>(); 
  for(double i = 0; i <= myStopTime; i += mySnapInterval) 
  { 
   snapTimes.add(i); 
  } 
  nextSnap = snapTimes.pop(); 
   
  time = 0; 
 
  // take an initial snapshot 
  System.out.println("Running simulation: " + this); 
  mySnapshots.put(nextSnap, this.takeSnapshot()); 
  nextSnap = snapTimes.pop(); 
   
  // Any time a parasite divides or virion replicates: 
  // Generate tau for new cells or virions 
  // Put tau values into the priority queue 
  // Tau for next event is minimum value in queue 
  while(time < myStopTime) 
  { 
   // (#) Pick reaction from P with minimum tau_r 
   rxn = myPopulation.peek(); 
   // Update time 
   time = rxn.getTau(); 
   // Change numbers of molecules to reflect the reaction 
   if(rxn instanceof Parasite) 
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   { 
    // parasite is dividing 
    cell = (Parasite)rxn; 
    numVirions = cell.getVirionCount(); 
    // use squashed normal distribution 
    mean = numVirions/2.0; 
    sd = Math.sqrt(mean)/2.0/DIVISION_SD_SCALE; 
    d1 = (int) Math.round(sd*myRand.nextGaussian() + 
mean); 
    if(d1 < 0) 
    { 
     d1 = 0; 
    } 
    else if(d1 >= numVirions) 
    { 
     d1 = numVirions; 
    } 
    d2 = numVirions - d1; 
    // if the dividing parasite was at maximum virions, 
we need to 
    // restart virus replication 
    if(numVirions >= myMaxVirions) 
    { 
     for(Virion v : cell.getVirionsView()) 
     { 
      v.setTau(time + this.pickVirusTau()); 
      needsUpdating.add(v); 
     } 
    } 
    // create and populate daughter cell 
    daughter = new Parasite(time + 
this.pickParasiteTau()); 
    needsUpdating.add(daughter); 
    for(int i = 0; i < d2; i++) 
    { 
     vir = cell.removeVirion(0); 
     vir.setHost(daughter); 
     daughter.addVirion(vir); 
    } 
    // pick new tau value for the parent cell 
    cell.setTau(time + this.pickParasiteTau()); 
    needsUpdating.add(cell); 
   } 
   else if(rxn instanceof Virion) 
   { 
    // virus is replicating 
    vir = (Virion)rxn; 
    cell = vir.getHost(); 
    // create new virion 
    newVir = new Virion(cell, 0); 
    cell.addVirion(newVir); 
     
    if(cell.getVirionCount() >= myMaxVirions) 
    { 
     // maximum number of virions reached, so stop 
replication 
     for(Virion v : cell.getVirionsView()) 
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     { 
      v.setTau(Double.POSITIVE_INFINITY); 
      needsUpdating.add(v); 
     } 
    } 
    else 
    { 
     // set tau for new virion and one that 
replicated 
     vir.setTau(time + this.pickVirusTau()); 
     needsUpdating.add(vir); 
     newVir.setTau(time + this.pickVirusTau()); 
     needsUpdating.add(newVir); 
    } 
   } 
    
   // Rebuild tau queue to account for changes 
   myPopulation.removeAll(needsUpdating); 
   myPopulation.addAll(needsUpdating); 
   needsUpdating.clear(); 
    
   // take a snapshot, if applicable 
   if(time >= nextSnap) 
   { 
    mySnapshots.put(nextSnap, this.takeSnapshot()); 
    nextSnap = snapTimes.poll(); 
   } 
   // Loop back to (#) 
  } 
 } 
 
 /** 
  * Select a random length of time that a parasite will wait before 
dividing. 
  * @return the time 
  */ 
 private double pickParasiteTau() 
 { 
  return myCellPDF.sample(); 
 } 
  
 /** 
  * Select a random length of time that a parasite will wait before 
dividing. 
  * @return the time 
  */ 
 private double pickVirusTau() 
 { 
  return myVirusPDF.sample(); 
 } 
  
 /** 
  * Takes a snapshot of the current parasite population. 
  * @return a map with the number of parasites containing a given number 
  * of virions 
  */ 
 private HashMap<Integer, Long> takeSnapshot() 
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 { 
  int numVirions; 
  Long count; 
  HashMap<Integer, Long> histo = new HashMap<>(); 
   
  for(Process p : myPopulation) 
  { 
   if(p instanceof Parasite) 
   { 
    // increment the bin for parasites with this many 
virions 
    numVirions = ((Parasite)p).getVirionCount(); 
    count = histo.get(numVirions); 
    if(count == null) 
     histo.put(numVirions, 1L); 
    else 
     histo.put(numVirions, count + 1L); 
   } 
  } 
  return histo; 
 } 
 
 @Override 
 protected void compute() { 
  int index; 
  Parasite cell; 
  Simulation sim1, sim2; 
  PriorityQueue<Process> pop1, pop2; 
   
  if(myPopulation.size() > 200) 
  { 
   // this simulation is too big, so split it up by turning it 
into 
   // two jobs with half as many parasites 
   index = 0; 
   pop1 = new PriorityQueue<>(); 
   pop2 = new PriorityQueue<>(); 
   for(Process p : myPopulation) 
   { 
    if(p instanceof Parasite) 
    { 
     cell = (Parasite)p; 
     // add parasite and its virions to one 
population or the other 
     if(index%2 == 0) 
     { 
      pop1.add(cell); 
      pop1.addAll(cell.getVirionsView()); 
     } 
     else 
     { 
      pop2.add(cell); 
      pop2.addAll(cell.getVirionsView()); 
     } 
     index++; 
    } 
   } 
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   sim1 = new Simulation(pop1, myCellT2, myVirusT2, 
myMaxVirions,  
     myStopTime, mySnapInterval); 
   sim2 = new Simulation(pop2, myCellT2, myVirusT2, 
myMaxVirions,  
     myStopTime, mySnapInterval); 
   // launch the two simulations and wait for them to complete 
   ForkJoinTask.invokeAll(sim1, sim2); 
    
   this.combine(sim1, sim2); 
  } 
  else 
  { 
   // we've got a small enough simulation, so just run it 
   this.run(); 
  } 
 } 
 
 /** 
  * Merges two sub-simulations back into this one. 
  * @param sim1 
  * @param sim2 
  */ 
 private void combine(Simulation sim1, Simulation sim2) { 
  long count; 
  Integer numVirions; 
  Parasite cell; 
  HashMap<Integer, Long> histo1, histo2; 
   
  // clear the out-of-date population 
  myPopulation.clear(); 
  // add each sub-population 
  for(Process p : sim1.myPopulation) 
  { 
   if(p instanceof Parasite) 
   { 
    cell = (Parasite)p; 
    myPopulation.add(cell); 
    myPopulation.addAll(cell.getVirionsView()); 
   } 
  } 
  for(Process p : sim2.myPopulation) 
  { 
   if(p instanceof Parasite) 
   { 
    cell = (Parasite)p; 
    myPopulation.add(cell); 
    myPopulation.addAll(cell.getVirionsView()); 
   } 
  } 
  // combine snapshots 
  for(Entry<Double, HashMap<Integer, Long>> e : 
sim1.getSnapshots().entrySet()) 
  { 
   if(!mySnapshots.containsKey(e.getKey())) 
   { 
    // this snapshot is not present in the parent list 
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    mySnapshots.put(e.getKey(), e.getValue()); 
   } 
   else 
   { 
    histo1 = mySnapshots.get(e.getKey()); 
    histo2 = e.getValue(); 
    for(Entry<Integer, Long> eh : histo2.entrySet()) 
    { 
     numVirions = eh.getKey(); 
     if(histo1.containsKey(numVirions)) 
     { 
      // add this entry to a preexisting one 
      count = histo1.get(numVirions); 
      count += histo2.get(numVirions); 
      histo1.put(numVirions, count); 
     } 
     else 
     { 
      // add a new entry 
      histo1.put(numVirions, eh.getValue()); 
     } 
    } 
   } 
  } 
  for(Entry<Double, HashMap<Integer, Long>> e : 
sim2.getSnapshots().entrySet()) 
  { 
   if(!mySnapshots.containsKey(e.getKey())) 
   { 
    // this snapshot is not present in the parent list 
    mySnapshots.put(e.getKey(), e.getValue()); 
   } 
   else 
   { 
    histo1 = mySnapshots.get(e.getKey()); 
    histo2 = e.getValue(); 
    for(Entry<Integer, Long> eh : histo2.entrySet()) 
    { 
     numVirions = eh.getKey(); 
     if(histo1.containsKey(numVirions)) 
     { 
      // add this entry to a preexisting one 
      count = histo1.get(numVirions); 
      count += histo2.get(numVirions); 
      histo1.put(numVirions, count); 
     } 
     else 
     { 
      // add a new entry 
      histo1.put(numVirions, eh.getValue()); 
     } 
    } 
   } 
  } 
 } 
 
 /* (non-Javadoc) 
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  * @see java.lang.Object#toString() 
  */ 
 @Override 
 public String toString() { 
  return "Simulation [cellT2=" + myCellT2 + ", virusT2=" + 
myVirusT2 
    + ", maxVirions=" + myMaxVirions + ", stopTime=" 
    + myStopTime + ", processes=" + myPopulation.size() + 
"]"; 
 } 
 
} 
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Parasite.java 
 
This class defines the properties of a parasite. It holds the time when this parasite will 
divide and also keeps track of the virions contained within this parasite. 
 
package nrs; 
 
import java.util.Collection; 
import java.util.Collections; 
import java.util.LinkedList; 
import java.util.List; 
 
public class Parasite extends Process { 
 private LinkedList<Virion> myVirions; 
 
 public Parasite() { 
  this(Double.POSITIVE_INFINITY, Collections.<Virion> emptyList()); 
 } 
  
 public Parasite(double tau) 
 { 
  this(tau, Collections.<Virion> emptyList()); 
 } 
  
 /** 
 Constructs a new parasite with some virions and a given time when 
 it will divides. 
 @param tau when this parasite will divide 
 @param virions the virions inside this parasite 
 */ 
 public Parasite(double tau, Collection<Virion> virions) 
 { 
  super(tau); 
  myVirions = new LinkedList<Virion>(virions); 
   
  // make sure all virions are assigned to me 
  for(Virion v : myVirions) 
  { 
   v.setHost(this); 
  } 
 } 
  
 /** 
  * Copy constructor for parasites. 
  * @param p the parasite to copy 
  */ 
 public Parasite(Parasite p) 
 { 
  super(p.getTau()); 
  myVirions = new LinkedList<Virion>(); 
  Virion copy; 
  for(Virion v : p.myVirions) 
  { 
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   copy = new Virion(v); 
   copy.setHost(this); // set the cloned host 
   myVirions.add(copy); 
  } 
 } 
 
 /** 
  *  
  * @return the virions 
  */ 
 public List<Virion> getVirionsView() { 
  return Collections.unmodifiableList(myVirions); 
 } 
 
 /** 
  * @return 
  * @see java.util.LinkedList#size() 
  */ 
 public int getVirionCount() { 
  return myVirions.size(); 
 } 
 
 /** 
  * @param e 
  * @return 
  * @see java.util.LinkedList#add(java.lang.Object) 
  */ 
 public boolean addVirion(Virion e) { 
  return myVirions.add(e); 
 } 
  
 public Virion removeVirion(int index) 
 { 
  return myVirions.remove(index); 
 } 
 
 /** 
  * Simply calls the Process equals method, which compares objects based 
on 
  * their tau values. 
  * @param obj the other process 
  */ 
 @Override 
 public boolean equals(Object obj) { 
  return super.equals(obj); 
 } 
 
 /* (non-Javadoc) 
  * @see nrs.Process#hashCode() 
  */ 
 @Override 
 public int hashCode() { 
  return super.hashCode(); 
 } 
 
} 
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Virion.java 
 
This class implements the properties of a virion. It keeps track of when this virion will 
next replicate and what parasite it is infecting. 
 
package nrs; 
 
 
public class Virion extends Process { 
  
 private Parasite myHost; 
  
 public Virion(Parasite host, double tau) { 
  super(tau); 
  myHost = host; 
   
 } 
  
 /** 
  * Copy constructor for virions. 
  * @param v the virion to copy 
  */ 
 public Virion(Virion v) 
 { 
  super(v.getTau()); 
  this.myHost = v.myHost; 
 } 
 
 /** 
  * @return the host 
  */ 
 public Parasite getHost() { 
  return myHost; 
 } 
 
 /** 
  * @param host the host to set 
  */ 
 public void setHost(Parasite host) { 
  myHost = host; 
 } 
 
 /** 
  * Simply calls the Process equals method, which compares objects based 
on 
  * their tau values. 
  * @param obj the other process 
  */ 
 @Override 
 public boolean equals(Object obj) { 
  return super.equals(obj); 
 } 
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 /* (non-Javadoc) 
  * @see nrs.Process#hashCode() 
  */ 
 @Override 
 public int hashCode() { 
  return super.hashCode(); 
 } 
 
} 
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Process.java 
 
This generic class defines processes in a next-reaction Gillespie simulation. The Parasite 
and Virion classes represent cell division and virus replication processes, so they inherit from 
this class. 
 
package nrs; 
 
/** 
 * Generic class defining processes in a next-reaction Gillespie simulation. 
 * 
 */ 
public class Process implements Comparable<Process> { 
 private double myTau; 
  
 public Process(double tau) 
 { 
  myTau = tau; 
 } 
 
 /** 
  * Gets the absolute time when this process will next occur. 
  * @return the time 
  */ 
 public double getTau() 
 { 
  return myTau; 
 } 
  
 /** 
  * Set the absolute time when this process will next occur. 
  * @param tau the time 
  */ 
 public void setTau(double tau) 
 { 
  myTau = tau; 
 } 
 
 /* (non-Javadoc) 
  * @see java.lang.Comparable#compareTo(java.lang.Object) 
  */ 
 @Override 
 public int compareTo(Process o) { 
  return Double.compare(this.myTau, o.myTau); 
 } 
 
 /* (non-Javadoc) 
  * @see java.lang.Object#hashCode() 
  */ 
 @Override 
 public int hashCode() { 
  final int prime = 31; 
176 
 
  int result = 1; 
  long temp; 
  temp = Double.doubleToLongBits(myTau); 
  result = prime * result + (int) (temp ^ (temp >>> 32)); 
  return result; 
 } 
 
 /* (non-Javadoc) 
  * @see java.lang.Object#equals(java.lang.Object) 
  */ 
 @Override 
 public boolean equals(Object obj) { 
  if (this == obj) 
   return true; 
  if (obj == null) 
   return false; 
  if (!(obj instanceof Process)) 
   return false; 
  Process other = (Process) obj; 
  if (Double.doubleToLongBits(myTau) != Double 
    .doubleToLongBits(other.myTau)) 
   return false; 
  return true; 
 } 
} 
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Preface 
The first draft of this chapter was written by JIR. The final version presented here incorporates 
comments from SMB. 
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5.1 – Project Goals 
Given that Leishmania RNA Virus 1 (LRV1) exacerbates the severity of leishmaniasis in 
both mouse models and human disease (Ives et al. 2011; Hartley et al. 2016; Adaui et al. 2015; 
Ito et al. 2015; Cantanhede et al. 2015; Bourreau et al. 2015), tools for detecting and eliminating 
LRV1 could prove useful in treating human leishmaniasis. These tools would also be useful in 
the laboratory to probe the relationship between Leishmania parasites, LRV1, and the host 
immune system. Until recently, detection of LRV1 has been limited to time- and labor-intensive 
techniques not conducive to use in a clinical or resource-limited setting. (Widmer et al. 1989) 
Furthermore, with a single serendipitous exception, (Ro et al. 1997) it had been impossible to 
eliminate LRV1 from infected parasites. The first portion of this work, Chapter 2, describes a 
toolkit of methods for detecting and quantifying LRV1, with an emphasis on simple, relatively 
rapid techniques that could be adapted for clinical use. The greater portion of this work focuses 
on the discovery of effective LRV1 inhibitors (Chapter 3) and the investigation of their mode of 
action (Chapter 4). Finally, Appendix B lays the groundwork for attempting to moderate the 
immune effects of LRV1 by inhibiting it in a mouse model of leishmaniasis. Appendix A 
describes a drug screening setup for efficiently identifying Leishmania inhibitors, LRV1 
inhibitors, and Leishbunyavirus inhibitors at the same time. In this chapter, I will summarize my 
findings, discuss their wider implications, and propose future work to expand upon them. 
5.2– Development of Tools for the Detection of LRV1: Techniques and Uses 
In Chapter 2, we set out to collect or develop a wide range of tools for detecting, 
quantifying, and studying LRV1. These began with the “traditional” technique of detecting the 
dsRNA viral genome by purifying total parasite RNA and running it on a gel. (Tarr et al. 1988; 
Widmer et al. 1989) This method, although sequence-agnostic and useful for identifying new 
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viruses, is also time-consuming and requires specialized laboratory apparatus. Quantitative PCR 
of reverse transcribed viral RNA is a close relative of this method. It too requires significant time 
and resources, but also depends upon the precise sequences of the particular virus in question. 
Alternately, an antibody raised against the LRV1 capsid can also be used to detect LRV1. (Cadd 
et al. 1993) Although in this work the antibody was exclusively visualized by 
immunofluoresence imaging, for our drug screening efforts in Chapter 3 we modified the 
procedure for analysis by flow cytometry, effectively performing the same analysis over larger 
numbers of parasites. The capsid antibody, however, is limited to strains of LRV1 that share the 
epitopes it recognizes. In fact, although the antibody was raised against the LRV1 from an L. 
guyanensis strain, it was unable to recognize the virus from another L. guyanensis strain. The 
most promising approaches utilized an antibody that recognizes double-stranded RNA. (Bonin et 
al. 2000) This effectively allowed us to combine the efficiency of the capsid-based approach 
with the sequence independence of the RNA band approach. Importantly, the antibody was able 
to selectively stain LRV1+ parasites immobilized on a nitrocellulose membrane. Such assays are 
ideal for adaptation to clinical or field work, particularly since they were effective on samples 
taken directly from mouse lesions. I believe that with relatively little development cost these 
blotting methods could be converted into easy-to-use diagnostics that would enable healthcare 
workers to tailor leishmaniasis treatment depending on the presence or absence of LRV1. 
In the laboratory, antibody tools have proved highly useful for my research. As 
previously mentioned, we adapted the anti-capsid antibody for use in a flow cytometer, which 
allowed us to rapidly screen for LRV1 inhibitors by monitoring changes in average LRV1 
burden. I also utilized the anti-capsid antibody with the membrane blotting technique as a rapid 
way to locate virions in density gradient fractions as I optimized my virus purification protocol. 
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5.3– The Impact of LRV1 on Leishmaniasis and Approaches to Target it 
Studies of the role of LRV1 in disease and parasite biology were initially limited by the 
stability and non-infectivity of LRV1. Controlled comparisons of LRV+ and LRV- parasites 
were limited to a single isogenic pair of LRV+ and LRV- parasite strains generated through the 
fortuitous loss of LRV1 in a Leishmania guyanensis strain. (Ro et al. 1997) Recently, our lab 
leveraged the RNAi pathway present in the Leishmania (Viannia) sub-genus to knock down and 
eventually eliminate LRV1. (Lye et al. 2010; Brettmann et al. 2016) However, this technique 
requires genetic manipulation of the parasite, which makes it a slow and laborious way to 
eliminate the virus. Furthermore, RNA interference constructs are limited to targets with well-
conserved sequences, so an individual construct would not be applicable to more than a few virus 
strains. 
To remove this bottleneck and work towards clinically-relevant treatments for LRV1, we 
set out to identify small molecule inhibitors of LRV1 (Chapter 3). Given our relatively limited 
screening capacity, we sought to assemble a small library of compounds with a high likelihood 
of activity. Since polymerases are an essentially ubiquitous feature of viruses, nucleoside analogs 
compose a large proportion of anti-viral compounds. We hoped that an already well-
characterized anti-viral compound could be repurposed to inhibit LRV1 in human leishmaniasis. 
In addition, Leishmania parasites are purine auxotrophs (Carter et al. 2008), and thus avidly 
scavenge all natural nucleobases and nucleosides, plus a number of purine analogs such as 
allopurinol, increasing the likelihood of identifying a successful nucleoside analog inhibitor of 
LRV1. (Marr 1983; LaFon et al. 1985) As a result, we selected a number of known anti-viral 
nucleoside analogs and a wide range of other nucleoside analogs as the core of our screen. Other 
members of the viral family Totiviridae can be eliminated by growth cycle arrest, so we also 
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tested compounds like cyclohexamide. (Bhatti et al. 2011; Fink and Styles 1972) Finally, we 
included protease inhibitors because previous reports had proposed a role for a parasite cysteine 
protease in the maturation of LRV1 virions. (Carrion et al. 2003) 
Out of this screen of approximately 80 compounds, we identified two closely-related 
inhibitors of LRV1. These were 2‟-C-methyl-adenosine (2CMA) and its 7-deaza analog 
(7d2CMA). Both were relatively potent inhibitors of LRV1 replication, with EC50 
concentrations of 3 and 5 µM, respectively. By using moderate concentrations of 2CMA to 
reduce LRV1 levels, we were able to isolate drug-treated Leishmania clones either with or 
without LRV1. We utilized these strains to confirm our previous findings that LRV1-infected 
parasites induce greater pathology and parasite burden than uninfected parasites. Since both 
compounds are purine analogs, we hypothesized that they were taken up by the purine salvage 
pathway and converted to nucleotides, which would then inhibit the LRV1 RNA-dependent 
RNA polymerase (RDRP). 
5.4 – Insights into the LRV1 RDRP via its Inhibition by 2CMA Triphosphate 
In Chapter 4, I investigated the mechanism of action of 2CMA. Because 2CMA and 
7d2CMA are adenosine analogs, I hypothesized that the drug triphosphates would inhibit the 
LRV1 RDRP. This was supported by prior work done on both of these compounds that identified 
them as inhibitors of the Hepatitis C Virus (HCV) RDRP. (Carroll et al. 2003; Olsen et al. 2004) 
In addition, in Chapter 3 I used the PHYRE2 protein structure prediction server to build a 
tentative three-dimensional model of the LRV1 RDRP. (Kelley and Sternberg 2009) This 
structure, including the active site, was highly similar to known HCV RDRP structures, which 
further suggested that the drugs would bind the RDRP. Theoretically, 2CMA could inhibit LRV1 
in a similar mode of action to ribavirin by being incorporated into the viral genome and then 
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inducing fatally-large numbers of mutations. (Cameron and Castro 2001) However, treating 
parasites with 100 µM 2CMA resulted in complete inhibition of LRV1 replication, which we 
would expect if a critical viral enzyme like the RDRP were inhibited, but not if the virus was 
simply accumulating mutations. 
Running radiolabeled RDRP products out on an agarose gel revealed the presence of two 
distinct products: a discrete band the size of the viral genome and a continuum of 100-500 base-
pair small products (Chapter 4). Based on their small size and preliminary data suggesting that 
they are single-stranded, I believe that the small products represent abortive transcripts produced 
by the RDRP in the context of an in vitro assay. In a similar vein, the full-length product appears 
to be dsRNA and likely represents the replicase activity of the RDRP. Intriguingly, production of 
full-length RNA is more sensitive to 2CMA triphosphate (2CMA-TP) than the short products. In 
purifying LRV1 virions on density gradients, I was able to partially separate three populations of 
virion with characteristic densities. The lightest population (low-density virions) had a density 
suggesting that the virions were mostly empty of viral RNA, with the remainder containing 
mostly immature ssRNA viral genomes. Thus, in the viral RDRP assays, these virions would be 
largely replicating their genomes, rather than making viral transcripts. Interestingly, the low-
density virions were the most sensitive to 2CMA-TP. These results suggest that the RDRP 
replicase activity may be more sensitive to 2CMA-TP, likely due to some structural 
rearrangement of the active site to switch from replicating ssRNA to transcribing ssRNA from a 
dsRNA template. This hypothesis could be tested by purifying the LRV1 RDRP and measuring 
its activity in the presence of 2CMA-TP and synthetic ssRNA or dsRNA substrates. 
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5.5 – Mechanism of Action of 2CMA 
One of the useful features of 2CMA and 7d2CMA is that they are much more potent 
against LRV1 than against the parasite. I believe that this difference is the result of the decreased 
fidelity and increased promiscuity of viral RNA polymerases relative to cellular RNA 
polymerases. This is a common paradigm that has acquired great importance due to HCV, which 
has a particularly low-fidelity polymerase. (Moustafa et al. 2014; Castro et al. 2005; Cameron 
and Castro 2001) In this model, increased promiscuity would allow the LRV1 RDRP to accept 
non-natural nucleotides that the host RNA polymerase would reject. One piece of supporting 
evidence is the ease with which I identified compounds with moderate activity when activated 
with thymidine kinase (TK, Appendix A). Although one compound, 2‟-C-methyl-cytidine, was 
similar to 2CMA, the other compounds had markedly different structures. This suggests that the 
LRV1 RDRP will accept a range of nucleoside analogs, although it is worth noting that most 
active compounds are modified on the ribose moiety, not the nucleobase. 
5.6– Metabolism of 2CMA and its Significance for Drug Potency 
In Chapter 4, I demonstrate that 2CMA-TP inhibits the LRV1 RDRP, but its potency is 
much lower than expected, with IC50 concentrations from 130 to over 600 µM compared to 
2CMA and its 3 µM EC50 in parasites in cell culture. I eliminated the possibility that this was 
non-specific competition between a non-substrate nucleotide and a natural nucleotide by treating 
purified LRV1 virions with high concentrations of 2‟-deoxy-adeonsine triphosphate (dATP). 
Despite being modified at the 2‟-C position, dATP did not inhibit the viral RDRP. 
To reconcile the apparent discrepancy between the IC50 of 2CMA-TP in vitro and the 
EC50 of 2CMA in vivo, I measured the intracellular concentrations of 2CMA-TP. In order to do 
this, I developed a protocol for extracting and quantifying the nucleotide pools of Leishmania 
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cells as well as a facile technique for measuring the volume of live parasites, which allowed me 
to calculate the effective concentrations of 2CMA-TP within cells. These are detailed in Chapter 
4. These experiments demonstrated that the low EC50 is achieved because the parasites 
accumulate high intracellular concentrations of 2CMA-TP. This phenomenon can be easily 
explained by Leishmania’s ability to scavenge nucleosides. 
Unexpectedly, high concentrations of adenine in the parasites‟ medium did not 
significantly compete with LRV1 inhibition by 2CMA. Furthermore, in an unpublished 
experiment I showed that adenosine does not compete with 2CMA either. I believe these results 
show that adenosine and 2CMA are salvaged via different pathways. Unlike the other purine 
nucleosides, adenosine can be processed in two ways. Prior work has shown that the majority of 
adenosine is hydrolyzed to adenine and then converted to hypoxanthine by adenosine 
aminohydrolase. (Boitz and Ullman 2013; Boitz et al. 2012; Carter et al. 2008) However, 
Leishmania also express an adenosine kinase protein that can directly phosphorylate adenosine to 
adenosine monophosphate. (Datta et al. 1987; Bhaumik and Datta 1988) Because 2CMA and 
7d2CMA are only modified on the sugar moiety, they would only retain activity if 
phosphorylated directly by adenosine kinase. Thus, the excess adenosine and adenine would be 
processed independently of any 2CMA or 7d2CMA. 
5.7– Simulating LRV1 Inhibition Reconciles 2CMA and 2CMA-TP Potency 
In order to more clearly demonstrate that LRV1 inhibition in parasites can be explained 
by LRV1 RDRP inhibition by high intracellular 2CMA-TP concentrations, I developed a 
computational model of parasite and LRV1 replication (Chapter 4). The parasite population in 
the model starts with exactly 16 virions per cell, and the parasites and viruses are allowed to 
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replicate. By changing the relative replication rates of parasites and viruses, I can reproduce 
much of the behavior of LRV1 in our studies of 2CMA.  
This model indirectly illustrates the importance of the mechanisms that limit the number 
of LRV1 virions per parasite. Prior work has shown that the number of virions per parasite is 
regulated (Weeks et al. 1992), and that this regulation is not accomplished via the parasite RNA 
interference pathway. (Brettmann et al. 2016) In the absence of a detailed mechanistic 
understanding of this regulation, I explored various methods for simulating it. The fact that 
LRV1 titer slowly rebounded after being partially eliminated with 2CMA (Chapter 3) 
demonstrates that under some circumstances, LRV1 can replicate faster than the parasites. 
However, setting the virus replication time shorter than the parasite doubling time caused viral 
titer to increase exponentially toward infinity. Simply preventing viral replication past an 
arbitrary maximum number of virions generated unnatural distributions of virions within the 
simulated parasite population. In this situation, the virus replicates up to the maximum number 
before the parasite divides again, leading to an artificially large proportion of parasites with the 
maximum viral titer, plus a significant population of recently divided parasites with half the 
maximum number. This does not match with the roughly Gaussian distributions of LRV1 titers 
we observe via flow cytometry (Chapter 3). In addition, the geometric mean of virion number 
per parasite in such simulations is significantly less than the maximum allowed virion number. 
Thus, in order to match the average viral titer observed in vivo, the maximum number of virions 
must be increased. This yields an even less natural result, where the proportion of parasites with 
the mean viral titer is small, unlike in vivo where the mean and mode closely coincide. 
Another possibility, initially proposed by Weeks et al., is that the virus and parasite 
replication rates are linked under normal conditions. (Weeks et al. 1992) For the purposes of my 
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model, this would cause the effective parasite and virus replication rates to be equal. Doing so 
causes the average number of virions per cell to remain stable without a cap on virus titer. In 
addition, the distribution of virion numbers becomes roughly Gaussian and centers on the 
average number. Under this hypothesis, treating parasites with 2CMA eliminates LRV1 by 
uncoupling the rate of virus replication from the rate of parasite replication. 
In Chapter 3, we showed that LRV1 is lost by random dilution when completely inhibited 
by 2CMA. This indicates that each daughter cell receives on average 50% of the virions in its 
parent. In the simulation, parasite division was originally handled by randomly assigning each of 
the mother cell‟s virions to one of the daughter cells, a process equivalent to using a binomial 
distribution to choose the number of virions for each cell. However, this method led to the 
accumulation of parasites without virus, even without inhibiting viral replication. These “cured” 
parasites arose when a parasite divided and all the virions were assigned to one daughter cell. For 
a parasite with 16 virions, this has a 1 in 6.6×105 chance of occurring, but with fewer virions, the 
probability increases rapidly. Given that a standard liquid culture of parasites replicates from 
1×106 cells to ~2.5×108 cells in 48 hours, assigning virions randomly would “cure” at least 3800 
cells, and these would continue to replicate as well. Thus, a purely random assignment scheme 
would slowly “cure” an increasing proportion of the parasites until the virus was lost entirely. 
On the other hand, the parasites could hypothetically utilize some active method to assign 
exactly 50% of the virions to each daughter upon division. This avoids the problem of randomly 
“curing” parasites, but does not fit the data presented in Chapter 3. When parasites were treated 
with sufficient 2CMA to block LRV1 replication completely, removing 2CMA after 3 rounds of 
cell doublings revealed that 31% of parasites had entirely lost the virus. Assuming perfect 50% 
virion assignment, none of these parasites should have been cured. Instead, each would contain 
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16 23 = 2 virions. This suggests that the true assignment mechanism gives each daughter close 
to 50% of the mother cell‟s virions, plus a small margin of error. Such a distribution may be 
achieved as a side effect of the distribution of LRV1 virions in parasites. Immunofluorescence 
imaging of viral capsid protein in Chapter 2 shows points of capsid distributed relatively 
uniformly across the parasite cytoplasm. Dividing the parasites in half would thus assign each 
daughter cell approximately 50% of the virions. 
5.8– Testing LRV1 Treatment in a Mouse Model of Leishmaniasis is Feasible 
In Appendix B, I present preliminary data and theoretical calculations supporting the 
feasibility of an attempt to inhibit or eliminate LRV1 from parasites in a mouse model of 
leishmaniasis. This work was motivated in part by a recent report that 7d2CMA is capable of 
inhibiting Zika virus in a mouse model. (Zmurko et al. 2016) The EC50 of 7d2CMA against Zika 
in cell culture (10 µM) was similar to that for LRV1 in cell culture (5 µM). The other motivating 
factor was the discovery that 1 µM 2CMA, a concentration previously thought completely 
ineffective, could slowly eliminate LRV1 from infected parasites in culture. 
 The pattern of virus loss under these conditions suggests that rather than slowly diluting 
the virus out of all cells at the same time, low concentrations of 2CMA seemingly increase the 
chances of stochastic virus loss during cell division. Interestingly, this result sheds some light on 
the validity of an assumption made in implementing my simulation of LRV1 and parasite 
replication. When simulating the distribution of virions to daughter cells upon parasite division, I 
found that the probability of randomly assigning all the virions to one daughter had a strong 
influence on the simulation (discussed in greater detail in section 5.7). Too large of a probability 
generated a growing population of parasites cured by random loss upon cell division. The 
resulting population distribution, where most parasites contain 16 virions and a growing minority 
189 
 
contains none, closely resembles the long-term effect of 1 µM 2CMA treatment. Given this 
similarity, I suspect that 1 µM 2CMA has a small effect on the rate of LRV1 replication that, 
although it does not prevent most parasites from recovering their full population of 16 virions 
prior to cell division, does slow replication sufficiently that a minority of parasites divide before 
the virus population has recovered. In such parasites, the probability of stochastically assigning 
the virions to one daughter cell rises significantly. 
Based on these encouraging results, I utilized pharmacokinetic data collected for 
Hepatitis C Virus research to predict the behavior of 2CMA and 7d2CMA in mice. (Eldrup et al. 
2004; Olsen et al. 2004) After comparing the available dosing routes for mice, I determined that 
the optimal dosing regimen is daily subcutaneous injections of 80 mg/kg 7d2CMA. This scheme 
is relatively simple to perform, relatively low stress for the mice, and should deliver the greatest 
amount of 7d2CMA to the parasites. Deciding when to begin 7d2CMA treatment will depend on 
the precise question being asked. The most fundamental question is whether any drug could 
reduce the effects of LRV1 on disease severity by eliminating or inhibiting the virus. For this 
purpose, we want to use the highest dose possible as soon as the mice are infected. This yields 
the highest probability of seeing any effect on LRV1 or disease severity. The other major 
question is whether, in clinical leishmaniasis cases, inhibiting LRV1 would have any effect. In 
this situation, the patient would only receive treatment after they noticed a lesion developing. We 
know that cultured macrophages begin responding to LRV1 within hours of being infected with 
LRV1+ parasites (Ives et al. 2011), so it is possible that the deleterious immune response would 
be irreversibly induced before the patient went to the clinic. To simulate this situation, we can 
infect mice with LRV1+ parasites and wait to begin 7d2CMA treatment until lesions begin 
forming. 
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5.9– Tools for Improving Nucleoside Analog Phosphorylation in vivo 
In Appendix B, I described a drug screen intended to identify compounds that could 
inhibit Leishmania, LRV1, or the newly-discovered Leishbunyavirus (LBV). When we first 
designed this screen, we had three goals in mind. First, we were unsure if 7d2CMA was potent 
enough to use against LRV1 in mice, so we hoped to improve it or another compound‟s potency. 
Second, with the recent discovery of LBV and its impact on disease severity, we wanted a screen 
that would identify LBV inhibitors in addition to Leishmania and LRV1 inhibitors. Third, we 
hypothesized that compounds artificially phosphorylated by the thymidine kinase (TK) could 
represent potential candidates for phosphoramidate pro-drugs that would avoid the limitations of 
the initial nucleoside phosphorylation step. (McGuigan et al. 2010) Such pro-drugs could also 
escape the promiscuous nucleoside hydrolases that form an integral part of Leishmania 
nucleoside metabolism. (Carter et al. 2008) 
Based on the limited panel of compounds I tested, this approach did not yield any 
improvements or potential new nucleoside starting points for addressing the problems it was 
designed to solve. Although several compounds appeared to become moderate LRV1 inhibitors 
in the TK-expressing parasites, none are strong candidates for further study. There are a number 
of potential explanations for the dearth of solid hits. The compounds screened may not actually 
be good substrates for one of the activating enzymes or for the RNA polymerase itself. 
Treatment with immucillins may not inhibit the parasite nucleoside hydrolases sufficiently to 
avoid degrading the compounds. For LBV, however, we have insufficient data to draw solid 
conclusions. It may be worthwhile to screen a number of additional compounds for LBV 
inhibition to get a better idea of the screen‟s effectiveness for that virus. 
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5.10– Conclusions 
This work covers the discovery and characterization of a potential lead compound for 
preventing LRV1-associated disease exacerbation in humans (Chapter 3). In the process, it also 
provides an excellent example of the importance of the Leishmania purine salvage pathway in 
designing drugs for the parasite. Although the salvage pathway avidly accumulates 2CMA-TP 
and enables its potency in parasites (Chapter 4), the critical role of nucleoside hydrolases within 
the pathway also appears to prevent the activation of a number of compounds which would 
otherwise inhibit LRV1 (Appendix B). Beyond identifying a promising lead compound for future 
development, the information contained herein also provides the tools needed to efficiently 
screen for compounds inhibiting Leishmania, LRV1, and LBV. 
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A.1– Introduction 
Leishmania parasites utilize a complex network of enzymes to scavenge nucleosides and 
nucleobases from the extracellular milieu and interconvert them as needed. Purines, in particular, 
are avidly scavenged because the parasites lack a de novo synthesis pathway.(Carter et al. 2008) 
The nucleoside salvage pathways are thus logical targets for anti-Leishmania drugs, but also 
provide a robust avenue to inhibit Leishmania viruses, as seen in chapters 3 and 4. Because the 
Leishmania RNA virus (LRV) polymerase is only inhibited by nucleoside triphosphates, this 
limits one to analogs that are efficiently converted to nucleoside triphosphates by the parasite. 
Another constraint is that nucleosides in Leishmania can be hydrolyzed to nucleobases by a 
promiscuous nucleoside hydrolase (NH) enzyme. (Carter et al. 2008; Cui et al. 2001; Shi et al. 
1999)  For nucleosides other than adenosine, for which a dedicated adenosine kinase has been 
described, this may be the primary route of nucleoside metabolism. (Datta et al. 1987; Bhaumik 
and Datta 1988) For nucleoside analogs with modifications on the ribose moiety, hydrolysis by 
this NH effectively degrades the compound by separating the otherwise normal nucleobase from 
the modified ribose. An additional limitation is that the initial activation step from nucleoside to 
nucleoside monophosphate step is rate-limiting in many organisms. (McGuigan et al. 2010) 
Circumventing these restrictions could allow identification and development of more potent 
parasite or LRV1 inhibitors. 
This concept has already been implemented for other antiviral nucleosides. For example, 
the new phosphoramidate pro-drugs against Hepatitis C Virus are nucleoside monophosphate 
analogs that bypass the relatively slow initial phosphorylation step.(Kirby et al. 2015; McGuigan 
et al. 2010) Another tactic used in gene therapy research has been the development of enzymes 
which promiscuously activate existing nucleoside analogs. The best example of this is the Herpes 
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Simplex Virus (HSV) thymidine kinase (TK), which has been engineered to increase its affinity 
for other nucleoside analogs such as ganciclovir.(Black et al. 2001) Ganciclovir is not normally 
phosphorylated well by human cells, so introduction of this mutant TK gene dramatically 
increases their susceptibility to the drug. Originally, this gene was envisioned as a potential 
method of gene therapy, whereby relevant cells would be made to express the promiscuous TK, 
allowing their selective elimination with ganciclovir. It has also been employed in Leishmania 
major as a negative selectable marker for genetic screens. (LeBowitz et al. 1992; Davoudi et al. 
2005; Muyombwe et al. 1997) In a similar vein, expressing this TK in Leishmania could increase 
or enable activation of nucleoside analogs and thus reduce the dose required to eliminate LRV. 
However, this TK gene would still be competing with Leishmania NH enzymes for 
nucleoside analogs. Dr. Vern Schramm’s research group has developed a class of nucleoside 
analogs that could inhibit this competition. These compounds, called immucillins, were 
originally designed by the Schramm lab to inhibit human purine nucleoside phosphorylase, an 
enzyme not found in Leishmania that also hydrolyzes nucleosides.(Ho et al. 2010; Miles et al. 
1998) The defining characteristic of immucillins is the replacement of the ether group of the 
ribose sugar with a secondary amine (Figure A-1). Later work by the Schramm lab found that 
some immucillins inhibit the activity of the promiscuous Leishmania NH in vitro and the growth 
of certain species of parasites in vivo.(Freitas et al. 2015a; Shi et al. 1999; Freitas et al. 2015b) 
Treating parasites with immucillins, either alone or in a TK-expressing line, could reduce 
nucleoside analog degradation and improve potency. 
In selecting a Leishmania strain to test the TK and immucillin combination, we chose to 
deviate from our previous work, which largely utilized L. guyanensis MHOM/BR/75/M4147 
(LgyM4147). Instead, we utilized L. guyanensis LEM1684 (LgyLEM1684, WHO code 
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MHOM/BR/88/IM-3471), provided by U. Montpellier, France, which also bears LRV1. 
Additionally, LgyLEM1684 is also infected by a new Leishmania virus. This bunyavirus-like 
species, called Leishbunyavirus (LBV), was recently discovered by our lab. (Akopyants et al. 
2016)  Most Leishmania strains infected with LBV contain species LBV2.  LBVs, like other 
bunyaviruses, are tri-segmented negative-sense ssRNA viruses. Unpublished work by our lab has 
shown that LBV2 is associated with considerable pathology in our mouse model of 
leishmaniasis. Screening of a large number of Leishmania isolates from South America has 
shown that LBV2 is very common (unpublished). Both of these factors suggest that LBV2 may 
prove to be even more important than LRV1 for determining the severity of human 
leishmaniasis. Working with LgyLEM1684 instead of LgyM4147 therefore provides an 
opportunity to screen for inhibitors of L. guyanensis and its two clinically relevant viruses at the 
same time. 
A.2– Methods 
A.2.1 – Parasite Strains and Media 
This work was performed with two parasite strains: L. guyanensis LEM1684 (Lgy1684) 
and L. major MHOM/SU/73/5-ASKH (Lmj5ASKH; from Dr. Joaquim Clos, Hanover, Germany) 
Lg1684 was cultured in Schneider’s medium (Sigma), prepared as in Chapter 3. (Kuhlmann et al. 
2017) Lmj5ASKH was grown in M199 medium plus 40 mM HEPES (pH 7.4), 0.1 mM adenine, 
1 μg/mL biotin, 5 μg/mL hemin, 50 U/mL penicillin, 50 μg/mL streptomycin, 10% heat-
inactivated fetal bovine serum, and 2 μg/mL biopterin. Culture density was measured using a 
Coulter counter (Beckman Coulter). 
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A.2.2 – Creation of TK-Expressing Parasites 
Thymidine kinase mutant SR39 was amplified with PCR primers (Table A-1) that added 
a 5’ consensus CCACC Kozak sequence; a 3’ stop codon; and flanking AflII and BglII 
restriction sites to allow inserting the gene into pIR-series vectors. This PCR product was then 
blunt-end ligated into pCR-Blunt (Invitrogen) and sequenced using the amplification primers and 
two internal primers (Table A-1). The TK gene was excised with AflII and inserted into the (a) 
site of pIR3-HYG-LUC(b) (B7096), generating pIR3-HYG-mSR39TK(a)-LUC(b) (B7623) 
(Figure A-2). The TK construct was linearized with SwaI and transfected into LgyLEM1684 and 
Lmj5ASKH using the high voltage protocol. (Robinson and Beverley 2003) Transfected clones 
were selected on semi-solid medium containing 200 μg/mL or 50 μg/mL hygromycin for 
LgyLEM1684 and Lmj5ASKH, respectively. Four clones from each strain were grown up in 
liquid medium under the same hygromycin selection. For future work, clones LgyLEM1684 #12 
and Lmj5ASKH #10 were selected because they exhibited the greatest sensitivity to ganciclovir 
(Figure A-4). 
 
A.2.3 – Measuring TK Activity via Ganciclovir Sensitization 
Active thymidine kinase was detected using its ability to activate ganciclovir, thereby 
inhibiting parasite growth. The parental strains of LgyLEM1684 and Lmj5ASKH were grown in 
the presence of 0, 1, 10, or 100 μg/mL ganciclovir for 48 hours and the culture densities were 
measured. Clones transfected with the TK construct were grown with or without 10 μg/mL 
ganciclovir until the untreated cultures reached a density of approximately 1×107 cells/mL. 
Growth rates were calculated by fitting the culture density data to an exponential growth 
equation. 
202 
 
A.2.4 – Measuring LRV1 and LBV Levels in Parasites 
LRV1 levels were measured using a standard protocol previously developed in the lab, 
described in more detail in chapters 2 and 3. In brief, 2×107 parasites were fixed with 2% 
paraformaldehyde, stained with anti-capsid antibody, and visualized with an AlexaFluor-488 
linked secondary antibody. Capsid staining levels were then measured in single cells using flow 
cytometry.(Kuhlmann et al. 2017) 
LBV levels were measured using qRT-PCR. Total parasite RNA was extracted from 
1×108 parasites using 350 μL TRIzol reagent and the Direct-Zol RNA miniprep kit (Zymo 
Research), according to the manufacturer’s instructions. DNA was digested with DNase I 
(Ambion) for 1 hour at 37°C followed by cleanup with an RCC-25 column purification kit 
(Zymo Research). cDNA was synthesized using the SuperScript III kit and random hexamer 
primers (Invitrogen). Negative controls without reverse transcriptase were also performed. qPCR 
reactions were set up using Power SYBR Green master mix (Applied Biosystems) and run on a 
ViiA 7 thermocycler (Applied Biosystems). Relative LBV levels were measured using primers 
generating a 103-bp product from the middle of the LBV RNA polymerase gene (Table A-2, pair 
1). As an internal control, levels of RNA from the housekeeping gene KMP11 were measured 
using primers generating a 100-bp product (Table A-2). These reactions were run in triplicate 
and negative controls were run in duplicate. To estimate primer efficiency, 1 μL of cDNA from 
each reaction was pooled and diluted 1:5, 1:25, and 1:125. Each dilution was amplified in 
duplicate using the LBV or KMP11 primers. The PCR protocol included initial denaturation for 
10 min. at 95°C followed by 40 cycles of denaturation for 15 sec. at 95°C and amplification for 1 
min. at 60°C. Ct values were calculated using the ViiA 7 software. Relative quantitation was 
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accomplished via the Pfaffl method, which uses 1:5 serial dilutions of mixed cDNA to correct for 
non-ideal primer efficiencies.(Pfaffl 2001) 
A.2.5 – Parasite Susceptibility to Immucillins 
We received Immucillin A (IA), 4-deaza-1-aza-2-deoxy-1-(9-methylene)-Immucillin A 
(DADMe-IA or DIA), Immucillin H (IH), and DADMe-Immucillin H (DIH) as kind gifts from 
Dr. Vern Schramm (Figure A-1). Wild-type Lgy1684 parasites were seeded at 2×105 cells/mL in 
5 mL of Schneider’s medium plus 100 µM immucillin. Parasite growth was monitored for 48 
hours, after which LRV1 levels were measured using the flow cytometry technique described in 
the previous section. 
A.2.6 – Screening for Efficacy Enhancement by TK or Immucillins 
The compounds used in this screen (Table A-3) were initially obtained for use in the 
LRV1 inhibitor screen described in Chapter 3 (see Table S1). All compounds were tested at 100 
µM from 50 mM stocks in DMSO. For the first round of screening, compounds were tested 
against the parental Lgy1684 strain or Lg1684 TK clone #12 (Lgy1684-TK, see Figure A-4A). 
An additional parental Lgy1684 culture was treated with drug plus 5 µM of a mixture of all four 
immucillins, followed with another dose in 24 hours. Parasite growth was monitored for 48 hours 
before cells were harvested for measuring LRV1 and LBV levels. To reduce the number of 
samples in subsequent rounds of screening, compounds were tested against Lg1684 or Lg1684-
TK treated with the immucillin cocktail.    
A.3– Results 
A.3.1 – Parasites Express Active TK Enzyme 
In order to potentially improve the phosphorylation of nucleoside analogs, we over-
expressed the promiscuous HSV TK mutant SR39 in Lgy1684 and Lmj5ASKH. I confirmed that 
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up to 100 μg/mL ganciclovir has no effect on Lmj5ASKH and Lgy1684 parasites (Figure A-3). 
By contrast, clones of Lmj5ASKH and Lgy1684 containing the TK and luciferase genes were 
strongly inhibited by 10 μg/mL ganciclovir (Figure A-4). This demonstrated that those clones 
expressed significant amounts of active TK. Lg1684 TK clone #12 (Lg1684-TK) was utilized for 
subsequent experiments since it exhibited the strongest growth inhibition. 
A.3.2 – Lg1684 and its LRV1 Strain are Insensitive to Immucillins 
Based on prior reports, we expected that immucillins would inhibit parasite growth. 
(Freitas et al. 2015a; Freitas et al. 2015b) Since immucillins are nucleoside analogs, it was also 
possible that they would inhibit LRV1 as well. To test this, I grew Lgy1684 parasites in the 
presence of 100 µM of each immucillin for 48 hours. Growth rate and LRV1 levels per cell were 
then measured (Figure A-5). None of the compounds inhibited parasite growth, suggesting that, 
unlike L. infantum and L. amazonensis, L. guyanensis is not susceptible to these compounds. In 
addition, LRV1 was not inhibited by any immucillin. 
A.3.3 –LRV1 Screen Identifies Two Compounds Possibly Activated by TK 
To test the effects of immucillins and TK on compound efficacy, I began by screening 
compounds similar to known LRV1 inhibitors 2CMA and 7d2CMA. I began by testing 2’-C-
methyl-nucleosides (Figure A-6) against Lgy1684, Lgy1684-TK, and Lgy1684 treated with 
immucillins. Based on previously published data, I utilized two 5 µM doses of immucillin 
cocktail, one added at the start of the experiment and the second after 24 hours. The Schramm 
group observed that this dosing scheme significantly improved the potency of immucillins IA 
and IH against L. infantum. (Freitas et al. 2015b) As expected, 2CMA and 7d2CMA strongly 
inhibited LRV1 levels. Parasite growth was inhibited somewhat more for Lgy1684 than in our 
original screen with LgyM4147, but this may be explained by differences between strains. 
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(Kuhlmann et al. 2017) Treating Lgy1684 parasites with both the immucillin cocktail and the 
compounds did not induce additional inhibition of parasite growth or LRV1 levels. The TK gene, 
however, induced a 25% reduction in LRV1 capsid levels in parasites treated with 2’-C-methyl-
cytosine (2CMC) without changing parasite growth. Since 2CMC is not normally active against 
LRV1 in parasites, this suggests that phosphorylation by TK might have allowed 2CMC to be 
activated and inhibit LRV1. However, this is only one replicate and a relatively small 
improvement, so more work would be required to confirm it. 
In a second, larger round of screening, I combined the TK and immucillin treatments to 
identify compounds of interest more efficiently. A series of 2’-fluoro-2’-deoxy- (E1-E5) and 
cyclobutyl-adenine nucleoside analogs (E8-E10) were tested using the same protocol as for the 
initial screen. None of the compounds caused more than 20% reduction in parasite growth rates 
(Figure A-7A). The cyclobuytyl-adenine analogs, however, appeared to reduce LRV1 levels 
(Figure A-7B). In wild-type parasites, they induced ~20% increases in LRV1 levels, consistent 
with the results from the initial screen in Chapter 3 (see Table S2). In Lgy1684-TK parasites 
treated with immucillins, they induced 20-40% reductions in LRV1 levels relative to untreated 
controls. This data suggests that cyclobutyl-adenine derivatives, in particular 3’-hydroxyethyl 
cyclobutyl-adenine, might be able to inhibit LRV1 once activated. As with 2CMC, the effects 
reported here represent a single experiment and are relatively small, so additional experiments 
would be required to make firm conclusions. 
A.3.4– Preliminary LBV screen yields no hits 
Previous work in our lab (Dr. F. Matthew Kuhlmann, unpublished) showed that none of 
the compounds originally tested against LRV1 could inhibit LBV. To test whether 
phosphorylation by TK could allow otherwise inactive compounds to inhibit LBV, I measured 
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virus levels in wild-type Lgy1684 or Lgy1684-TK after treating with 2CMC or 2CMG. These 
compounds are similar to 2CMA, but the arrangement of the purine and pyrimidine salvage 
pathways in Leishmania suggests that in wild-type parasites they would be destroyed by 
nucleoside hydrolases and not phosphorylated. (Carter et al. 2008) Furthermore, the fact that 
2CMC inhibited LRV1 somewhat in Lg1684-TK suggested that 2CMC might have been 
activated by the TK. RNA purified from these parasites was analyzed by qRT-PCR using 
primers amplifying an internal portion of the virus’ RNA polymerase gene. As Dr. Kuhlmann 
previously observed, neither compound changed the amount of LBV in wild-type parasites. The 
TK gene also had no significant effect on LBV levels (Figure A-8).  
A.4 – Discussion 
In this preliminary study, I report the tentative identification of multiple nucleoside 
analogs that may inhibit LRV1 when phosphorylated by a promiscuous TK enzyme. Although 
the compounds identified in this work are not particularly potent, they illustrate the utility of a 
promiscuous TK gene to locate lead compounds worthy of future study. Obtaining tentative hits 
from two structurally unrelated classes of nucleoside analog in a screen of 12 compounds 
suggests that more potent LRV1 inhibitors could easily be found through further screens. 
With the goal of enhancing phosphorylation of nucleoside analogs in Leishmania, I 
expressed a promiscuous thymidine kinase in Lgy1684. Using ganciclovir susceptibility as a 
proxy for TK activity, I showed that the TK-expressing parasites produced significant amounts 
of active TK (Figure A-4). In a parallel effort to block drug degradation by the Leishmania 
nucleoside hydrolases, I treated parasites with a cocktail of four immucillins. Individually, none 
of these compounds had any effect on Lg1684 growth or LRV1 levels (Figure A-5). This is not 
entirely surprising, since these compounds have not been tested against members of the Viannia 
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sub-genus and thus might not be active against them. Furthermore, although all available 
immucillins were utilized to maximize potential NH inhibition, not all of them have been shown 
to inhibit Leishmania or NH. Work published by the Schramm lab showed that IA and IH inhibit 
both parasites and NH, while DIH inhibits parasites but not NH and DIA inhibited neither. 
(Freitas et al. 2015b) 
Screening for changes in anti-LRV1 activity induced by TK or immucillins identified two 
distinct types of compound. The first, 2CMC, induced a 20% drop in LRV1 levels when tested in 
TK-expressing parasites (Figure A-6B). This compound is the cytidine version of 2’-C-methyl-
adenosine, the first anti-LRV1 compound we identified, so its activity against LRV1, if 
confirmed, would not be surprising. Leishmania parasites are thought to incorporate cytidine into 
the pyrimidine nucleotide pool by first hydrolyzing it to cytosine. (Carter et al. 2008) This step 
would degrade 2CMC in wild-type parasites by removing the methyl-ribose from the cytosine 
nucleobase. 
 The second type of compound tentatively identified in this screen was a group of 
structurally-similar cyclobutyl-adenine compounds. In wild-type parasites, these compounds 
increased the levels of LRV1. In Lg1684-TK treated with immucillins, they reduced LRV1 
levels by 25-35% (Figure A-7B). Compound E10, 3’-hydroxyethyl-cyclobutyl-adenine, was the 
most affected, going from a 25% increase in wild-type parasites to a 35% decrease with TK and 
immucillins. The fact that all three examples of this compound class in the screen may be 
activated to varying extents suggests that those results should be followed up and other related 
compounds should be explored further for more potent LRV1 inhibitors. 
The Lgy1684 parasite strain was selected for this work because it also contains the LBV 
virus, a novel bunyavirus-like negative-sense ssRNA virus recently discovered by our lab. This 
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allows screening for Leishmania, LRV1, and LBV inhibitors at the same time. A preliminary 
look at the effect of TK activation on LBV levels did not reveal any significant effects. Since 
2CMC was activated sufficiently to slightly inhibit LRV1 in the same experiment, this result 
suggests that LBV might be resistant to 2CMC and its triphosphate. 
This screening technique could also be extended to search for inhibitors of other, less 
well-understood Leishmania viruses. When the LRV1 inhibitor 2’-C-methyl-adenosine (2CMA) 
was identified (Chapter 3), we tested it against LRV2, an Old World LRV species infecting L. 
major 5ASKH, and found it had no effect. Using the 2CMA-TP assay I developed for LRV1, I 
also found that L. major 5ASKH concentrates 2CMA-TP approximately as much as L. gy. 
M4147. This implies that LRV2 itself is resistant to 2CMA-TP. I have expressed active TK in L. 
major 5ASKH, so I could extend my pro-drug screen to find LRV2 inhibitors. Another potential 
target is Bottom virus, another Leishmania virus we have recently uncovered. However, we 
know little about this virus, so screening for inhibitors might be premature. 
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A.6 – Tables 
 
 
Table A-1: Primers used to amplify and sequence TK. 
(mSR39-TK) This primer pair is for amplifying TK mutant SR39. It includes flanking AflII and 
BglII restriction sites for insertion into pIR-series vectors. (Sequencing) These internal primers 
allow sequencing the ends of the TK ORF. 
Primer 
Pair 
ID # Direction Sequence (5’→3’) 
mSR39
-TK 
B7075 Forward CCGGGCTTAAGAGATCTCCACCATGGCTTCGTACCCCGG
CCATC 
B7076 Reverse CCCGGCTTAAGAGATCTTTAGTTAGCCTCCCCCATCTCCC
GG 
Seque
ncing 
B2288 Reverse GCAGTAGCGTGGGCATTTT 
B2289 Forward CCCCCAACGGCGACCTGT 
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Table A-2: Primer pairs for quantifying LBV virus levels in L. guyanensis LEM1684.  
The LBV primers amplify ~100 bp segments from the middle of the largest viral genome segment. 
Pair 1 has superior performance over Pair 2. The KMP11 primers amplify a ~100 bp segment of 
the KMP11 housekeeping gene. (Zangger et al. 2013)  
Primer Pair ID # Direction Sequence (5’→3’) 
LBV 
Pair 1 
B7937 Forward GGTACAAGGGAGGGTCTTTATG 
B7938 Reverse AATATGAAGCGTGGAGACTGG 
LBV 
Pair 2 
B7939 Forward GAGGAGCCTCGGAATAAGAATG 
B7940 Reverse TACGGAGGTTCATTGGTAGGA 
KMP11 
Standard 
B5548 Forward GCCTGGATGAGGAGTTCAACA 
B5549 Reverse GTGCTCCTTCATCTCGGG 
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Table A-3: Compounds tested in this study.  
More details about each compound are available in Chapter 3, Table S1. 
ID Name 
E1 2’-fluoro-2’-deoxycytidine 
E2 2’-fluoro-2’-deoxyuridine 
E3 2’-fluoro-2’-deoxyadenosine 
E4 2’-fluoro-2’-deoxyguanosine 
E5 2’-fluoro-2’-deoxyinosine 
E6, 2CMA 2’-C-methyl-adenosine 
E7, 2CMG 2’-C-methyl-guanosine 
2CMC 2’-C-methyl-cytidine 
7d2CMA 7-deaza-2’-C-methyl-adenosine 
E8 3’-azido-3’-hydroxyethyl α-cyclobutyl-adenine 
E9 3’-azido-3’-hydroxyethyl β-cyclobutyl-adenine 
E10 3’-hydroxyethyl cyclobutyl adenine 
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A.7 – Figures 
 Immucillin A Immucillin H 
 
 DADMe-Imm. A DADMe-Imm. H 
 
Figure A-1: Chemical structures of the immucillins used in this study. 
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Figure A-2: Diagram of Leishmania construct expressing the HSV TK gene.  
TK gene is marked by a blue arrow (mSR39-TK). The construct (SMB7623) is based on pIR3-
HYG, which includes intergenic regions (IR) and splice acceptor sites (SA) that allow proper 
maturation of mRNAs transcribed from 3 positions in the construct. The first contains the TK 
gene, the second contains a luciferase gene for visualizing parasites in mice, and the third 
contains the hygromycin resistance gene (HYG). When linearized with SwaI, it can recombine 
into the ribosomal small subunit (SSU) locus using the L. major SSU flanking sequences. 
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Figure A-3: Effect of ganciclovir on growth of wild-type Leishmania parasites.  
Cultures were grown for 48 hours in the presence of varying amounts of ganciclovir. No growth 
inhibition was observed.   
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A. 
 
B. 
 
 
Figure A-4: Effect of 10 μg/mL ganciclovir on parasites transfected with TK expression 
construct.  
Growth rates of LgyLEM1684 (A) or Lmj5ASKH (B) TK-transfected clones grown for 72 or 96 
hours, respectively, in the presence of 10 μg/mL ganciclovir (black bars) or no drug (white 
bars).  
218 
 
A. 
 
B. 
 
Figure A-5: LgyLEM1684 and its LRV1 strain are insensitive to a panel of immucillins.  
(A) Growth rates of cultures grown with 100 µM of each compound. (B) LRV1 levels after 
growth for 48 hours in each compound, as measured by capsid staining intensity via flow 
cytometry. (n=1)  
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A. 
 
B. 
 
Figure A-6: Initial round of TK/immucillin screening.  
LgyLEM1684 parasites were grown in the presence of 100 µM of each compound. (A) Effect of 
each compound on the growth rate of the parasites. (B) Effect of each compound on the levels of 
LRV1 capsid staining in parasites. (n=1)  
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A. 
 
B. 
 
Figure A-7: Second round of screening with TK/immucillins.  
Graphs compare drug effects in wild-type Lg1684 (black bars) or Lg1684-TK treated with the 
immucillin cocktail (white bars). Parasites were grown in the presence of 100 µM of each 
compound. (A) Effect of each compound on the growth rate of the parasites. (B) Effect of each 
compound on the levels of LRV1 capsid staining in parasites. (n=1)  
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Figure A-8: Levels of LBV virus RNA are unchanged by 2CMC and 2CMG, even in the presence 
of the TK enzyme.  
RNA from compound-treated parasites was analyzed by qRT-PCR (n=3), using KMP11 
transcript levels as an internal control (n=3).  
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Appendix B: Feasibility of LRV1 Cure in Mouse 
Model of Leishmaniasis 
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Preface 
SMB and JIR designed the experiments. JIR performed the experiments and analyzed the data. 
JIR performed the background research and modeling with technical advice from Suzanne 
Hickerson. The first draft of this appendix was written by JIR and the final version presented 
here incorporates comments from SMB. 
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B.1– Introduction 
Leishmania RNA Virus 1 (LRV1) has been shown to play a role in disease severity in 
both mouse models of leishmaniasis and human Leishmania infections. (Periera et al. 2013; 
Castiglioni et al. 2017; Hartley et al. 2016; Ives et al. 2011; Bourreau et al. 2015; Cantanhede et 
al. 2015; Ito et al. 2015) It is possible that this increase in disease severity could be avoided by 
reducing or eliminating LRV1 from parasites in a mammalian host. The potential merit of this 
concept was reinforced by work showing that immunizing mice with the LRV1 capsid protected 
them from virus-enhanced disease severity.(Castiglioni et al. 2017) However, macrophages 
infected with LRV1+ parasites produce increased pro-inflammatory cytokines within 6 hours of 
infection.(Ives et al. 2011) This suggests that the immune response to LRV1 may occur soon 
after infection. Thus, treating LRV1 only after a lesion develops might be too late to have any 
effect on disease progression. To answer this question, we need to be able to inhibit LRV1 in a 
mouse model of Leishmania infection. 
In Chapter 3, we describe the discovery of two nucleoside analogs, 2’-C-methyl-
adenosine (2CMA) and 7-deaza-2CMA (7d2CMA), which inhibit LRV1 in cultured parasites. 
These compounds were both developed initially as Hepatitis C Virus (HCV) inhibitors.(Eldrup et 
al. 2004; Olsen et al. 2004) Based on its rapid degradation in animals, 2CMA was not pursued as 
an HCV inhibitor.(Eldrup et al. 2004) 7d2CMA, on the other hand, was not degraded by human 
enzymes and was able to inhibit HCV in a chimpanzee model.(Eldrup et al. 2004; Carroll et al. 
2009) Recently, 7d2CMA was also shown to inhibit Zika virus in cell culture with an EC50 
similar to the one we measured against LRV1. The drug was then successfully utilized to reduce 
Zika virus replication in a mouse model of infection. (Zmurko et al. 2016) Based on these 
results, we hypothesized that 7d2CMA might be sufficiently potent to significantly reduce or 
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eliminate LRV1 in our mouse model of leishmaniasis. Furthermore, inhibiting LRV1 would 
reduce its deleterious effects on the mouse immune response. 
B.2 – Methods 
B.2.1 – Treatment of LRV+ Parasites with Low 2CMA 
L. guyanensis M4147 (LgM4147) parasites identical to those used to originally identify 
2CMA were grown for this experiment using the same formulation of Schneider’s medium (see 
Chapter 3 for more details). (Kuhlmann et al. 2017) Log phase cells were passed into 5-mL 
cultures of Schneider’s medium at 2×105 cells/mL and grown in the presence of 1 µM 2CMA or 
DMSO for 48 hours. The culture density was measured using a Coulter Counter and cells were 
passed into fresh medium at 2×105 cells/mL with 1 µM 2CMA or DMSO. At each passage, 
LRV1 levels were measured by flow cytometry using the protocol described in Chapter 2. 
Briefly, 2×107 cells were fixed with 2% paraformaldehyde and stained with 1:20,000 anti-LRV1 
capsid antibodies followed by 1:1000 AlexaFluor488-labeled goat anti-rabbit IgG. Parasites 
stained only with secondary antibody were used to measure background staining. DMSO-treated 
parasites were used as a positive control for LRV1+ parasites. LRV-low parasites were identified 
by gating on the range covered by background staining, while LRV-high parasites were those 
with capsid staining above background (Figure B-1). 
B.2.2 – Predicting the Pharmacokinetics of 2CMA and 7d2CMA in Mice 
The relevant pharmacokinetic (PK) parameters were taken from Olsen et al. where 
7d2CMA was studied as a potential treatment for Hepatitis C virus (HCV). (Olsen et al. 2004) 
Parameters for 2CMA were obtained from Eldrup et al. where it was used as a baseline HCV 
inhibitor for comparison to other, more potent nucleosides.(Eldrup et al. 2004) Lacking 
measured parameters for mice, those measured for rats were used instead. Standard PK equations 
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were utilized to predict the behavior of 2CMA and 7d2CMA upon dosing in mice. (Kallen 2007) 
For these calculations, I needed to estimate the notional “volume” of distribution (VD) for a 
mouse. This allows one to predict the initial plasma concentration resulting from a given 
intravenous (IV) dose of drug. By definition, 
 𝑉𝐷 = 𝐴(0)𝐷(0) (1) 
where 𝐴 0  is the amount of drug administered and 𝐷(0) is the resulting initial plasma 
concentration. 
The rate at which a drug is excreted or degraded in a particular animal is expressed as 
 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑒𝑙𝑖𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 =  −𝑑𝐴 𝑡 𝑑𝑡 = 𝐶𝑙𝑃 𝑡 𝐷(𝑡) (2) 
where 𝐶𝑙𝑝(𝑡) is the clearance function. In linear PK systems, where the elimination rate is 
independent of drug concentration, the value of 𝐶𝑙𝑃(𝑡) is usually constant. For the purposes of 
these calculations, I assumed this was the case. As a first-order approximation, I also assumed 
that elimination of 2CMA and 7d2CMA is described by an exponential equation, which is 
usually true for linear PK systems: 
 𝐴 𝑡 = 𝐴 0  𝑒−𝑘𝑡  (3) 
Taking the derivative of equation (3) and combining it with equation (2) gives 
 𝑑𝐴(𝑡)
𝑑𝑡 = −𝑘 𝐴 0  𝑒−𝑘𝑡 = −𝐶𝑙𝑃  𝐷 𝑡  (4) 
Setting 𝑡 = 0 reduces equation (4) to 
 𝑘 𝐴 0 = 𝐶𝑙𝑃  𝐷(0) (5) 
Thus the rate constant for elimination of drug is 
 𝑘 = 𝐶𝑙𝑃  𝐷 0 𝐴 0  (6) 
Since k is an exponential rate constant, it can be rewritten as 
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 𝑘 = ln 2𝑡1/2 (7) 
where 𝑡1/2 is the time required to reduce 𝐴 0  by half. Published PK data on 7d2CMA and 
2CMA included the values of 𝐶𝑙𝑃 and 𝑡1 2 . Combining equations (6) and (7) and solving for 
𝐷 0   allows it to be calculated for any drug dose 𝐴 0   
 𝐷 0 = 𝐴 0 ln 2𝐶𝑙𝑃  𝑡1 2  (8) 
Note that this also allows one to calculate the volume of distribution for the system, using 
equation (1) 
 𝑉𝐷 = 𝐴(0)𝐷(0) = 𝐶𝑙𝑃  𝑡1 2 ln 2  (9) 
If 𝑉𝐷 is assumed to be constant over time, the concentration of drug at time t becomes 
 𝐷 𝑡 = 𝐷 0 𝑒−𝑘𝑡 = 𝐴 0 ln 2𝐶𝑙𝑃  𝑡1 2 exp − ln 2𝑡1 2 𝑡  (10) 
Equation (10) was used to predict the plasma concentrations of 2CMA and 7d2CMA after an IV 
dose, where all drug is delivered immediately to the bloodstream. For oral doses of drug, the 
amount of drug delivered to plasma is a certain percentage of the original dose. This is given as 
bioavailability (B) and was corrected using the equation 
 𝐴 0 = 𝐵 × 𝐴𝑜𝑟𝑎𝑙  0  (11) 
For continuous dosing schemes such as implantable pumps, the steady-state drug plasma 
concentration can be calculated by noting that the rate of elimination from equation (2) will be 
equal to the rate of drug input (R)  
 −
𝑑𝐴 𝑠𝑠 
𝑑𝑡 = 𝐶𝑙𝑃𝐷 𝑠𝑠 = 𝑅 (12) 
Thus, at steady state the plasma concentration will be 
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 𝐷 𝑠𝑠 = 𝑅𝐶𝑙𝑃 (13) 
This equation is also applicable to regularly repeated bolus doses. At steady state, the average 
rate of drug input will be 
 𝑅 =  𝐵 × 𝑀𝐷𝐷𝐼  (14) 
where MD is the amount of drug in the recurring maintenance dose and DI is the time between 
doses. Combining equations (13) and (14) gives the average steady state plasma concentration 
 𝐷  𝑠𝑠 = 𝐵 × 𝑀𝐷𝐶𝑙𝑃 × 𝐷𝐼 (15) 
Importantly, this equation shows that a given steady state concentration may be achieved using 
low doses at short intervals or large doses at long intervals. However, increasing the dose 
interval makes the actual plasma concentration 𝐷(𝑡) become increasingly erratic. 
To estimate the relative intensity of drug treatment achieved using a given dose and 
delivery method, I calculated the area under the curve (AUC). The AUC is the integral of drug 
concentration over the course of the experiment, and is an approximate measure of the total drug 
exposure for a particular dosing scheme. For IV routes, AUC was simply the integral of equation 
(10) from 0 to 24 hours. When considering oral dosing routes, I assumed that the drug was 
absorbed at a constant rate until the time of maximum concentration was reached, at which point 
the concentration began to decay exponentially.  
B.3– Results 
B.3.1 – Low 2CMA Levels Progressively Cure LRV1+ Parasites 
One significant concern when designing a dosing regimen is whether drug plasma 
concentrations below the EC50 will have any effect. Based on previously reported titrations 
(Chapter 3), 1 µM 2CMA has no measurable effect on mean LRV1 levels in parasites after 48 
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hours.(Kuhlmann et al. 2017) To determine the long-term effect of low 2CMA doses on LRV1 
levels, I treated LRV1+ LgyM4147 parasites with 1 µM 2CMA over 4 passages and 215 hours. 
At each passage, I analyzed LRV1 levels using flow cytometry. This revealed that the proportion 
of LRV1-low parasites increased linearly as time treated with 2CMA increased (Figure B-2). 
Interestingly, this change manifested as a LRV-low peak on the capsid-staining histograms 
(Figure B-1), rather than a uniform reduction in the LRV1 levels of all parasites. This pattern 
suggests that low doses of 2CMA induce LRV1 loss in a small proportion of parasites as they 
divide. 
B.3.2 – Mouse Treatment with 7d2CMA is Feasible 
Given that 2CMA concentrations well below its EC50 had a significant impact on LRV1 
levels in parasites, I set out to predict whether similar concentrations could be achieved in our 
mouse model of leishmaniasis. I used previously published PK parameters for rats, making the 
assumption that metabolism would be similar in mice.(Eldrup et al. 2004; Olsen et al. 2004) In 
order for a daily dose of 2CMA to yield an average plasma concentration greater than its EC50 
(~3 µM), it would be necessary to use 250 mg/kg doses. Due to the limited solubility of 2CMA 
and 7d2CMA (~8 mg/mL) this delivering this much drug would require using volumes at the 
extreme upper end of recommended limits (Table B-2). Furthermore, the plasma concentration of 
2CMA would drop below 1 µM within 2.5 hours. Thus, 2CMA cannot be used to inhibit LRV1 
in mice. The PK parameters for 7d2CMA are much more favorable. A 50 mg/kg daily dose 
would be sufficient to maintain an average plasma concentration above its 5 µM EC50. The 
7d2CMA plasma concentration would also remain above 1 µM for 9 hours. This suggests that an 
effective plasma concentration of 7d2CMA could be achieved in mice. 
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Due to factors such as dose volume limitations and incomplete drug absorption, the route 
of administration has a strong effect on the amount of drug delivered. I evaluated the possible 
dosing routes based on three criteria: suitability for repeat dosing, technical skill required, and 
amount of drug delivered (Table B-2).(Diehl et al. 2001; Turner et al. 2011) Gastric gavage – 
injecting drug directly into the stomach – was used successfully to treat Zika virus with 
7d2CMA.(Zmurko et al. 2016) However, it suffers from low bioavailability and large amounts of 
7d2CMA are taken up by the liver.(Olsen et al. 2004) Subcutaneous injection is simple and safe 
for long-term repeated treatment and delivers the full dose without bioavailability issues or liver 
degradation. Intravenous injection has similar PK behavior, but requires skillful surgical 
installation of a port for extended experiments. Intraperitoneal injection – directly into the body 
cavity – has frequent complications and is subject to first-pass degradation in the liver. 
Intradermal and intramuscular injections are not typically used in mice because the skin and 
muscles are too small to withstand most injections, especially repeated ones.(Diehl et al. 2001) 
An alternative method is delivering the drug continuously via an implantable pump. These are 
able to maintain stable plasma concentrations over extended periods. However, the low solubility 
of 7d2CMA limits the amount of drug that can be delivered. (DURECT Corporation 2017a, b) 
Based on their simplicity and relative safety, subcutaneous injection and gastric gavage are the 
two best dosing options for 7d2CMA. 
I utilized the equations described in the methods section to compare the amounts of drug 
delivered using once-daily subcutaneous injection and gastric gavage (Table B-1). Ultimately, 
the amount of drug delivered by a particular dosing scheme can be summarized by the integral of 
drug concentration over time, which is referred to as the area under the curve (AUC). I calculated 
this value, plus the maximum drug concentrations in plasma and time with drug above 1 µM if 
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mice were given 7d2CMA once daily. Based on the previously published treatment of Zika with 
7d2CMA (Zmurko et al. 2016) and the maximum recommended dose volumes, I compared 
7d2CMA plasma concentrations for daily 50 and 80 mg/kg doses. As a reference point, 
theoretical values were calculated where the plasma 7d2CMA concentration was held constant. 
This roughly corresponds to the amount of drug encountered by parasites in cell culture treated 
with a given concentration of drug. Due to the relatively low bioavailability of 7d2CMA (51%), 
gastric gavage could only achieve an AUC value of 108 hr*µM, on par with a theoretically 
constant concentration of 5 µM 7d2CMA. Subcutaneous injection, on the other hand, gives a 
much higher AUC value of 190 hr*µM. This demonstrates that subcutaneous injection of 
7d2CMA would deliver significantly more drug than gastric gavage. 
B.4 – Discussion 
This work suggests that it will be feasible to inhibit LRV1 in our mouse model of 
leishmaniasis using 7d2CMA. The fact that treating parasites with 2CMA concentrations well 
below its EC50 still lowers LRV1 levels implies that even relatively limited amounts of drug 
would still have a significant effect on LRV1 levels in our mouse model. Based on a simple 
model using published PK data, it is possible to generate plasma 7d2CMA concentrations in our 
mouse model of leishmaniasis sufficient to inhibit LRV1. Thus, we should be able to test 
whether reducing or eliminating LRV1 during a Leishmania infection will avoid the exacerbated 
disease severity usually generated by LRV1+ parasites. 
The long-term low 2CMA experiment shows that a concentration of 2CMA low enough 
to have no significant effect after one passage in culture is still able to reduce LRV1 levels in 
exposed parasites. Interestingly, this treatment generates a population of LRV1-low parasites 
rather than uniformly reducing the number of LRV1 virions in all parasites (Figure B-1). This 
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pattern suggests that low doses of 2CMA lead to the stochastic loss of LRV1 in a subset of cells. 
This fits with the fact that this strain has, on average, 15 virions per cell.(Kuhlmann et al. 2017) 
If drug pressure lowers the average number of virions per cell slightly, this would increase the 
probability of a daughter cell receiving no virions upon cell division. These relatively rare events 
would then slowly increase the proportion of LRV1-negative parasites, which would only be 
noticeable after long-term treatment with drug. 
Another piece of evidence supporting the feasibility of inhibiting LRV1 with 7d2CMA is 
that it has previously been used to treat Zika virus in mice.(Zmurko et al. 2016) In cell culture, 
7d2CMA has similar EC50s against Zika (10 µM) and LRV1 (5 µM). Since giving daily 50 
mg/kg doses of 7d2CMA to Zika-infected mice via gastric gavage significantly inhibited Zika 
virus, we can be reasonably confident that the same dose would inhibit LRV1 as well. Another 
important implication of the Zika experiment is that 7d2CMA can be effective at sites other than 
the liver. The concentration of 7d2CMA in the liver has been shown to far exceed the plasma 
concentration (Olsen et al. 2004), but Zika virus is not liver-specific like HCV and thus would 
not benefit from that distribution. 
Since 7d2CMA treatment seemed likely to have an effect on LRV1 in our mouse model 
of leishmaniasis, I evaluated various potential administration routes and dosing amounts. Gastric 
gavage was considered in light of its successful use to treat Zika virus. However, this route 
suffers from several drawbacks, including low bioavailability and the potential for fatal adverse 
events when dosing the mice. Subcutaneous injections avoid both of these problems, while also 
avoiding the initial round of liver metabolism. This can easily be seen by considering the 
predicted effects of giving 7d2CMA by either route (Table B-1), which shows that the average 
plasma concentration and total AUC are roughly twice as high when 7d2CMA is given by 
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subcutaneous injection. In fact, the total AUC from an 80 mg/kg subcutaneous injection of 
7d2CMA would be significantly greater than if the plasma concentration were maintained at 5 
µM, the drug’s EC50. 
These PK predictions should also be considered in light of the washout experiments 
reported in Chapter 4. They demonstrated that 2CMA-TP has a half-life of 4-8 hours in parasites 
after 2CMA has been removed from the medium. This means that drug taken up and activated by 
parasites in mice following the daily drug dose would be retained longer than the plasma 
concentrations would suggest. As a result, the effect of a given dose of 7d2CMA on LRV1 in 
parasites in a mouse is likely to be significantly higher than predicted. This provides further 
support for the viability of inhibiting LRV1 in mice. 
Taken together, this evidence suggests that treating infected mice daily with 80 mg/kg 
7d2CMA via subcutaneous injection is likely to inhibit LRV1. By starting 7d2CMA treatment 
either immediately or after a lesion has begun forming, we can determine whether delayed 
treatment of LRV1 would avoid the enhanced parasite numbers and pathology normally 
characteristic of LRV1+ parasites. If delayed inhibition of LRV1 reduces its effects in our mouse 
model, then further efforts should be undertaken to identify a drug capable of treating LRV1 in 
human leishmaniasis. 
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B.6– Tables 
 
Table B-1: Summary of once-daily dosing options for treating mice with 7d2CMA.  
AUC is an approximate measure of the total intensity of the drug dose over a given amount of 
time (here 24 hours), and is calculated as the integral of drug concentration over that time. The 
AUC values allow one to sort the dosing routes by how much drug they deliver to the plasma. 
The “Theoretical” route represents an idealized dosing route where the plasma 7d2CMA 
concentration is held constant. This provides an approximation of the amount of drug seen by 
parasites in culture. For these, the AUC is simply the concentration times 24 hours. 
Administration Route Dose AUC (24 hrs) 
(hr*μM) 
Peak [7d2CMA] 
(μM) 
Time Above 
1 µM [7d2CMA] 
Theoretical (low) 1 µM 24 1 μM n/a 
Gastric Gavage 50 mg/kg 67 26 μM 7.6 hrs 
Gastric Gavage (high) 80 mg/kg 108 42 μM 8.6 hrs 
Subcutaneous 50 mg/kg 119 52 μM 9.1 hrs 
Theoretical (EC50) 5 µM 120 5 μM n/a 
Subcutaneous (high) 80 mg/kg 190 82 μM 10.2 hrs 
Theoretical (high) 10 µM 240 10 μM n/a 
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Table B-2: Summary of treatment options for administering 7d2CMA to lab mice.  
Information obtained from Diehl et al. or Turner et al. unless otherwise noted. (Diehl et al. 2001; 
Turner et al. 2011) 
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Gastric Gavage 
Pros Cons Dosing 
35. Published method(Zmurko et al. 2016)  
36. Slower absorption of drug 
37. Simulate human dosing – not primary 
goal here 
38. More forgiving of irritating or impure 
drug preparations 
39. Potentially fatal adverse events 
40. Requires “moderate technical skill and 
confidence”(Turner et al. 2011) 
41. Lower bioavailability (51% of IV route 
for 7d2CmA) 
42. First-pass metabolism significant for 
7d2CmA 
 ~100x more drug in liver than 
blood(Olsen et al. 2004) 
43. Variable uptake and metabolism based 
on feeding/drinking/sleeping times 
44. High volumes may be forced into lungs 
or into intestines 
45. 5-10 mL/kg/day is recommended, 
maximum 50 mL/kg/day(Diehl et al. 
2001; Turner et al. 2011) 
 Allows 40-80 mg/kg/day of 
7d2CmA 
 In rats, 20 mg/kg dose gives 0.2 μM 
7d2CmA in plasma after 24 hrs 
46. 0.5% carboxymethylcellulose is too 
much, use 0.2%(Zmurko et al. 2016) 
Subcutaneous Injection 
Pros Cons Dosing 
47. Simple to perform(Turner et al. 
2011) 
48. Avoids first-pass metabolism 
49. Slower absorption rate 
 Can also use oily “depots” for 
extended release. 
50. Irritating substances can cause 
abscesses. 
51. 5-10 mL/kg/day 
recommended(Diehl et al. 2001; 
Turner et al. 2011) 
 40 mL/kg/day maximum 
 40-320 mg/kg/day of 7d2CmA 
(Table B-2, page 1) 
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Intravenous Injection 
Pros Cons Dosing 
52. 100% drug delivery 
53. Avoids first-pass metabolism 
54. Instant drug delivery, no extended 
uptake 
55. Requires port or cannula for daily 
injections 
 Good surgical skill required for 
long-term installation (Turner et 
al. 2011) 
56. 5 mL/kg/day recommended (Diehl 
et al. 2001) 
 Can go up to 25 mL/kg/day by 
slow infusion (5-10 min) 
 40-200 mg/kg/day of 7d2CmA 
57. Can use pumps with a catheter 
58. Port (internal) or cannula (external) 
 Port preferred since cannot be 
chewed on 
Intraperitoneal Injection 
Pros Cons Dosing 
59. Simple to perform (Turner et al. 
2011) 
60. Slower absorption rate, but faster 
than subcutaneous 
61. Relatively frequent complications 
limit use for repeated doses (Diehl 
et al. 2001) 
62. Subject to first-pass metabolism 
63. 10-20 mL/kg/day recommended 
(Diehl et al. 2001; Turner et al. 
2011) 
 80-160 mg/kg/day of 7d2CmA 
(Table B-2, page 2) 
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Implantable Pumps(DURECT Corporation 2017b, a) 
Pros Cons Dosing 
38. Maintain constant plasma concentration 
of drug 
64. Require surgical implantation 
65. Limited by drug solubility 
66. Programmable 
 Prohibitively expensive ($250 
per pump) 
 Pumps would require refilling 
daily 
39. Osmotic 
 Best option is 1-week pump, which 
could maintain ~0.8 μM 7d2CmA 
in plasma. 
40. Programmable 
 Mouse pump (SMP-300) can 
maintain ~4 μM drug for 16 days 
 Alternately, could achieve ~1 μM 
drug for ~30 days or anything in 
between 
(Table B-2, page 3) 
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B.7 – Figures 
 
Figure B-1: LRV-high and LRV-low parasites identified by flow cytometry.  
The ‘No Primary’ peak (red) is parasites stained only with the secondary antibody and 
represents background staining by the secondary antibody. The ‘Untreated’ peak (black) 
is LRV+ parasites treated with DMSO rather than 2CMA. The ‘2CMA-Treated’ trace 
(blue) shows the distribution of LRV1 in a culture treated with 1 µM 2CMA for 4 
passages. 
  
243 
 
 
 
Figure B-2: LRV1 levels during treatment with 1 µM 2CMA.   
Plot shows the changes in LRV1 levels over the course of 4 passages in 1 µM 2CMA (n=1). Grey 
lines show the geometric mean of the LRV-high (▲) and –low (▼) parasite populations. Black 
line shows the proportion of LRV-low parasites in the culture (●). 
 
